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Résumé 91 
Le facteur le plus important de pronostic de l'asthme professionnel 92 
(AP) est la durée des  symptômes avant le retrait de lʼexposition à lʼagent 93 
causant lʼAP. La qualité de vie réduite, la détresse psychologique et les 94 
maladies psychiatriques sont des conditions souvent associées à l'AP. 95 
Notre objectif était d'identifier les facteurs, incluant le statut 96 
socioéconomique, qui ont  une influence sur lʼintervalle de temps nécessaire 97 
pour présenter une requête à une agence médicolégale à la suite de 98 
lʼapparition de symptômes dʼasthme et de confirmer qu'un tel délai est 99 
associé à un moins bon pronostic respiratoire et à des coûts directs plus 100 
élevés. En outre, nous avons examiné la relation entre les variables cliniques 101 
et socio-économiques dʼune part et leur influence sur les facteurs 102 
psychologiques et économiques dʼautre part chez des travailleurs atteints 103 
d'AP. Ensuite, nous avons voulu évaluer si les individus souffrant de détresse 104 
psychologique (DP) et de morbidité psychiatrique pourraient être identifiés en 105 
utilisant un instrument mesurant la qualité de vie (QV). 106 
Lʼétude a été effectuée auprès dʼindividus ayant déposé des 107 
demandes d'indemnisation pourʼAP auprès du Commission de la sécurité et 108 
de la santé du travail du Québec (CSST). Les données ont été recueillies au 109 
moment de la réévaluation, soit environ deux ans et demi après le diagnostic. 110 
Outre la collecte des marqueurs cliniques de l'asthme, les individus ont été 111 
soumis à une évaluation générale de leur histoire sociodémographique et 112 
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médicale, à une brève entrevue psychiatrique (évaluation des soins primaires 113 
des troubles mentaux, PRIME-MD) et à un ensemble de questionnaires, 114 
incluant le Questionnaire sur la qualité de vie - AQLQ(S), le Questionnaire 115 
respiratoire de St. George (SGRQ) et le Psychiatric Symptom Index (PSI). 116 
Soixante personnes ont été incluses dans l'étude. Etre plus âgé, avoir 117 
un revenu supérieur à 30 000$ CA etêtre atteint dʼAP dû à un allergène de 118 
haut poids moléculaire ont une association positive avec le nombre dʼannées 119 
dʼexposition avec symptômes avant le retrait. Au cours de la période de suivi, 120 
le nombre dʼannées dʼexposition avec symptômes était plus grand chez les 121 
individus ayant une hyperréactivité bronchique persistante. Par ailleurs, la 122 
présence de symptômes au poste de travail pendant moins d'un an est 123 
associée à une réduction des coûts directs. Les paramètres de QV et de DP 124 
avaient des corrélations modérées avec les marqueurs cliniques de lʼAP. Les 125 
plus fortes associations avec ces variables ont pu être observées dans les 126 
cas de la sévérité de l'asthme, des statuts dʼemploi et matrimonial, du revenu 127 
et de la durée de la période de travail avec l'employeur. Un seuil de 5,1 au 128 
niveau de la sous-échelle de la fonction émotionnelle de lʼAQLQ(S) sʼest 129 
avéré avoir la meilleure valeur discriminante pour distinguer les individus 130 
avec ou sans détresse psychiatrique cliniquement significative selon le PSI. 131 
Nous avons été en mesure d'identifier les variables socio-économiques 132 
associées à un intervalle plus long dʼexposition professionnelle en présence 133 
de symptômes dʼasthme. De même, une plus longue période d'exposition a 134 
été associée à un moins bon pronostic de la maladie et à des coûts de 135 
vi 
compensation plus élevés. Ces résultats s'avèrent utiles pour la surveillance 136 
de lʼAP qui pourrait cibler ces sous-groupes d'individus. La QV et la PS sont 137 
fréquemment réduites chez les individus atteints d'AP qui perçoivent une 138 
compensation. Elles sont associées à des marqueurs cliniques de lʼasthme et 139 
à des facteurs socio-économiques. En outre, nos résultats suggèrent que le 140 
questionnaire de lʼAQLQ(S) peut être utilisé pour identifier les individus avec 141 
un niveau de détresse psychologique potentiellement significatif. 142 
 143 
Mots-clés : Analyse des coûts, délai de diagnostic, économie, asthme 144 
professionnel, troubles psychiatriques, détresse psychologique, qualité de 145 
vie, Québec, dépistage, facteurs socioéconomiques. 146 
147 
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Abstract 147 
The most important factor in the prognosis of occupational asthma 148 
(OA) is the length of exposure with symptoms prior to removal from exposure. 149 
Impaired quality of life, psychological distress and psychiatric disease are 150 
conditions frequently associated with OA.  151 
Our goal was to identify factors, including socio-economic status, that 152 
can influence the delay in submitting a claim to a medicolegal agency after 153 
the onset of asthmatic symptoms, and to confirm that such a delay is 154 
associated with a worse respiratory prognosis and higher direct costs. 155 
Further, we examined the association between clinical and socio-economic 156 
variables and their influence on psychological and cost outcomes in 157 
individuals with OA. Next, we wanted to evaluate whether individuals with 158 
clinically significant psychological distress (PD) and psychiatric morbidity 159 
could be identified by using a quality of life (QOL) measurement instrument.   160 
This is a study of individuals who filed claims for compensation for 161 
occupational asthma from the Workersʼ Compensation Board of Quebec (the 162 
CSST). Data were collected at re-evaluation, approximately two and a half 163 
years after diagnosis. Besides collecting clinical markers of asthma, 164 
individuals underwent a general socio-demographic and medical history 165 
evaluation, a brief psychiatric interview (Primary Care Evaluation of Mental 166 
Disorders, PRIME-MD) and completed a battery of questionnaires, including 167 
the Asthma Quality of Life Questionnaire - AQLQ(S), the St. Georgeʼs 168 
viii 
Respiratory Questionnaire (SGRQ), and the Psychiatric Symptoms Index 169 
(PSI). 170 
Sixty individuals were included in the study. Being older, having a 171 
revenue of >$30,000 Can. (CAD$) and having OA due to high- molecular- 172 
weight agents were all positively associated with the number of years of 173 
exposure with symptoms before removal from exposure. Individuals with 174 
persistent airway hyperresponsiveness at follow-up had a higher number of 175 
years with symptoms. Experiencing symptoms in the workplace for less than 176 
one year generated lower direct costs. QOL and PD parameters had 177 
moderate correlations with clinical markers of OA. Asthma severity, 178 
employment and marital status, income and length of employment with the 179 
employer showed the strongest associations with QOL and PD. More 180 
impaired QOL was associated with higher direct costs for compensation. A 181 
cut-off of 5.1 on the AQLQ(S) emotional function subscale had the best 182 
discriminative value to distinguish individuals with or without clinically 183 
significant psychological distress according to the PSI. 184 
 We  were able to identify socio-economic variables that were associated 185 
with a longer interval during which individuals remained symptomatic in the 186 
workplace before being removed from exposure. This longer exposure time 187 
was associated with worse disease outcomes and higher compensation 188 
costs. These findings could prove to be useful in surveillance programs that 189 
could be preferentially targeted for these subgroups of individuals. Impaired 190 
QOL and PD are frequent among individuals with OA receiving compensation 191 
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and are associated with clinical markers of OA and socio-economic factors. 192 
Further, our findings suggest that the AQLQ(S) questionnaire could be used 193 
to identify individuals with potentially clinically significant levels of 194 
psychological distress. 195 
 196 
Keywords: Costs and Cost Analysis, Diagnosis Delay, Economics, 197 
Occupational Asthma, Psychiatric disorder, Psychological Distress, Quality of 198 
Life, Quebec, Screening, Socioeconomic Factors 199 
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1. Introduction 396 
 397 
In this chapter, I will first briefly discuss the definition and specific 398 
features of asthma that is caused by the workplace. I will discuss which tests 399 
can be used to diagnose and treat occupational asthma (OA), and report on 400 
the expected natural course in individuals who remain exposed to the causal 401 
agent in the workplace and how the outcome differs in those individuals who 402 
are able to decrease or stop their exposure. I will then highlight the strong and 403 
important association of socio-economic and psychological factors with health 404 
in general before summarizing findings of past studies on the association of 405 
OA with various socio-economic and psychological factors. I will also briefly 406 
explain how a claim made to the compensation agency in Quebec/Canada is 407 
handled and what compensation is offered to individuals whose claim is 408 
accepted. 409 
 410 
 411 
412 
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1.1. Asthma in the workplace 412 
 413 
1.1.1. Definition of asthma 414 
 415 
The Global Initiative for Asthma (GINA), launched in 1993, brings 416 
together committees made up of leading asthma experts from around the 417 
world to develop guidelines for asthma care. According to GINA, “Asthma is a 418 
chronic inflammatory disorder of the airways in which many cells and cellular 419 
elements play a role. The chronic inflammation is associated with airway 420 
hyperresponsiveness (AHR) that leads to recurrent episodes of wheezing, 421 
breathlessness, chest tightness, and coughing, particularly at night or in the 422 
early morning. These episodes are usually associated with widespread, but 423 
variable, airflow obstruction within the lung that is often reversible either 424 
spontaneously or with treatmentʼʼ (www.ginasthma.org). Asthma has been 425 
classified by Rackeman into two different types based on causative factors: 426 
extrinsic asthma is often due to an allergy to antigens and frequently occurs 427 
before the age of 30, while intrinsic asthma usually occurs later in life, 428 
secondary to chronic or recurrent infections of the bronchi, sinuses, or tonsils 429 
and adenoids (1). 430 
To avoid exacerbation of asthmatic attacks and further progression of 431 
the disease, triggering situations or substances should be avoided whenever 432 
possible. The treatment of asthma involves treating the underlying 433 
22 
inflammation and bronchospasm. It has been estimated that about 300 million 434 
people worldwide are affected by asthma. The global prevalence of asthma 435 
ranges from 1% to 18% of the population in different countries, and the 436 
number of disability-adjusted life years (DALYs) lost due to asthma is similar 437 
to years lost for diabetes, cirrhosis of the liver or schizophrenia (2). 438 
 439 
 440 
Work-related Asthma 441 
 442 
Several terms are used to describe asthma in relation to the workplace, 443 
as summarized in the American College of Chest Physiciansʼ (ACCP) 444 
statement on work-related asthma (3) (Figure 1): 445 
   23 
	  
	  
 446 
Figure 1: Different subtypes of work-related asthma  447 
 448 
Work-related asthma (WRA) is the term used to define asthma that is 449 
induced or exacerbated at the workplace. In population studies, a diagnosis of 450 
WRA is assigned to respondents with self-reported physician-diagnosed 451 
asthma who report that their work environment is causing asthma symptoms 452 
(4). Self-reporting of work-related symptoms and exposure to airway irritants 453 
can, however, be prone to recall bias in individuals with lung disease. 454 
Evidence for this comes from studies investigating the association of 455 
occupational exposure to airway irritants with chronic obstructive lung 456 
disease. In an American study, the association between self-reported 457 
24 
exposure and chronic obstructive lung disease was much stronger than a 458 
more objective measure of exposure by a job-exposure matrix (5). 459 
 460 
 461 
Work-exacerbated Asthma 462 
 463 
Work-exacerbated asthma (WEA) is the term used in the case of 464 
workers with pre-existing or concurrent asthma (asthma that occurs at the 465 
same time but is not caused by workplace exposures) that is worsened by 466 
work-related factors like airway allergens, irritants and exercise (3). Subjects 467 
may notice an increased frequency or severity of asthma symptoms and/or 468 
may need to increase their medication in order to control symptoms during or 469 
after their work days. In rare cases WEA and OA may coexist in workers: 470 
Subjects who work at different workplaces may become sensitized to an 471 
allergen causing OA. Their asthma may be exacerbated by other irritating 472 
factors encountered during work; for example, when performing a job task 473 
without exposure to the allergen or at a different workplace.  474 
 475 
 476 
477 
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Occupational Asthma 477 
  478 
Occupational asthma (OA) is the term used for asthma that starts 479 
when the subject is exposed to a substance present in the workplace. Rarely, 480 
it may occur in subjects with a history of childhood asthma that became 481 
quiescent during adolescence before resurfacing as a consequence of 482 
occupational exposure through a sensitizing or irritating mechanism (3). OA 483 
can be divided into two categories: 484 
 485 
Immunological OA appears after sensitization to a substance that is 486 
specific to the workplace. Symptoms appear after a latency period that seems 487 
to vary according to the nature of the agent (6). For some allergens, an 488 
allergic immunoglobulin E (IgE)-mediated mechanism has been 489 
demonstrated, whereas for others the mechanisms of sensitization are 490 
presently unclear. Another approach often used is to distinguish allergens 491 
according to their molecular weight: high-molecular-weight (HMW) allergens 492 
are often proteins with a mass >10 kd, while low-molecular-weight (LMW) 493 
allergens are those such as chemicals, like diisocyanates.  494 
 495 
Non-immunological OA may occur after a single or multiple high- 496 
concentration exposures to an inhaled non-specific irritant in the workplace. 497 
Subjects complain of symptoms within the first 24-48 hours of exposure and 498 
26 
demonstrate non-specific AHR. Brooks defined this condition in 1985 as 499 
asthma occurring after a single exposure to high levels of an irritating vapour, 500 
fume or smoke, and suggested the term reactive airways dysfunction 501 
syndrome (RADS) (7).  502 
 503 
 504 
1.1.1.4. Etiologies of OA 505 
 506 
Substances that are known to cause immunological OA encompass a 507 
broad spectrum of natural and synthetic chemicals found in a diverse range of 508 
materials and industrial processes. These agents can be divided into two 509 
broad categories by their mechanism of action: immunological is the 510 
sensitizer-induced form of OA and non-immunological is the irritant-induced 511 
form of OA (8). In immunological OA, asthma is induced through an IgE- 512 
dependent mechanism, whereas in some patients specific IgEs are 513 
apparently not involved despite a clear asthmatic reaction in specific 514 
inhalation challenges (8). Etiologic agents can be classified according to their 515 
propensity for IgE-dependent or non-dependent action (9), as shown in Table 516 
1. 517 
 518 
519 
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 519 
HMW Agents Selected 
Examples 
LMW Agents Selected 
Examples 
Plant antigens Cereals, flour; 
green coffee 
beans; tobacco; 
gums 
Isocyanates Polyurethane foam 
production and end-
user applications 
(auto-spray 
painters) 
Animal antigens Rodents; cats and 
dogs; farm 
animals; mites 
Wood dusts Western red cedar 
(carpenters and 
sawmill workers) 
Bioaerosols Moulds and 
bacteria 
Highly reactive 
compounds 
Anhydrides, amines 
and acrylates 
Enzymes Detergent 
enzymes, amylase 
in baking 
Aldehydes Glutaraldehyde and 
formaldehyde 
Latex Gloves (health-
care workers and 
others) 
Colophony Solder fluxes 
Seafood Crabs, prawns and 
fish 
Dyes Reactive dyes 
(textile workers) 
Drugs Antibiotics; 
psyllium laxatives 
Persulfate Hairdressers 
  Metals Metal plating 
(chrome, nickel and 
cobalt), platinum 
(catalysts) 
Table 1: Illustrative examples of specific agents (and workers) associated 520 
with sensitizer-induced OA 521 
 522 
OA induced by these two groups of allergens differs in clinical 523 
presentation, the type of reaction produced during inhalation tests and the 524 
characteristics of the population at risk, as shown in Table 2 (3).  525 
 526 
527 
28 
 527 
Characteristic Sensitizer-induced OA Irritant-induced 
OA 
 IgE-dependent IgE-independent  
Clinical    
Interval between 
onset of exposure 
and symptoms 
Longer Shorter Within hours 
Pattern of asthmatic 
reaction on specific 
inhalation testing 
Immediate, dual Late, atypical Testing not done 
Epidemiologic    
Prevalence in 
exposed population 
<5% >5% ? 
Host predisposition Atopy, probably 
smoking 
? ? 
Table 2: Types of OA according to Chan-Yeung and Malo 528 
 529 
The most common agents for asthma without latency or irritant-induced 530 
asthma are chlorine and ammonia (9).   531 
 532 
 533 
1.1.1.5. Epidemiology of Work-related Asthma 534 
 535 
There is much debate in the medical community about how to define 536 
asthma and about the “gold standard” for the diagnosis of asthma (10). One 537 
way of defining asthma in studies is by asking study participants if they have 538 
ever been diagnosed by a physician as having asthma. Respiratory 539 
symptoms can be misinterpreted by a physician as being caused by asthma, 540 
especially if no objective investigation with lung function and bronchial 541 
challenge testing is performed. Diseases such as chronic bronchitis, chronic 542 
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obstructive pulmonary disease (COPD), vocal cord dysfunction or upper 543 
airway cough syndrome are known to present with symptoms similar to 544 
asthma. In a recent study, Aaron and co-workers objectively assessed 545 
subjects with self-reported physician-diagnosed asthma and found that one- 546 
third of patients did not have asthma on the basis of bronchial provocation 547 
test (BPT) results and problem-free withdrawal of medication (11). 548 
Toelle and co-workers have suggested that in epidemiologic studies, 549 
asthma should be defined as having airway hyperresponsiveness (AHR) plus 550 
recent wheezing in the 12 months prior to study (12). However, it is well 551 
known that not all patients with asthma do have AHR or complain of wheezing 552 
(13).  553 
Not surprisingly, different definitions of OA exist. By consensus, a 554 
widely used definition of OA has been formulated: “Occupational asthma is a 555 
disease characterized by variable airflow limitation and/or 556 
hyperresponsiveness and/or inflammation due to causes and conditions 557 
attributable to a particular occupational environment and not to stimuli 558 
encountered outside the workplace.” (14)  559 
Depending on the population studied and the objective of the 560 
epidemiologic studies, the definition of OA can vary. When using a broader 561 
definition of WRA, this includes WEA and the two forms of OA: non- 562 
immunological OA and immunological OA. This precludes the general 563 
comparability of prevalence and incidence determined in different 564 
30 
epidemiologic investigations. Furthermore, different methods can be used to 565 
determine the frequency (incidence and prevalence) of OA (Table 3).   566 
 567 
 Advantages Disadvantages 
Epidemiological studies 
-In the general population Global coverage 
Large sample size due to low 
prevalence in the study 
population and therefore high 
costs, participation rate variable. 
-In the population at risk 
(apprentices, workers) 
Smaller sample size and more 
extensive evaluation possible 
Target population needs to be 
identified, selection bias 
(healthy worker effect) 
-In outpatients consulting for 
asthma Minimal costs 
Selection bias, only subjects 
investigated for asthma 
included. 
Database/register (e.g. 
Scandinavian countries) 
Almost all of the population 
included Only basic information available. 
Medico-legal statistics 
All subjects compensated for 
OA, information about diagnosis 
often available 
Subjects with OA who are not 
insured or do not claim 
compensation are not 
registered, so information about 
diagnosis may be lacking. 
Sentinel System Minimal costs 
Different diagnostic studies 
done, interest in reporting OA 
cases may decline over time. 
Table 3: Methods for the determining the frequency of OA 568 
 569 
OA is one of the most prevalent occupational respiratory diseases in 570 
the industrialized world. It has been estimated in systematic reviews and 571 
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meta-analysis that between 9% and 15% of diagnosed cases do have a 572 
professional origin (15). However, later studies have estimated a higher 573 
population-attributable risk of occupational exposure for adult-onset asthma in 574 
the United States (37%) (4) and Finland (29% for males and 17% for females) 575 
(16). In the European Community Respiratory Health Survey (ECRHS), the 576 
population-attributable risk for adult asthma due to occupational exposure 577 
ranged from 10% to 25%, equivalent to an incidence of new-onset OA of 250- 578 
300 cases per million people per year (17). 579 
 580 
 581 
1.1.1.6. Risk factors for OA 582 
 583 
1.1.1.6.1 Level of exposure 584 
 585 
Studies have provided strong evidence supporting a dose-response 586 
relationship between the level of exposure to occupational agents and the 587 
development of IgE-mediated sensitization and work-related respiratory 588 
symptoms (18). For isocyanates - considered LMW agents - an exposure- 589 
response gradient has been documented for respiratory symptoms, 590 
sensitization (reflected by specific IgE and IgG) and  the development of OA 591 
(19, 20). For acid anhydrides such as trimellitic anhydride (TMA), a dose- 592 
response relationship has been shown for respiratory symptoms and 593 
32 
sensitization (21). However, there are studies of bakers and laboratory animal 594 
workers showing that high-level exposures to flour or laboratory animal 595 
allergens may have a protective effect on the development of sensitization 596 
and respiratory symptoms (22-24).  597 
 598 
 599 
1.1.1.6.2. Mode of exposure 600 
 601 
In animal models, skin exposure has been shown to initiate IgE- 602 
mediated sensitization, eosinophilic airway inflammation and bronchial 603 
hyperresponsiveness (18). In humans, airway and skin exposure to offending 604 
allergens often occur simultaneously; however, there is evidence that OA to 605 
isocyanates consistently occurs in work settings with low diisocyanate 606 
exposure, due either to intermittent peak exposures or to skin exposure (25, 607 
26). 608 
 609 
 610 
1.1.1.6.3. Co-exposure to pollutants 611 
 612 
Co-exposure in the workplace to environmental pollutants such as 613 
ozone, nitrogen dioxide, diesel exhaust particles and endotoxin can act as an 614 
adjuvant in allergic responses to inhalant allergens (18). Individual smoking 615 
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has been identified as a risk factor for work-related sensitization in laboratory 616 
animal workers (27). However, this finding was not present in larger and 617 
better controlled studies, and could not be shown in workers exposed to LMW 618 
agents (28). Smoking has also been identified as a risk factor for persistent 619 
respiratory symptoms after acute irritant inhalation exposure leading to 620 
irritant-induced OA (29). 621 
 622 
 623 
1.1.1.6.4. Atopy  624 
 625 
Atopy is defined as either a positive skin prick test (SPT) response or 626 
specific IgE response against a series of common aero-allergens (28). Atopy 627 
has been shown to be a risk factor for the development of sensitization and 628 
OA to HMW agents and to some LMW agents (18). In a follow-up study of 629 
laboratory animal workers in the Netherlands, a combination of atopy and 630 
elevated IgE (>100 IU/mL) when starting work with animals was associated 631 
with subsequent sensitization over the following two years (30). Other studies 632 
have shown that atopy is a stronger risk factor for sensitization in those with 633 
low levels of exposure compared with those having medium- to high-level 634 
exposure (24, 28, 31). 635 
 636 
 637 
34 
1.1.1.6.5. Genetic factors 638 
 639 
Several genes have been shown to be associated with OA to LMW and 640 
HMW occupational allergens. While some of these loci seem to have 641 
protective properties, others confer a higher risk for OA (18). Identified genes 642 
are involved in protection against antioxidant stress, α-1-antitrypsin 643 
production and regulation of native immune pathways (18, 32). However, 644 
most of the data available are derived from cross-sectional studies and show 645 
only weak associations; some of the associations could not be confirmed in 646 
studies carried out in other samples (18). 647 
 648 
 649 
1.1.1.6.6. Bronchial hyperresponsiveness 650 
 651 
Increased non-specific bronchial hyperresponsiveness has also been 652 
considered a risk factor for subsequent development of OA: Gautrin and co- 653 
workers investigated apprentices in animal health technology and found that 654 
increased baseline immediate skin reactivity to pets (cats and dogs) and 655 
higher degrees of non-specific AHR were risk factors for the development of 656 
probable OA at follow-up after 3.5 and 8 years (33, 34). 657 
 658 
 659 
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1.1.1.6.7. Rhinitis 660 
 661 
In the ECRHS, rhinitis was associated with asthma in cross-sectional 662 
analysis and shown to be a risk factor for the subsequent development of 663 
asthma at follow-up (35, 36). In individuals evaluated for WRA, Castano and 664 
co-workers showed that occupational rhinitis (OR) frequently coexists with OA 665 
(37). Symptoms of work-related rhinoconjunctivitis are risk factors for the later 666 
development of asthma in the workplace in apprentices and workers handling 667 
laboratory animals (38, 39), as shown in a study of patients in the Finnish 668 
Register of Occupational Diseases (40). The acknowledgement of OR as a 669 
risk factor for the development of OA has led the European Academy of 670 
Allergy and Clinical Immunology (EAACI) Task Force on Occupational 671 
Rhinitis to state in its position paper that the prevention of work-related rhinitis 672 
may also provide an excellent opportunity to prevent OA (41).  673 
 674 
 675 
1.1.1.6.8. Sex 676 
 677 
Most occupational health and exposure assessment studies have been 678 
carried out in male populations, so the findings cannot easily be extrapolated 679 
to estimate the risk for female workers. In workers processing snow crab, it 680 
has been shown that female workers were more likely to have OA and allergy 681 
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to snow crab than their male co-workers (42). Atopy is a risk factor for the 682 
development of OA to HMW allergens such as snow crab, and the risk for 683 
atopy is greater for females than for males of working age (43). There is 684 
accumulating evidence of a sex difference in susceptibility to exposure to 685 
tobacco smoke, irritants and allergens that needs to be taken into account 686 
when interpreting studies reporting a difference in respiratory disease rates 687 
according to sex (44). Furthermore, there is evidence that immune response 688 
in women differs from that in men, and that women are at much higher risk of 689 
developing autoimmune diseases than men (45). 690 
While “sex” is the term usually used to refer to biological differences 691 
between men and women, “gender” most often refers to what is socially 692 
recognized as feminine and masculine (46). Further analysis in workers 693 
processing snow crab indicates that female workers more often perform work 694 
where higher exposure to snow crab allergen is present than their male co- 695 
workers (47). Eng et al. conducted a broad-based telephone survey of male 696 
and female workers in New Zealand that showed major differences in 697 
occupational exposure patterns between female and male workers, indicating 698 
that these exposure differences were present between and within occupations 699 
(48). Both studies highlight the fact that for OA, not only sex but also gender 700 
differences must be taken into account when interpreting results of research 701 
studies investigating risk factors. 702 
 703 
 704 
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1.1.2. Diagnosis of work-related asthma in Quebec 705 
 706 
WRA is a major health challenge. Acute WRA can render suffering 707 
subjects unable to work, often for a prolonged period of time. OA can cause 708 
acute as well as long-term disability, which adversely affects quality of life and 709 
socio-economic factors.  710 
To diagnose WRA, subjects undergo a comprehensive medical history 711 
in order to identify the presumed causal agent, followed by objective tests at 712 
the physicianʼs office or at the workplace. When the offending allergen is in 713 
doubt, it may be necessary for industrial hygienists to inspect the workplace in 714 
order to identify irritating or sensitizing substances. Subjects who were 715 
exposed to high levels of irritants within a short time normally develop 716 
respiratory symptoms within the next 24 hours and often require emergency 717 
treatment. Whenever possible, WRA should be investigated with objective 718 
testing before the patient is advised to change profession or workplace. 719 
 720 
 721 
1.1.2.1. Occupational history 722 
 723 
In all working subjects with new-onset, worsening or difficult to treat 724 
asthma, WRA needs to be considered, and a detailed history of temporal 725 
relationships between asthma symptoms and work should be established. 726 
38 
Information about subjectsʼ profession, work status and exposure 727 
characteristics must be obtained. Specific work environments have been 728 
shown to be associated with an increased risk of more severe asthma, 729 
especially in adult-onset asthma (49).  730 
In real life, clinicians often neglect the importance of taking such a 731 
detailed occupational history. Shofer and co-workers conducted a structured 732 
retrospective comparison of occupational respiratory health history 733 
documented by clinicians in an academic medical centre, with data 734 
documented by patients on a structured questionnaire. While a job title was 735 
documented in 75% of patient medical records, additional occupational 736 
history data such as duties, exposures at work and use of protective 737 
equipment were charted much less frequently (50). 738 
Dyspnoea, wheezing, chest tightness and cough are the cardinal 739 
symptoms of asthma as well as WRA. However, there are specific questions 740 
a physician who suspects that the patientʼs asthma is related to the workplace 741 
should ask (see Table 4) (3).  742 
 743 
- Were there changes in work processes in the period preceding the onset of 
symptoms? 
- Was there an unusual work exposure within 24 hours before the onset of initial 
asthma symptoms? 
- Do asthma symptoms differ during times away from work such as weekends or 
holidays or other extended times away from work? 
- Are there symptoms of allergic rhinitis and/or conjunctivitis symptoms that are 
worse with work? 
Table 4: Key questions suggested in the American College of Chest 744 
Physiciansʼ Consensus Statement on Diagnosis and Management of WRA 745 
746 
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 746 
When work processes are changed, subjects may be exposed to new 747 
agents causing sensitization or increased exposure to previously occurring 748 
agents. Sometimes the work process of co-workers is changed, or the 749 
subjectʼs workplace is moved to another place where he or she starts to be 750 
exposed to a sensitizing agent. Work conditions may have changed, such as 751 
new ventilation and exposure to cold air, exhaust gases or second-hand 752 
smoke. Sometimes, as in WEA, the underlying asthma worsens when 753 
subjects decrease their medication use, or during the spring/summer when 754 
the allergen concentration (e.g. pollen) rises.  755 
After chemical spills or other high-level exposures to airway irritants, 756 
subjects may develop respiratory symptoms within short periods of time that 757 
result in them seeking emergency care. This form of WRA is called non- 758 
immunological OA. One form of non-immunological OA is RADS, initially 759 
described by Brooks and co-workers in 10 individuals who developed a 760 
persistent asthma-like illness after a single exposure to high levels of an 761 
irritating vapour, fume or smoke. In all subjects, the symptoms developed 762 
within a few hours and often minutes after exposure. All had bronchial 763 
hyperreactivity on methacholine testing (7). However, some subjects do not 764 
meet the criteria for RADS and develop symptoms after days and for a shorter 765 
period of time. Many of these subjects are exposed to lower concentrations of 766 
irritants over some days or weeks (51). 767 
40 
Often, a temporary pattern of symptoms related to exposure at the 768 
workplace can be established. When workers return to their workplace, they 769 
may notice an increase in symptoms the first day or at the end of the workday 770 
or realize that their symptoms slowly increase during the working week. On 771 
weekends the symptoms may disappear, but in subjects with long-standing 772 
illness this improvement may be insignificant. This correlation between 773 
symptoms and workplace exposure is present in about 88% of subjects with 774 
immunological OA; however, 76% of subjects without proven OA do also see 775 
improvement of symptoms when they are away from work (52). Chan-Yeung 776 
et al. reported that, even after a change of workplace, symptoms and non- 777 
specific AHR can persist in workers with asthma caused by Western red 778 
cedar: roughly 60% of workers still had asthma exacerbations after a mean 779 
follow-up period of four years (53).  780 
All subjects with asthma should be questioned about upper respiratory 781 
and eye symptoms. This is especially true for subjects evaluated for OA. 782 
Rhinoconjunctivitis symptoms often precede or occur simultaneously with 783 
lower airway symptoms. Rhinitis may either be caused or exacerbated by 784 
exposures at the workplace. Occupational rhinitis is an inflammatory disease 785 
of the nose characterized by intermittent or persistent symptoms (i.e. nasal 786 
congestion, sneezing, rhinorrhea, and itching), variable nasal airflow 787 
limitation, and/or hypersecretion due to causes and conditions attributable to 788 
a particular work environment and not to stimuli encountered outside the 789 
workplace. The main concept of this broad definition is the causal relationship 790 
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between exposures at the workplace and the development of the disease 791 
(54).  792 
Immunological occupational rhinitis is characterized by the acquisition 793 
of sensitization. This category includes occupational rhinitis caused by high 794 
and low molecular weight agents (55). Irritant-induced occupational rhinitis 795 
includes cases of occupational rhinitis caused by low molecular weight 796 
agents. This involves non-allergic, less well-known pathogenic mechanisms 797 
and is further sub-classified into acute irritant, chronic irritant, and corrosive 798 
rhinitis (55). Subjects with work-aggravated rhinitis have pre-existing rhinitis, 799 
the symptoms of which are triggered by exposure to irritants at the workplace 800 
(fumes, vapours, and dust) (55). 801 
As mentioned earlier, work-related rhinitis symptoms are common in 802 
workers exposed to laboratory animals (42%) or who work in swine 803 
confinement units (62%). Vandenplas and co-workers have identified a 804 
positive relationship between symptoms such as nasal or ocular itching and 805 
the diagnosis of OA confirmed by specific inhalation challenge (SIC) (56). In 806 
the same study, work-related loss of voice was negatively associated with the 807 
diagnosis (56). Allergic rhinitis may precede asthma (57), and it has been 808 
shown that effective treatment of rhinitis can decrease the risk for emergency 809 
room visits or hospitalization for asthma (58). Contact urticaria has been 810 
described in snow-crab processing workers (59) and in health-care workers 811 
exposed to natural rubber latex (60).  812 
 813 
42 
1.1.2.2. Immunologic assessment 814 
 815 
Atopy has been shown to be a risk factor for immunological OA in 816 
health-care personnel exposed to HMW allergens such as natural rubber 817 
latex (61) and in laboratory-animal handlers (62), but not in workers exposed 818 
to diisocyanates (63). 819 
In immunological OA due to HMW allergens, specific IgE titers are 820 
elevated. Two methods are used to show sensitization: performing SPT or 821 
measuring specific IgE antibody assays (radioallergosorbent test (RAST)).  822 
SPT is usually performed on the medial aspect of the forearm. Small 823 
drops of standardized allergen, histamine and isotonic saline solutions are 824 
applied on the untreated skin and inoculated with a prick needle (Figure 2).  825 
 826 
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 827 
Figure 2: Performing SPT on the forearm 828 
 829 
The patient is told not to rub or scratch the skin until the test is read 830 
after 15 minutes. The diameter of the induration is noted and recorded. An 831 
induration of up to 3mm in diameter is considered negative. This test detects 832 
tissue-bound IgE (64). False positive results can occur in subjects with 833 
dermographism, whereas false negative results can occur if patients are on 834 
treatment with antihistamines or suffer from immunodeficiency syndromes 835 
that affect type I allergic reactions. Sensitivity is decreased if subjects are 836 
tested after not being exposed to the allergen for a prolonged time (65). 837 
Another limitation is that commercially available allergen solutions are often 838 
not standardized, in particular in the case of occupational agents.  839 
44 
SPTs have been shown to have high sensitivity for OA to HMW 840 
allergens with only moderate specificity. Vandenplas et al. investigated a 841 
sample of 45 workers evaluated for OA to natural rubber latex. In their sample 842 
sensitivity of the SPT for OA was 100%, specificity was 21%, positive 843 
predictive value 75% and negative predictive value 50%. The negative 844 
predictive value of SPTs for OA rose when the clinical history was 845 
incorporated into logistic regression analysis (64).  846 
The RAST was developed in the late 1960s and marketed in 1974 by 847 
Pharmacia Diagnostics AB in Sweden. In brief, the patientʼs serum is 848 
incubated with the test kit containing specific allergens bound to a solid-phase 849 
support. The patientʼs specific IgE binds to the allergens of the test kit. 850 
Excess serum and unbound IgE are removed. Radio-labelled antihuman IgE 851 
antibody is added to the test kit, binding to the tail of the patientʼs specific IgE 852 
and building a sandwich complex. Unbound radio-labelled antihuman IgE is 853 
then removed and the sample is measured with a radioactivity counter. The 854 
radioactivity measured is proportional to the proportion of radio-labelled 855 
antihuman IgE, which is proportional to the amount of patient-specific IgE 856 
(66). This method has been further elaborated by using enzyme-based 857 
immunoassay systems with higher precision (67). In vitro, specific IgE 858 
measurements have been shown to be less sensitive to detecting specific IgE 859 
antibodies to HMW-allergens; in workers at enzyme manufacturing plants, 860 
SPTs with enzyme solutions had 100% sensitivity compared to 62% 861 
sensitivity for specific IgE antibody assays (68). The value of immunologic 862 
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assessment is lower in the case of LMW allergens. Extracts of these 863 
allergens often cause unspecific irritative cutaneous reactions. Specific IgEs 864 
have been described for a minority of LMW allergens: trimellitic anhydride 865 
(TMA) in plastic industry workers (69) and platinum salts in workers at a 866 
platinum refinery (70). 867 
 868 
 869 
1.1.2.3. Non-invasive measures of airway inflammation 870 
 871 
Sputum cell counts and measurement of exhaled nitric oxide (ENO) are 872 
measurements that assess airway inflammation in asthmatic subjects.  873 
Because they are easy to perform, their use has been evaluated in patients 874 
with OA.  875 
For induced sputum cell counts, sputum is induced by using inhalations 876 
of increasing concentrations (3%, 4% and 5%) of hypertonic saline after 877 
inhalation of a short-acting bronchodilator (71). As hypertonic saline can 878 
cause bronchoconstriction, spirometry is performed to monitor lung function. 879 
Immediately afterwards, patients are asked to rinse their mouth, take a sip of 880 
water and blow their nose in order to minimize oral contamination of the 881 
sputum sample. They are then asked to try to bring up sputum into a 882 
container. The sputum is then processed and analyzed according to 883 
standardized procedures (72). An increase in sputum eosinophilia can be 884 
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observed after exposure to HMW allergens such as oilseed rape flour in 885 
farmers (73) and to different types of flours after SIC in a laboratory (74), as 886 
well as after exposure to LMW allergens such as cyanoacrylates (75), red 887 
cedar wood dust  (76) and diisocyanates (77). However, sometimes 888 
diisocyanates (78) as well as metal working fluids (79) and grain dust (80) can 889 
induce sputum neutrophilia, though it is likely that this finding reflects different 890 
phenotypes of asthma (81). Lemiere and co-workers investigated 10 subjects 891 
with OA and observed a significant increase in sputum eosinophilia at work, 892 
which was not observed among controls (82). Girard and co-workers 893 
demonstrated that the addition of sputum cell count analysis to peak 894 
expiratory flow measurement (PEF) monitoring performed during work and 895 
during a period off work improved the specificity of diagnosis for 896 
immunological OA confirmed by SIC: a >2% increase in sputum eosinophils 897 
improved specificity by 26% (83).  898 
Not all subjects with asthma are able to produce sputum for analysis. 899 
Matsuoka and co-workers estimated that only 73% of the asthmatics they 900 
investigated who were scheduled to undergo sputum cell count analysis 901 
produced sputum, and patients with long-standing disease and non-smokers 902 
were less likely to produce induced sputum successfully (84). Analysis of 903 
induced sputum cell counts is not available everywhere, as special equipment 904 
and expertise are needed to achieve reliable and reproducible results.  905 
Measurement of ENO is a new non-invasive measurement of airway 906 
inflammation in asthma. NO is an endogenous messenger with a diverse 907 
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range of effects, including non-adrenergic, non-cholinergic neurotransmission 908 
as well as vascular and non-vascular smooth muscle relaxation (85, 86). 909 
Many questions remain to be answered about the role of NO in lung disease. 910 
NO has been described as a pro-inflammatory mediator with 911 
immunomodulatory effects that has been thought to predispose to the 912 
development of AHR (85). However, under physiological conditions NO is a 913 
weak mediator that causes smooth muscle to relax and provides protection 914 
against AHR (87). Epithelial inducible nitric oxide synthase activity is the 915 
major determinant of NO concentration in exhaled breath (88).  916 
ENO is elevated in asthmatic subjects who are not currently on steroid  917 
treatment compared with non-asthmatic subjects (89). Atopy is a significant 918 
factor associated with elevated ENO in asthmatic and non-asthmatic subjects 919 
(90). ENO levels are elevated in subjects with non-specific AHR: 83% of 920 
asthma patients with AHR to mannitol and 88% of asthma patients with AHR 921 
to methacholine do have ENO levels >20 ppb (91). ENO levels have been 922 
shown to reflect sputum eosinophilia (92); Smith and co-workers have 923 
validated a treatment algorithm based on ENO measurements that makes it 924 
possible to reduce inhaled corticosteroids without compromising asthma 925 
control (93).  926 
ENO levels may rise in asthmatic and non-asthmatic subjects after 927 
gassing incidents with exposure to ozone in bleachery workers (94) or 928 
toluene, xylene and methylethyl ketone solvents used by leather workers (95). 929 
It has been shown that ENO levels rise with respiratory symptom severity in 930 
48 
workers with laboratory animal allergy (96). Health-care workers had a 931 
significant increase in ENO levels one hour after a latex challenge but after 22 932 
hours, levels remained significantly increased only in latex-sensitized 933 
subjects, this being related to AHR (97). However, there were no significant 934 
differences in ENO levels in latex-sensitized health-care workers when a 935 
comparison was made between the beginning and the end of a work week 936 
(98).  After SIC with different agents, Piipari and co-workers demonstrated 937 
that ENO levels significantly increased mainly in subjects with pre-SIC ENO 938 
levels of <14.5ppb and a late asthmatic reaction, while subjects with pre-SIC 939 
ENO levels of >14.5 ppb and  significant bronchoconstriction saw no 940 
significant increase in ENO (99). A rise in ENO occurred in two-thirds of 941 
subjects with a positive SIC test with diisocyanates, but also in half of 942 
subjects with a negative test (100). 943 
Although ENO measurement is a promising new tool in non-invasive 944 
evaluation of airway inflammation, it has several limitations. Smoking can 945 
decrease ENO levels (101); however, smokers who are asthmatic still have 946 
elevated levels (102) and ENO levels tend to rise in smokers who stop 947 
smoking (103). Respiratory manoeuvres are known to transiently reduce ENO 948 
(104), and infection (105) and nitrate-rich meal intake (106) can transiently 949 
raise ENO levels.  950 
Newer methods such as analysis of breath volatile organic compounds 951 
have been shown to help in discriminating healthy controls from patients with 952 
asthma, and also in identifying clinically important disease phenotypes related 953 
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to sputum inflammation and a measure of asthma control (107). However, to 954 
date this method has not been specifically applied in the investigation of 955 
individuals with OA. 956 
 957 
 958 
1.1.2.4. Lung function tests 959 
 960 
Lung function tests make it possible to measure the severity of airflow 961 
limitation, its reversibility and its variability. Two different methods have been 962 
proven to reliably assess these parameters: spirometry and peak expiratory 963 
flow measurement. Two-thirds of human beings have a diurnal rhythm of 964 
airway calibre, but asthmatic subjects have an exaggeration of this rhythm, 965 
especially if their asthma is not well controlled (108).  966 
The volumetric spirometer measures lung volumes with a water bell or 967 
a bellows wedge, whereas the flow-measuring spirometer measures flow with 968 
a pneumotachograph, turbines or ultrasound and determines the volumes by 969 
extrapolation from measured flow values. Data are expressed in figures such 970 
as forced vital capacity (FVC), forced expiratory volume in one second 971 
(FEV1) and PEF, or graphically as volume-time curve or flow-volume loop. 972 
With these values, we can calculate the Tiffenau Index by dividing the FEV1 973 
value by the FVC value. Values below 0.70 are considered abnormal. It is 974 
then possible to perform a bronchodilator test (Figure 3). The subject inhales 975 
50 
two puffs of a short-acting bronchodilator. After 15 minutes spirometry is 976 
repeated and FEV1 and FVC values are compared with previously obtained 977 
values.  Increases in the FEV1 value of ≥12% and ≥200ml are seen as 978 
diagnostic of asthma (109). 979 
 980 
 981 
Figure 3: Flow volume curves during bronchodilator test  982 
 983 
Population studies have obtained reference values for FVC, FEV1 and 984 
PEF based on age, sex and height (110). To be reproducible and 985 
comparable, measurements need to be performed according to published 986 
guidelines (111).  987 
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Lung function can be measured before and after the working shift, and 988 
the difference between these parameters is recorded as “cross-shift” 989 
changes. However, the value of determining cross-shift changes is limited, as 990 
subjects can have late asthmatic responses that occur after the work shift 991 
ends. It is also difficult to standardize the measurement as indirect work 992 
exposure when changing work clothes or leaving the workplace through an 993 
area of exposure. As workers may work on different shifts, the influence of 994 
spontaneous circadian variation adds further confusion to the interpretation of 995 
results (112, 113).  996 
Patients can take their own peak flow measurements with compact and 997 
inexpensive devices. Patients are instructed to measure PEF on work days as 998 
well as days off and record the values in a diary. A minimum of four 999 
measurements is recommended; more frequent measurements do not seem 1000 
to increase sensitivity and specificity (114). Ideally, the measurement period 1001 
includes a time where the worker is on holiday for at least two weeks. 1002 
According to the GINA guidelines, a diurnal variation in PEF of more than 1003 
20% suggests a diagnosis of asthma (115). Figure 4 shows an example of a 1004 
PEF graph with a classic pattern of OA (116).  1005 
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 1006 
Figure 4: Self-recorded peak flow measurement showing classic pattern of 1007 
OA 1008 
 1009 
When analyzing PEF recordings of subjects with OA, three different 1010 
reaction patterns may be noted: immediate reaction, late reaction and flat 1011 
reaction.  1012 
Immediate reactions are indicated by a drop in lung function in the first 1013 
hour after the worker is exposed to the allergen. Lung function values may 1014 
improve shortly after leaving the workplace; for example, during lunch break 1015 
or in the evening after leaving work.  1016 
Late reactions normally start several hours after the start of exposure 1017 
at work and progress even once the worker has left the workplace. Workers 1018 
frequently complain of symptoms in the evening after work or during the 1019 
following night.  1020 
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Flat reactions are demonstrated in subjects with chronic exposure and 1021 
fixed airway obstruction. The diurnal variability of PEF recordings is blunted.  1022 
Reading peak flow recordings requires experience and even in experts, 1023 
the results can vary, as demonstrated by Baldwin and co-workers (117). This 1024 
favours a standardized approach using computer programs like OASYS-2 1025 
(OASYS Research Group, Midland Thoracic Society; Birmingham, UK) that 1026 
were developed to analyze and simplify the reading of PEF recordings (118). 1027 
Although PEF variability is higher in workers with OA compared to 1028 
workers with WEA, the method is too insensitive to reliably distinguish 1029 
between the subjects (119). PEF recordings depend on the effort of the 1030 
patients. PEF manoeuvres have been shown to be less reproducible if 1031 
performed by the patient alone compared to performance under the 1032 
supervision of a technician (120). Malo and co-workers asked patients 1033 
evaluated for OA to perform PEF with a data-logging PEF device and write 1034 
down the values in a diary. Only 52% of the recorded values and 71% of the 1035 
indicated timing of the measurements in the diary corresponded with the 1036 
stored values in the data-logging device (121).  1037 
The Agency for Healthcare Research and Quality reviewed studies 1038 
evaluating PEF in OA confirmed by specific inhalation challenge. The pooled 1039 
estimate of sensitivity was 63.6 %(95% CI: 43.4 to 79.9%); for specificity , it 1040 
was 77.2 %(95% CI: 66.5 to 85.2%) (122).  1041 
1042 
54 
1.1.2.5. Non-specific bronchial provocation tests 1042 
 1043 
AHR is a hallmark of asthma that can be assessed by performing 1044 
bronchial provocation tests (BPTs) using direct (methacholine, histamine) or 1045 
indirect stimuli (exercise, hypertonic saline, adenosine-monophosphate and 1046 
mannitol) (123). One of the advantages of using indirect stimuli to assess 1047 
non-specific AHR is that all the common stimuli that provoke an asthma 1048 
attack in daily life, such as allergens, cold air, exercise, sulphur dioxide and 1049 
fog, act indirectly to cause airways to narrow (124).  1050 
In asthmatics, responsiveness to indirect BPT is a better reflection of 1051 
indices of airway inflammation, such as sputum eosinophils or ENO, than that 1052 
to direct BPT with methacholine (125). In a study of active firefighters, a BPT 1053 
using mannitol had higher efficiency and Youden index than a BPT using 1054 
methacholine (126). Indirect BPTs are more specific for diagnosis of asthma 1055 
(127-129), although they are less sensitive for identifying AHR in a laboratory 1056 
study population (130). Using a direct BPT for a young, healthy population 1057 
often produces false-positive responses in subjects without asthma 1058 
symptoms (131-134). Exercise-induced bronchoconstriction can be missed in 1059 
direct BPTs, such as with a histamine or methacholine challenge (135, 1060 
136)but it may be better diagnosed using indirect BPTs (137-139). 1061 
A BPT using mannitol has been shown to be well correlated with other 1062 
indirect BPTs; for elite athletes, a PD10 to mannitol had a sensitivity of 96% 1063 
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to diagnose a 10% decline in FEV1 during eucapnic voluntary hyperpnea 1064 
(140). The protocol for performing a BPT using mannitol has been 1065 
standardized and validated, allowing easy comparisons. For most subjects, 1066 
the duration of the test is <20 min. Compared to current wet aerosol tests, 1067 
such as those using methacholine, the equipment used for this test is simple 1068 
to use, inexpensive, and does not require any maintenance and cleaning 1069 
(141). As with all BPTs, only an office spirometer is required.  1070 
For current, widely-used direct tests with methacholine and histamine, 1071 
solutions of appropriate concentrations need to be prepared by hospital 1072 
pharmacies according to the particular protocol. These solutions need to be 1073 
transported to the location where the test is to be performed, and the cold 1074 
chain needs to be maintained; otherwise, the vials cannot be used. In 1075 
comparison, mannitol test kits come ready to use and can be stored at room 1076 
temperature for longer time than methacholine solutions, allowing testing at 1077 
the subjectsʼ workplace (142). 1078 
For patients with OA who were investigated to assess their 1079 
impairment/disability approximately 2 years after their initial diagnosis, we 1080 
found that this test is a better marker of disease activity and can differentiate 1081 
subjects based on disease severity. Further, concomitant assessment of 1082 
airway responsiveness and collecting sputum can be performed at the same 1083 
time (143). 1084 
However, the current standard in the evaluation of OA is to perform an 1085 
indirect test with methacholine or histamine (3). Methacholine chloride, a 1086 
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parasympathomimetic synthetic analog of acetylcholine, stimulates 1087 
muscarinic, postganglionic parasympathetic receptors that cause the 1088 
bronchial smooth muscle cells to contract (144). During the test, doubling 1089 
concentrations of methacholine chloride in isotonic saline are nebulized and 1090 
inhaled by the patient. After each dose step, spirometry is performed. There 1091 
are different protocols for the administration of methacholine which have been 1092 
published as internationally accepted guidelines (138, 145). The test is 1093 
continued until the maximum concentration has been inhaled or a drop in the 1094 
FEV1 of more than 20% from baseline occurs that allows intrapolation of the 1095 
theoretical concentration leading to a fall of 20%, called PC20. Subjects with a 1096 
PC20 of 8 mg/ml or less are considered to have bronchial 1097 
hyperresponsiveness. The results of a PC20 between 8 and 16 mg/ml are 1098 
considered indeterminate, and values greater than or equal to 16 mg/ml are 1099 
considered normal (146).  1100 
It should  be mentioned that non-specific BPTs are not 100% sensitive 1101 
for the diagnosis of OA. As with SPT, non-specific BPTs may be negative 1102 
when subjects have not been exposed for a prolonged period to a sensitizer 1103 
that causes their asthma (147), even in subjects with a positive reaction to a 1104 
specific inhalation challenge (148). Baur and co-workers demonstrated that 1105 
non-specific BPTs cannot reliably differentiate asthma patients from 1106 
occupationally exposed non-asthmatic subjects, or distinguish between OA 1107 
and non-OA (149). Nevertheless, performing a non-specific BPT can help to 1108 
determine the work-relatedness of asthma. It has been shown that a 3.2-fold 1109 
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increase in non-specific AHR has a sensitivity of 48% and a specificity of 64% 1110 
in OA confirmed by SIC (150). Non-specific BPTs may become negative 1111 
some weeks after a patient is no longer exposed to an occupational allergen, 1112 
as shown by Cartier et al. (151), whereas other workers still have non-specific 1113 
AHR years after stopping exposure, as demonstrated in snow-crab workers 1114 
(152) and workers exposed to red cedar wood dust (153). It has been shown 1115 
that maximum improvement in non-specific AHR occurs in the first two years 1116 
after stopping exposure and at a slower rate thereafter (154).  1117 
 1118 
 1119 
1.1.2.6. Specific inhalation challenge 1120 
 1121 
This method has been called the reference standard test for the 1122 
diagnosis of asthma and OA (122). This test is performed on workers who 1123 
have a high probability of immunological OA. There are two methods of 1124 
laboratory SIC: the realistic method and the method that is carried out with 1125 
dust-generating machines. If specific agents cannot be identified or the SIC 1126 
test is inconclusive, patients may undergo workplace challenge testing (155). 1127 
In the “realistic method,” workers perform their duties in the lung 1128 
function laboratory, usually in small ventilated cubicles under regular 1129 
monitoring with spirometry. The work process is simulated as close as 1130 
possible, e.g. a baker with probable OA to wheat flour stirs or mixes flour, 1131 
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while a painter uses the presumed product by painting a piece of wood. It is 1132 
possible to monitor the concentration of isocyanides with an MDI monitor to 1133 
avoid irritant or toxic exposure in the chamber.  1134 
To further standardize the exposure procedure, closed-circuit dust 1135 
generators have been developed (156) that produce dust, aerosols and 1136 
vapours; the concentration of these products in the inhaled air is then 1137 
monitored precisely.  1138 
SIC can help to identify the specific agent by sequentially testing a 1139 
worker who may be exposed to several potential asthma-causing substances 1140 
(157).  1141 
 1142 
 1143 
1.1.2.7. Workplace challenge testing 1144 
 1145 
Sometimes, however, when a specific agent cannot be identified, 1146 
workplace exposures are too complex to simulate, or SICs are not available, 1147 
testing needs to be performed at the workplace. On a control day, spirometry 1148 
is performed while the subject is performing a task that does not causes 1149 
symptoms or away from the workplace. On the day of exposure, the subject 1150 
performs the tasks incriminated as causing asthma (3, 155).  1151 
Although the SIC test is seen as a reference standard, it has several 1152 
limitations. SIC tests are not available in all regions of the world. SIC testing 1153 
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requires specialized facilities and expertise that are expensive and time- 1154 
consuming (3, 158).  1155 
SIC can yield false positive as well as false negative results. False 1156 
positive results may occur in patients with unstable asthma or patients who 1157 
are exposed to irritating levels of a provocation agent (3). False negative 1158 
results may occur if the wrong agent has been tested or if the work 1159 
environment created in the laboratory does not present the same triggers as 1160 
those encountered in the workplace. If patients are on anti-asthmatic 1161 
medications to control their asthma, the medication may influence the test 1162 
results. As with SPT and non-specific AHR, SICs can become negative after a 1163 
certain time away from exposure to the causing agent, although this 1164 
occurrence is low (158, 159). 1165 
Despite its high cost and complexity, SIC should be performed when it 1166 
is available. An accurate diagnosis of immunological OA is crucial: further 1167 
exposure to the causing agent needs to be avoided, with the consequence 1168 
that the worker needs to change his or her profession or workplace to avoid 1169 
further deterioration in the disease and long-term functional impairment (160, 1170 
161). Compensation for OA by workersʼ compensation boards for loss of 1171 
income and compensation for functional impairment averages about $50,000 1172 
CAD$ in Québec,  and  workers with OA generally present at a relatively 1173 
young age, which makes rehabilitation possible and most often fruitful for the 1174 
worker (162).  1175 
 1176 
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 1177 
1.1.3. Management of patients with occupational asthma 1178 
 1179 
The management of WRA is the same as for subjects with non-WRA. 1180 
Asthma control is the goal of medical treatment and may require a “step up” in 1181 
asthma treatment that has already been started (www.ginasthma.org). For 1182 
individuals with immunological OA, full cessation of exposure to the causing 1183 
allergen should be achieved. Harm reduction would mean that the worker 1184 
remains exposed to the causing agent, but at a reduced level of exposure. 1185 
This can be achieved, for example, by reducing the time the worker is 1186 
exposed to the agent, by using personal protective devices such as a face 1187 
mask, or by replacing powdered latex gloves with non-powdered gloves. A 1188 
recent systematic review and meta-analysis, however, indicated, that 1189 
reduction of exposure cannot be routinely recommended as an alternative to 1190 
cessation of exposure: continued reduced exposure was associated with a 1191 
lower likelihood of improvement or recovery and a higher risk of worsening of 1192 
asthma symptoms and non-specific AHR compared with complete cessation 1193 
of exposure (163). Complete cessation could be achieved by relocation within 1194 
the same workplace so that there is no longer exposure to the agent, a 1195 
change in work processes (e.g. replacing the causing agent with a new 1196 
agent), or a change of profession.  1197 
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Individuals with non-immunological OA or WEA may continue to work 1198 
at their workplace. But control of work processes and monitoring of exposure 1199 
levels are needed to ensure that the subject is not exposed to high 1200 
concentrations of airway irritants. In those with WEA, the goal must be to 1201 
achieve asthma control by decreasing asthma triggers in the workplace 1202 
whenever possible and by adding or increasing the dose of anti-inflammatory 1203 
treatment such as inhaled steroids or leukotriene antagonists or by 1204 
considering anti-IgE treatment with omalizumab (www.ginasthma.org). 1205 
Individuals with OA and WEA have been shown to have similar impairment in 1206 
quality of life when evaluated in tertiary-care centres, and to have similar 1207 
socio-economic outcomes when unemployment rates are compared with 1208 
patients with OA (164-166).  1209 
 Given the high prevalence of psychological distress and psychiatric 1210 
disorders in the population of individuals with WRA, patients need to be 1211 
evaluated for these conditions by specialists. Treatment options such as 1212 
psychotherapy or medication should be considered, although so far there are 1213 
no data available about the effects of such a treatment on OA-specific 1214 
outcomes (167).  1215 
1216 
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1.1.3.1. Natural history of OA 1216 
 1217 
Figure 5 shows the natural course of OA based on a review article by 1218 
Malo and Chan-Yeung (168). The steps in disease progression are shown in 1219 
boxes, while the modulating factors are listed below the time axis.  1220 
 1221 
 1222 
Figure 5: Natural history of immunological OA 1223 
 1224 
The interval between onset of exposure and events such as allergic 1225 
sensitization and the development of upper or lower respiratory symptoms is 1226 
called the latency period. In workers exposed to laboratory animals, maximum 1227 
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sensitization occurs in the first two years after the start of exposure to the 1228 
animals (39, 169). The interval is sometimes shorter for OA to LMW agents 1229 
(6). In general, upper respiratory symptoms and conjunctivitis precede lower 1230 
respiratory symptoms in workers exposed to HMW allergens, while this is not 1231 
always the case in workers exposed to LMW allergens (39, 170). However, 1232 
about 10% of workers exposed to HMW or LMW agents may develop 1233 
respiratory symptoms after more than 10 years of exposure to the allergens 1234 
(171). 1235 
 1236 
 1237 
1.1.3.2. Prognostic factors for OA 1238 
 1239 
Complete avoidance of exposure is considered the best standard of 1240 
care for individuals with OA (3, 163, 172). Even when this can be achieved, 1241 
many will continue to have respiratory symptoms and lung function 1242 
impairment. A shorter duration of symptoms and a preserved FEV1 prior to 1243 
cessation of symptoms seems to be a predictor of favourable subsequent 1244 
outcome of OA in workers exposed to red cedar wood dust (53). In a 1245 
systematic review investigating predictors for symptomatic recovery and 1246 
persistent non-specific AHR, Rachiotis et al. reported that despite complete 1247 
avoidance of exposure, about 32% (95% CI 26-38%) have persistent 1248 
symptoms and 73% (95% CI 66-79%) have persistent bronchial 1249 
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hyperresponsiveness (173). In this analysis, higher age was associated with 1250 
a higher risk for persisting respiratory symptoms. There was a trend to a 1251 
higher risk for persisting respiratory symptoms in individuals who had a longer 1252 
duration of symptomatic exposure in their workplace and in those who were 1253 
diagnosed during a study in the workplace (p=0.120 and p=0.052 1254 
respectively). The time interval since the end of exposure, duration of 1255 
employment and classification of the causing allergen as LMW or HMW were 1256 
not associated with symptomatic recovery. In persistent non-specific AHR, 1257 
OA to LMW agents was identified as a significant predictor (173). Descatha 1258 
investigated 229 individuals with immunological OA recruited by occupational 1259 
health departments in France. In multivariate analysis, a longer duration of 1260 
symptoms before diagnosis of OA was positively associated with moderate to 1261 
severe OA when adjusting for several important co-factors (OR = 1.12, 95% 1262 
CI 1.05–1.18, P < 0.001)) (174).  1263 
 Those individuals who become symptom-free and lose their bronchial 1264 
hyperresponsiveness to unspecific stimuli due to complete avoidance of 1265 
exposure and medical treatment should not be re-exposed again, since this 1266 
can still cause asthmatic reactions, as shown by Lemière and co-workers in 1267 
an experimental setting (159, 175).  1268 
1269 
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1.1.3.3. Asthma severity and Asthma control 1269 
 1270 
In the past, overall asthma severity has been defined by incorporating 1271 
different features such as respiratory symptoms, medication requirements, 1272 
and physiologic abnormalities such as lung function, AHR and morbidity (e.g. 1273 
number of asthma exacerbations) (176). GINA (www.ginasthma.org) 1274 
subdivides asthma into four categories by severity, based on the level of 1275 
symptoms, airflow limitation and lung function variability (Table 5). The worst 1276 
feature of these parameters determines the severity classification.  1277 
 1278 
1279 
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 1279 
Intermittent 
Symptoms less than once a week 
Brief exacerbations 
Nocturnal symptoms not more than twice a month 
-­‐ FEV1 or PEF ≥ 80% predicted 
-­‐ PEF or FEV1 variability <20% 
Mild Persistent 
Symptoms more than once a week but less than once a day 
Exacerbations may affect activity and sleep 
Nocturnal symptoms more than twice a month 
-­‐ FEV1 or PEF ≥ 80 % predicted 
-­‐ PEF or FEV1 variability < 20-30 % 
Moderate Persistent 
Symptoms daily 
Exacerbations may affect activity and sleep 
Nocturnal symptoms more than once a week 
Daily use of inhaled short-acting B2-agonist 
-­‐ FEV1 or PEF 60-80 % predicted 
-­‐ PEF or FEV1 variability > 30% 
Severe Persistent 
Symptoms daily 
Frequent exacerbations 
Frequent nocturnal asthma symptoms 
Limitation of physical activities 
-­‐ FEV1 or PEF ≤ 60% predicted 
-­‐ PEF or FEV1 variability > 30% 
Table 5: Classification of asthma severity by clinical features before treatment 1280 
(from the Global Strategy for Asthma Management and Prevention, 2008. 1281 
Copyright Global Initiative for Asthma (GINA), www.ginasthma.org.) 1282 
 1283 
It is important to remember that the classification needs to be carried 1284 
out before starting treatment. Asthma severity involves both the severity of 1285 
the underlying disease and its responsiveness to treatment 1286 
(www.ginasthma.org). For example, a subject may be classified as having 1287 
severe persistent disease at initial presentation. After some weeks of 1288 
successful treatment with anti-inflammatory medication, the subject may be 1289 
classified as having mild persistent disease and, after a period of non- 1290 
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adherence to therapy or the occurrence of new asthma-exacerbating factors, 1291 
may be reclassified as having moderate persistent disease.  1292 
Nowadays, this classification is mainly used for the initial classification 1293 
of asthma patients prior to the start of treatment or inclusion in an asthma 1294 
study, but it is a poor predictor of what medications are needed to achieve 1295 
asthma control. The latest edition of the GINA guidelines 1296 
(www.ginasthma.org) suggests that asthmatics need to be assessed on a 1297 
regular basis to determine the level of control of their asthma (Table 6).  1298 
 1299 
Characteristic Controlled Partly controlled Uncontrolled 
Daytime symptoms None (twice or 
less/week) 
More than 
twice/week 
Limitations of 
activities 
None Any 
Nocturnal 
symptoms/awakening 
None Any 
Need for 
reliever/rescue 
treatment 
None (twice or 
less/week) 
More than 
twice/week 
Lung function (PEF 
or FEV1) 
Normal <80% predicted 
or personal best 
Three or more 
features of partly 
controlled asthma 
present in any 
week 
Exacerbations None One or more/year One in any week 
Table 6: Levels of asthma control 1300 
(from the Global Strategy for Asthma Management and Prevention, 2010. 1301 
Copyright Global Initiative for Asthma (GINA), www.ginasthma.org.) 1302 
 1303 
 1304 
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1.1.3.4. Harm reduction or complete avoidance of exposure 1305 
 1306 
It is recognized that avoidance of asthma triggers (e.g. smoking 1307 
cessation, reducing exposure to second-hand smoke and occupational 1308 
agents or medications known to cause symptoms) needs to be achieved to 1309 
improve asthma control and reduce the need for medication 1310 
(www.ginasthma.org). Removal from exposure to the sensitizing agent is 1311 
therefore usually recommended as the most effective therapeutic approach in 1312 
current guidelines (3, 172). However, this goal can be difficult to achieve, 1313 
since subjects may be unwilling to change their profession if symptoms are 1314 
mild at the beginning, the therapy seems to be effective and they fear losing 1315 
their job, with the consequent loss of income. It has been estimated in several 1316 
European countries and in British Columbia/Canada that about one-third of 1317 
workers remain exposed at the workplace after a diagnosis of OA (177). 1318 
Beach et al. conclude in their systematic review of studies on the 1319 
management of workers with OA that subjects with continued exposure had 1320 
worse outcomes, such as increased respiratory symptoms, airway obstruction 1321 
and non-specific AHR, compared to workers who left exposed workplaces 1322 
(122). Workers who continue to work in their environment without any change 1323 
in exposure seem to have an increase in the severity of their asthma (178), 1324 
an increased FEV1 decline (179) and higher medication use and expenses 1325 
(178, 180). Unfortunately, there is not much evidence to show that asthma 1326 
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anti-inflammatory medication can alter the long-term deterioration of asthma if 1327 
exposure remains unchanged (179, 181).  1328 
Since workers with OA are sometimes unwilling to avoid complete 1329 
exposure in order to keep their jobs, studies have investigated the outcome of 1330 
OA with continued but reduced exposure. Reduced exposure can be 1331 
achieved by changing work processes or substances at the workplace, 1332 
relocating the workplace to a less exposed area or using respiratory 1333 
protective equipment.  1334 
However, respiratory protective equipment should not be regarded as 1335 
the single therapeutic option, especially in patients with severe disease. To 1336 
date, there is no convincing evidence to support the widespread use of 1337 
respiratory protective equipment in workers with OA, as only short-term 1338 
effects have been documented and respiratory protective equipment, which 1339 
can be impractical to use, may therefore not be able to provide complete 1340 
protection (182). 1341 
For health-care workers, harm reduction can be achieved by personal 1342 
avoidance of natural rubber latex-containing protection devices such as 1343 
gloves and masks and distribution of non-powdered low-protein latex gloves 1344 
to co-workers. This strategy has been associated with improvements in 1345 
asthma severity, quality of life scores and bronchial hyperreactivity (183). 1346 
Workers with OA due to platinum salts that have been transferred to other 1347 
workplaces within the production building or outside the building but inside the 1348 
plant saw a similar improvement in their respiratory symptoms and 1349 
70 
sensitization measured by IgE compared to workers who left the plant (184).  1350 
Recent systematic reviews and a meta-analysis have confirmed the finding 1351 
that reduced exposure can lead to an improvement or even resolution of 1352 
symptoms and non-specific AHR compared to workers with continued 1353 
exposure. However, data also show that continued reduced exposure is 1354 
associated with a lower likelihood of improvement and recovery from OA 1355 
symptoms and a higher risk of worsening symptoms and increasing non- 1356 
specific AHR (163, 173, 182). 1357 
Only limited information is available about the effects of harm reduction 1358 
on employment status and income. Burge investigated electronics workers 1359 
with OA to colophony in the UK over a follow-up period of one to four years, 1360 
and reported that only about 35% of those who had left the electronics factory 1361 
were employed at follow-up (185). Adverse socio-economic findings were 1362 
confirmed in health-care workers in Belgium by Vandenplas and co-workers, 1363 
who found the proportion of individuals with a major loss of income to be 1364 
higher among those who ceased exposure to natural rubber latex gloves 1365 
compared to those who markedly reduced exposure to airborne latex at 1366 
follow-up (183).  1367 
The limited evidence and often adverse socio-economic impact on 1368 
individuals with OA who have left their workplace point to the fact that current 1369 
guidelines consider harm reduction to be a reasonable and pragmatic 1370 
approach in those individuals where a complete avoidance of exposure is not 1371 
achievable (3, 172). 1372 
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1.1.3.5. Medical treatment of work-related asthma 1373 
 1374 
The treatment of different forms of WRA is the same as for non-WRA 1375 
and is based on a stepwise approach, with the goal of achieving total asthma 1376 
control according to the GINA guidelines (www.ginasthma.org, Figure 6). For 1377 
the management of upper airway symptoms, evidence-based guidelines for 1378 
management have been developed by the Allergic Rhinitis and its Impact on 1379 
Asthma (ARIA) working group (186).  1380 
The mainstay in asthma treatment is to treat inflammation with steroids 1381 
if short-acting bronchodilators are not sufficient. Inhaled steroids have been 1382 
shown to improve asthma specific quality of life, PEF variability and non- 1383 
specific AHR in subjects with immunological OA who have left their workplace 1384 
(187), but there is limited evidence for the use of other anti-asthmatic drugs 1385 
(3). 1386 
 1387 
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 1388 
Figure 6: Management approach based on control of asthma symptoms  1389 
(from the Global Strategy for Asthma Management and Prevention, 2010. 1390 
Copyright Global Initiative for Asthma (GINA), www.ginasthma.org.) 1391 
 1392 
 1393 
1394 
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1.1.3.6. Immunotherapy 1394 
 1395 
This method involves administering increasing amounts of offending 1396 
allergens to patients with type I allergic disease. The active mechanism is 1397 
through modulation of T-cells and response of B-cells accompanied by 1398 
significant decreases of specific IgE and increases of specific IgG antibodies 1399 
(188). Immunotherapy has been shown to reduce respiratory symptoms, SPT 1400 
reactivity and medication use in health-care workers with OA to natural rubber 1401 
latex (189). Bakers treated with immunotherapy have been shown to have 1402 
fewer respiratory symptoms, decreased sensitization (measured as SPT 1403 
reactivity and specific IgE levels) and less non-specific AHR than subjects 1404 
who received placebo injections (190, 191). The ACCP consensus statement 1405 
on Diagnosis and Management of Work-Related Asthma notes that “…in the 1406 
absence of good control with pharmacotherapy and inability to completely 1407 
avoid the allergen, and where validated extracts are available, 1408 
immunotherapy for occupational allergens could be an effective treatment of 1409 
allergy to and asthma from HMW antigens in work environments.” (3) 1410 
 1411 
 1412 
1413 
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1.1.3.7. Prevention of occupational asthma 1413 
 1414 
Prevention can be classified into three categories: primary, secondary 1415 
and tertiary prevention. 1416 
Primary prevention aims to protect against the development of disease 1417 
and disability by: 1418 
-­‐ identifying workers susceptible to sensitization and avoiding 1419 
their exposure to known sensitizers; 1420 
-­‐ limiting exposure to known respiratory tract irritants in 1421 
general, and especially in subjects with already established 1422 
asthma to prevent the development of WEA; 1423 
-­‐ eliminating known respiratory tract irritants or sensitizers 1424 
from work processes if possible or making an effort to 1425 
contain these work processes as far as possible; 1426 
-­‐ limiting the number of workers exposed to known respiratory 1427 
tract irritants or sensitizers or the duration of exposure of 1428 
each individual to these substances; 1429 
-­‐ providing protective equipment for workers exposed to 1430 
known respiratory tract irritants or sensitizers.  1431 
Secondary prevention aims to diagnose the disease in its earliest 1432 
stages, before symptoms develop. At this stage the disease can be treated 1433 
successfully, its progression slowed or complications limited.  In a project  1434 
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recently carried out in Quebec, Labrecque and co-workers evaluated a 1435 
medical surveillance program that targeted more than 2,000 workers from the 1436 
motor vehicle body manufacturing industry who were exposed to 1437 
diisocyanates. Subjects in the screening group were informed about OA at a 1438 
session and asked to answer a self-descriptive screening questionnaire 1439 
related to symptoms of asthma (Figure 7) and its work-relatedness. The 1440 
questionnaire contained 5 validated questions from the ECRHS questionnaire 1441 
(192) and an additional question (numbers 6) on how respiratory symptoms 1442 
were related to the workplace. If three or more questions were answered 1443 
positively, workers were urged to contact their occupational-health centre for 1444 
further assessment. Compared to controls who were suffering from OA and 1445 
had been referred to the Workersʼ Compensation Board in the usual fashion, 1446 
i.e. without screening questionnaire, by referral from their own physician, 1447 
workers in the screened group had less non-specific AHR at diagnosis of OA 1448 
(193), less impairment as confirmed two years after the diagnosis, and lower 1449 
costs to the CSST (Quebec Workersʼ Compensation Board, CSST) for 1450 
functional impairment. 1451 
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 1452 
Figure 7: Questionnaire used by Labrecque and co-workers to screen for OA 1453 
in diisocyanate-exposed workers 1454 
 1455 
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Tertiary prevention is aimed at limiting medical impairment in subjects 1456 
with established disease by decreasing complications and disability, the 1457 
progression of the disease and by providing help with rehabilitation.  1458 
Liss and Tarlo (194) summarized methods for prevention of OA, as 1459 
shown in Table 7.   1460 
 1461 
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Table 7: Different methods of prevention for OA 1462 
  1463 
1464 
 Target Intervention Example of industry 
Primary prevention    
At the source    
Elimination Natural rubber latex 
(NRL) 
Change to non-NRL 
gloves 
Health care 
Substitution NRL Change to low-protein, 
non-powdered NRL 
gloves 
Health care 
    
Enclosure Detergent enzymes Encapsulation Detergent enzyme 
industry 
 Diisocyanates Robots in enclosed 
areas 
Foam-making plants 
For the worker    
Personal protective 
equipment 
Farm allergens Air supply respirator 
use 
Dairy farmers 
 Diisocyanates Air supply respirator 
use 
Spray painters 
Secondary prevention    
Medical surveillance Complex platinum salts Skin prick tests, 
questionnaire, 
spirometry 
Platinum workers 
 Diisocyanates Questionnaire, 
spirometry 
Foam-making and 
other diisocyanate 
workers 
 Enzymes Skin prick tests, 
questionnaire, 
spirometry 
Detergent enzyme 
industry 
Tertiary prevention    
Removal from further 
exposure 
All with sensitizer-OA Work in a separate 
building from where the 
sensitizer is used 
Any occupation using 
the specific agent 
Marked reduction in 
exposure 
NRL Avoid personal contact, 
and co-workers use 
low-protein low-powder 
NRL gloves 
Health-care workers 
 Farm allergens Air supply respiratory 
use 
Dairy farmers, 
laboratory animal 
workers 
Medical monitoring All with sensitizer-OA 
and possible re-
exposure 
Symptoms, medication 
needs, peak flows, 
spirometry and airway 
responsiveness 
Any occupation using 
the specific agent 
Asthma management All OA patients Environmental control, 
pharmacologic 
management 
 
Immunotherapy NRL-OA Specific 
immunotherapy 
Latex-sensitized 
workers 
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1.2. Social determinants of health 1464 
 1465 
Social factors are strongly associated with health status and mortality. 1466 
For example, people living in the most disadvantaged parts of Glasgow, 1467 
Scotland, were shown to have a 12-year-shorter life expectancy than people 1468 
living in more affluent parts of town (195). The same findings hold true, but on 1469 
a much larger scale, when comparing life expectancy between different 1470 
countries. In 2005, the World Health Organization (WHO) estimated life 1471 
expectancy for both sexes in the Russian Federation to be 64 years, 1472 
compared to 81 years in Sweden or Switzerland (196). Responding to 1473 
increasing concerns about persisting and widening inequities, the WHO set 1474 
up the Commission on Social Determinants of Health in 2005 to provide 1475 
advice on how to narrow the gaps (www.who.int./social_determinants/en). In 1476 
this chapter, I will discuss how various social and economic factors can have 1477 
an impact on health, life expectancy and mortality.  1478 
 1479 
 1480 
1.2.1. Sex and gender 1481 
 1482 
Life expectancy does differ in favour of women in various regions of the 1483 
world, with a mean difference of about 4 years. In the WHO health report, the 1484 
life expectancy of women in Canada is estimated at 82 , compared with 78 for 1485 
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men (196). Two factors may account for this finding. There are theories about 1486 
differences in body functions and physiology that differ between women and 1487 
men, and there are social and behavioural factors that can account for this 1488 
gap (46). 1489 
Women are known to respond to infection, vaccination and trauma with 1490 
increased antibody production and a different pattern of immune response 1491 
than men, and most autoimmune diseases are more prevalent in females 1492 
than in males (45). The incidence of vascular disease is higher in men than in 1493 
women. It has been hypothesized that ovarian sex steroid hormones are 1494 
responsible for the cardiovascular benefits in women, acting on the 1495 
endothelial function of the blood vessels (197).  It has been shown that 1496 
endothelial dysfunction – an early event in atherosclerosis – starts about 10 1497 
years earlier in men than in women (198). Coronary heart disease is less 1498 
common in premenopausal women, but that difference seems to disappear 1499 
after menopause; this is most likely related to reduced levels of female sex 1500 
hormones and an increased level of plasma androgens (199).  1501 
Adolescent and adult females have been shown to suffer more often 1502 
from respiratory allergies, asthma, food allergies and anaphylaxis than males 1503 
(200). The lifetime likelihood of developing asthma is greater in women than 1504 
in men (201). While the prevalence in prepubertal boys is higher than in girls, 1505 
asthma is becoming more prevalent after the age of 20 in the United States, 1506 
and continues to widen until the age at which women enter menopause (201). 1507 
This is paralleled by the finding that patients hospitalized for asthma who are 1508 
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more than 15 years old are more likely to be female, while those who are less 1509 
than 15 years old are more likely to be male (201).  1510 
Females with asthma have been shown to report more respiratory 1511 
symptoms and more impaired quality of life than males, even when the 1512 
analysis is controlled for lung function (202-204). Some of these differences 1513 
may be explained by the fact that females may have a higher prevalence of 1514 
anxiety symptoms, which can further decrease quality of life (203, 205). Other 1515 
reasons, such as more often improper metered-dose inhaler technique and 1516 
reduced inspiratory muscle strength, may further explain this difference (206, 1517 
207). However, women with asthma more often seem to have a primary-care 1518 
physician, are more likely to use peak flow meters regularly and have a 1519 
written asthma action plan, and are more likely to go for regular follow-up 1520 
visits for asthma than men (208-210).   1521 
An analysis of the 1994 Canadian National Population Health Survey 1522 
indicated that females had a lower level of education and more often reported 1523 
being unemployed, employed part-time, or employed in jobs with higher work 1524 
stress, such as jobs with low control, high psychological demands and high 1525 
job insecurity, than males. Females were reported to have lower household 1526 
incomes than males, were less often home-owners, and tended to have lower 1527 
scores of self-perceived control (an index score reflecting their belief that their 1528 
life chances were under their control) than males (211).  1529 
Behavioural factors do play a major role, as shown with cigarette 1530 
smoking: globally, a difference between men and women can be 1531 
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demonstrated in the incidence and mortality of lung cancer. At present, more 1532 
men than women die from lung cancer each year. However, in the developed 1533 
world, the incidence and mortality of lung cancer among women has sharply 1534 
increased while the same parameters decline slowly among men, a finding 1535 
that has been attributed to increased cigarette consumption by females in 1536 
recent years (212). Males seem to have higher rates of alcohol use disorders 1537 
than females (213), and the same is true for illegal substance abuse (214). 1538 
Females tend to have higher rates of suicidal ideation but males have higher 1539 
suicide rates (215). Another reason for the difference in mortality and life 1540 
expectancy could be that men are more likely to work in high-risk manual jobs 1541 
than females, making them prone to more severe occupational injuries and 1542 
diseases. 1543 
Several studies have reported that men are at higher risk for several 1544 
types and severities of work-related injuries in different workplace settings 1545 
than women (216-219). However, these differences are almost entirely 1546 
explained by differences in menʼs and womenʼs involvement in tasks with a 1547 
high risk of injury. Once that difference is taken into account, women may 1548 
even have a higher risk than men for occupational injuries (217, 220). 1549 
Eng and co-workers conducted a telephone interview survey in New 1550 
Zealand to investigate whether men and women working in the same 1551 
occupation were equally exposed to known workplace hazards. Their analysis 1552 
suggests that males are more likely to report exposure to welding fumes, 1553 
herbicides, wood dust, solvents, tools that vibrate, irregular hours and night- 1554 
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shift work than females. By contrast, women are more likely to report 1555 
repetitive tasks, working at high speed, and working in awkward or tiring 1556 
positions than do men (48).  1557 
 1558 
 1559 
1.2.2. Housing and neighbourhood conditions 1560 
 1561 
It is more likely that housing reflects rather than creates socio- 1562 
economic gradients. The neighbourhood we live in depends on our socio- 1563 
economic status (221). Clearly, disease and mortality rates vary across areas, 1564 
as has been demonstrated many times (222); however, less is known about 1565 
whether differences are due to a clustering of individuals with similar risk 1566 
profiles in the neighbourhood, or whether there are additional effects of the 1567 
neighbourhood, over and above individual risk factors (195). Residency in 1568 
deprived areas has been identified as a risk factor for diminished perceived 1569 
general and mental health (223, 224), coronary heart disease (225), violence 1570 
and murder (226, 227) and all-cause mortality (226, 228). The physical 1571 
environment may increase illness: air pollution, measured as total particulate 1572 
concentration and sulphur dioxide levels, has been demonstrated to increase 1573 
mortality (229). This was confirmed in a meta-analysis of studies that 1574 
investigated air pollution and mortality: Schwartz reported that airborne 1575 
particle concentration was a significant risk factor for elevated mortality (230). 1576 
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 Other studies have investigated the effect of poor housing conditions 1577 
on respiratory health. Strachan reported an increased risk of developing 1578 
wheezing and chesty coughs in children living in homes with damp and mould 1579 
exposure in the Edinburgh area (231). Another study found an increased 1580 
prevalence of respiratory symptoms in adults and children living in damp and 1581 
mouldy homes compared to adults and children living in dry dwellings (232). 1582 
Among inner-city children with sensitization to cockroaches, exposure to high 1583 
levels of this allergen at home was associated with increased health-care use 1584 
(233). Results of a subsequent study indicate that housing deterioration and 1585 
instability were associated with increased cockroach allergen concentrations 1586 
in kitchens and bedrooms (234). Further studies have shown a negative effect 1587 
of housing deprivation in childhood on increased mortality in adulthood (235). 1588 
 1589 
 1590 
1.2.3. Immigration status and health of ethnic minorities 1591 
 1592 
There are various reasons why subjects leave their country of usual 1593 
residence and move abroad. Most subjects move to developed countries to 1594 
improve their socio-economic conditions, while others are forced to flee their 1595 
country as refugees (236). Nevertheless, not all migrants leave their country 1596 
because of poverty, nor are these migrants less educated (236). We must be 1597 
cautious about using the term “immigrant” to refer to individuals from various 1598 
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countries who settle in developed countries. These individuals differ in 1599 
reasons for leaving their home country, prior exposure to workplace allergens 1600 
and genetic backgrounds (237).  1601 
These migrants often have better health status when they arrive in their 1602 
new country than the general population of the host country, mainly because 1603 
only migrants in good health complete the strenuous journey and pass 1604 
comprehensive medical screening before gaining entry to the host country 1605 
(238, 239). This may lead to the selection of healthy immigrants, as those 1606 
who are unfit to travel and work abroad are likely not to take such risks or will 1607 
not be allowed to enter the country due to health restrictions.  1608 
Immigrants who come to an industrial country such as Canada are 1609 
leaving communities where there is a relatively high mortality rate from 1610 
infectious diseases as well as maternal causes, and limited access to health 1611 
care, and going to a community with a high prevalence of cardiovascular 1612 
diseases but also better access to health care (240). After years of living in 1613 
the new environment and adapting to the local lifestyle, their level of mortality 1614 
from cardiovascular disease approaches the level for the host population 1615 
(241).  1616 
The distribution of the prevalence of atopy and asthma is not uniform 1617 
throughout the world and seems to be higher in developed and affluent 1618 
countries than in developing and less affluent countries (242-244). Several 1619 
studies have shown that immigrants from Central and South America who 1620 
settle in the United States or Italy often have less sensitization and less 1621 
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history of allergies than the general population of the host country. However, 1622 
these individuals seem to be more vulnerable than immigrants from other 1623 
ethnic backgrounds to developing allergies in the early phases of living in 1624 
their new host country (245-247). Sensitization to allergens and subsequent 1625 
asthma results from the interaction of environmental factors with the genetic 1626 
susceptibility of individuals (248). A history of asthma in the family, viral 1627 
infections in early childhood, prematurity, exposure to outdoor or indoor 1628 
pollutants and allergens at home or in the workplace, as well as living in an 1629 
urban area have been identified as risk factors for the development of asthma 1630 
(248). In a review, Rottem and co-workers suggest that in Western 1631 
industrialized countries, lifestyle and environmental factors facilitate atopy and 1632 
the development of asthma, and that 1) this effect is time-dependent; and 2) it 1633 
especially affects individuals who immigrate in early childhood (under 2 years 1634 
of age), since they are more prone to develop atopic disorders such as 1635 
asthma, hay fever and eczema (244, 249). In Sweden, migration from a low- 1636 
or median-income region of the world has been related to an increased risk of 1637 
asthma medication in children of immigrant families; this risk declines with 1638 
increasing age at immigration (250). In the ECRHS, a vast and important 1639 
study that assesses the prevalence and incidence of atopy and asthma in 1640 
several European countries, participants were divided into three groups 1641 
according to their immigration status: 1. immigrants, defined as individuals 1642 
who immigrated from a country outside Europe or one of the participating 1643 
countries; 2. emigrants, defined as immigrants from another country where 1644 
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the ECRHS took place; and 3. non-immigrants, or the host population in the 1645 
ECRHS participating countries. In this study, the rates of asthma symptoms 1646 
were higher in immigrants and emigrants compared to non-immigrants after 1647 
adjustment for smoking status, age, sex and study area, but atopy and 1648 
bronchial hyperresponsiveness were not more common in immigrants or 1649 
emigrants compared with non-immigrants (251). 1650 
Self-reported health tends to worsen after some time in the host 1651 
country and converge with the self-reported health of the host population 1652 
(238, 252). Self-perceived health among migrants and ethnic minorities may 1653 
even tend to be lower when compared with the majority populations in Europe 1654 
(253). When they arrive in the host country, migrants need to adapt to a new 1655 
physical and socio-economic environment and establish new social contacts. 1656 
They may face discrimination, which has been shown to be associated with 1657 
declining health (254). Furthermore, their past work experience or degrees 1658 
may not be recognized in the host country. The migrantʼs only chance of 1659 
earning money may be to work in an unskilled, poorly paid job. They are at 1660 
risk for precarious employment, and may need to work overtime or in 1661 
workplaces where their rights are not respected (236). A study conducted in 1662 
the Montreal area suggests that immigrants may be particularly vulnerable to 1663 
community unemployment, and that being unemployed is associated with 1664 
adverse outcomes such as psychological distress, obesity and poor self-rated 1665 
health status (255). 1666 
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 In Australia, it has been shown that migrant workers are at higher risk 1667 
for work-related fatalities, especially in the first five years after immigration 1668 
(256). In several countries, immigrantsʼ access to health care may be reduced 1669 
due to political, administrative and cultural reasons (257).  It has been shown 1670 
that immigrants may also have a lack of knowledge about the health-care 1671 
system and may therefore overuse emergency room services (258). 1672 
Furthermore, ethnic minorities are often underrepresented in research studies 1673 
without identifiable justification (259).  1674 
In conclusion, immigrants often present fewer health problems than the 1675 
host population when entering their new country of residence, due to a natural 1676 
and political selection of fit and healthy individuals who are able to undertake 1677 
the often long journey of migration. However, self-reported health can rapidly 1678 
decline when these individuals have to adapt to local conditions, work in 1679 
mainly manual occupations with a higher risk for occupational injuries or 1680 
diseases, and face discrimination. Furthermore, access to health care and 1681 
compensation might be more difficult for these individuals due to cultural or 1682 
language barriers. In the host country, it seems that these individuals are at 1683 
risk for developing asthma and that this risk is highest among those who 1684 
migrate during early childhood.  1685 
 1686 
 1687 
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1.2.4. Social exclusion and social support 1688 
 1689 
Social exclusion can result from unemployment, discrimination, racism 1690 
and stigmatization. At particular risk are subjects with a low income, those 1691 
who are unemployed, belong to an ethnic minority, have just arrived in the 1692 
country as an immigrant and are disabled or have left institutions such as 1693 
psychiatric hospitals, prisons or childrenʼs homes. Social exclusion may 1694 
preclude finding a decent job and housing and participation in social activities 1695 
in the community (260). Being ill can also lead to social exclusion. Subjects 1696 
with HIV or AIDS may be stigmatized or marginalized (261). The longer the 1697 
social exclusion lasts, the more the subject is exposed to the deleterious 1698 
factor of stress and the higher the risk of getting a stress-related illness, as 1699 
discussed above. Illness, increased risk of addiction, divorce and separation 1700 
may form a vicious cycle in subjects who are socially excluded.  1701 
There is good evidence that having social support has a positive effect 1702 
on physical and mental health. Zunzunegui and co-workers have shown that 1703 
individuals living in a Montreal neighbourhood and in the city of Moncton in 1704 
the Province of New Brunswick who reported a high level of social integration 1705 
and a strong network of friends also self-reported better health status (262). 1706 
Social support has been defined by Cobb as “information leading the subject 1707 
to believe that he is cared for and loved, is esteemed and valued and belongs 1708 
to a social network of communication and mutual obligation” (263). Being 1709 
engaged in a good marital relationship has been shown to be negatively 1710 
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associated with depression in males and females (264). However, the 1711 
opposite is also true: very close relationships such as an unhappy marriage 1712 
may have a negative effect on mental health, as indicated by Coyne and 1713 
Downey (265). The effect of marital status has been examined in studies of 1714 
cardiovascular morbidity and mortality. Being married seems to be beneficial 1715 
in terms of cardiovascular morbidity and mortality, mainly for males, whereas 1716 
females seem to benefit more from support by friends or relatives (266). In 1717 
the Whitehall study carried out in the UK, being married was associated with 1718 
better mental health, especially in men, while in women mental health was 1719 
best when support was provided by up to four close friends (266, 267). 1720 
Singles seem to have better health outcomes when compared to those in low- 1721 
quality marriages, as shown in hypertension research studies; therefore, 1722 
being married per se is not universally beneficial and “… rather the 1723 
satisfaction and support associated with such a relationship is important”, as 1724 
noted by Holt-Luntstad and co-workers (268).  Further, it is important to 1725 
consider that having poor health can be a barrier for individuals to maintaining 1726 
or participating in social relationships, as seen with US veterans (269).  1727 
Social support can act on health via two types of mechanisms. Social 1728 
support can have 1. direct effects on health; or 2. buffering effects on 1729 
stressors that lead to ill health (266). An example of the direct effects of social 1730 
support on health is if the subject is encouraged to change health-related 1731 
behaviours, such as stopping smoking or eating healthier food. An example of 1732 
the buffering effects on stressors would be if a woman discusses a potential 1733 
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threat (for example a violent husband) with a supporter who counsels her on 1734 
how to avoid situations and react if she is threatened (266). 1735 
Berkman and Syme conducted a survey in a population sample of 1736 
adults in California and reported that males and females with fewer social ties 1737 
had an increased relative risk for all-cause death during a nine-year follow-up 1738 
period, even after controlling for several co-variables, including socio- 1739 
economic status (270). Absence of social support has been shown to be 1740 
associated with the onset and relapse of depression, as shown by Paykel 1741 
(271). Kawachi and co-workers found a reduced incidence of stroke in 1742 
subjects with strong social networks (272), whereas the effect on myocardial 1743 
infarction was inconsistent (273, 274). It is important to mention that social 1744 
networks mainly made up of family members rather than friends or civic 1745 
engagement may actually increase individualsʼ stress and disease, as such 1746 
support may lead to social isolation and role engulfing, as seen in South 1747 
Asian women living in Canada (275). Furthermore, severe psychosocial 1748 
problems caused by family relationships were shown to be important risk 1749 
factors for the development of angina among men in Israel (276).  1750 
In civil servants living in the UK, emotional support by the closest 1751 
person was associated with better mental health in men and women (277, 1752 
278). In the Netherlands, ten Have and co-workers reported that individuals 1753 
who were already suffering from mental illness and had low self-perceived 1754 
social support were two to three times more likely to use primary or mental 1755 
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health care than those who had high self-perceived positive social support 1756 
(279). 1757 
There is also good evidence to support the association between low 1758 
social support and a poorer prognosis for cardiovascular and some other 1759 
diseases. Social support can have a positive influence on the prognosis of 1760 
disease by helping individuals to deal with stress caused by a disease. Social 1761 
isolation increases the risk of death after myocardial infarction (280, 281). 1762 
Social support may help people dealing with rheumatoid arthritis by limiting 1763 
depressed moods or disability caused by the disease (282). In melanoma- 1764 
cancer patients, social support by a structured psychiatric intervention, 1765 
including group therapy, reduces psychological distress and significant 1766 
immunological changes, leading to a lower recurrence and mortality rate 1767 
(283-285). In a study investigating the effects of social relationships on the 1768 
use of outpatient health services in adults in the US, Kouzis and Eaton 1769 
reported that the combination of high distress measured with the General 1770 
Health Questionnaire and low social support resulted in a fourfold increase of 1771 
health-care utilization (286). 1772 
Social support also plays a role in the length of time individuals are 1773 
away from work on medical leave. In British civil servants who participated in 1774 
the Whitehall study, a high level of negative aspects in a close relationship 1775 
with a person outside work was associated with increased rates of medical 1776 
leaves for psychiatric diseases (287); in the same cohort, similar findings 1777 
applied for sick leave for other conditions (288).  1778 
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As mentioned above, migrants may have problems gaining access to 1779 
the host countryʼs health system and need to establish new social contacts. 1780 
Migration to remote countries often destroys or disrupts established networks 1781 
with social interactions and support, which has been shown to increase the 1782 
risk of unfavourable stress and health behaviour such as smoking and 1783 
prenatal care in women from Puerto Rico moving to the USA (289).  1784 
Importantly, the socio-economic position of the individual seems to be 1785 
associated with self-perceived social support: Larger networks, more frequent 1786 
contact with network members and better quality of support were all 1787 
consistently associated with higher income and higher socio-economic status 1788 
in several investigations (266, 290, 291). 1789 
In this chapter, I have presented the argument that good social support 1790 
is in general beneficial for mental and overall health and is an important 1791 
prognostic factor in how individuals can deal with disease. Poor support is 1792 
associated with increased health-care use and absenteeism. However, we 1793 
should remember that poor health per se can hinder individuals from 1794 
maintaining social contacts and forming new contacts. Research shows that 1795 
social support is in general worse in individuals with lower socio-economic 1796 
status and income; this must therefore be considered an additional negative 1797 
factor leading to worse health in these populations. 1798 
 1799 
 1800 
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1.2.5. Single parenthood 1801 
 1802 
In 2001, Statistics Canada estimated the number of families with a 1803 
father and mother to be 7,249,010, with a median revenue of $61,200 CAD$, 1804 
and the number of single-parent families to be 1,404,260 with a median 1805 
revenue of $28,100 CAD$ (292). The National Council of Welfare in Canada 1806 
estimated that 85% of these single-parent families were headed by the 1807 
mother and that about 90% of these families were living in poverty (293). It 1808 
has been shown that single low-income mothers experience less social 1809 
support, more psychological distress and difficulties in caring for their infants, 1810 
as reported by Armstrong and co-workers (294). Single mothers were shown 1811 
to be more socially isolated, receive less emotional and parental support and 1812 
have more unstable social networks compared to married mothers (295). 1813 
Mothers of single-parent families with low incomes are less likely to believe in 1814 
or seek help than those with higher incomes, as shown by Keller and McDade 1815 
(296).  1816 
1817 
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1.2.6. Social gradient and personal or family income 1817 
 1818 
Poverty has a major impact on health and premature death. The risk 1819 
for poverty may be even higher in ethnic minority groups, guest workers, 1820 
disabled people, refugees and homeless people. Poverty means less access 1821 
to health care, decent housing, education and safe transportation (260). For 1822 
example, in Quebec, Pampalon and co-workers showed that premature death 1823 
rates for different diseases differ when comparing subjects in the most 1824 
materially deprived groups with subjects in the least materially deprived 1825 
groups. Men in the most materially deprived group had a premature mortality 1826 
rate for inferior respiratory tract infection that was 2.38 times higher than men 1827 
in the least materially deprived group (297).  1828 
Another possibility is to compare life expectancy in different 1829 
occupational groups. Saurel-Cubizolles and co-workers compared all-cause 1830 
mortality rates in different occupational groups in France.  After adjusting for 1831 
age, the relative risk of all-cause mortality was higher in lower-status 1832 
occupational groups compared with the reference group, which included 1833 
wealthy professionals and managers. In this study, unskilled male manual 1834 
workers had a relative risk of 2.5 compared to 1.0 for professionals and 1835 
managers (298).  1836 
Having access to a car or occupying oneʼs own home may be 1837 
“surrogate markers” for socio-economic status. Subjects who live in social 1838 
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housing or rented dwellings seem to have higher age-standardized rate ratios 1839 
for premature death compared to subjects who own their home, as do 1840 
subjects who do not have access to a car in their household compared to 1841 
subjects with access to one or more cars (299). In the Almeda Country Study, 1842 
residents of a federally designated poverty area were shown to have a higher 1843 
age-, race- and sex-adjusted mortality rate over a follow-up period of nine 1844 
years compared with residents of non-poverty areas (300).  1845 
 1846 
 1847 
1.2.7. Education and access to retraining schemes 1848 
 1849 
 Education is a very important parameter that can influence health and 1850 
life expectancy. Having a good education helps subjects to get jobs with 1851 
higher salaries and more job control. Subjects with a good educational 1852 
background find jobs more easily after a period of unemployment. Education 1853 
is also important because individuals can judge whether their behaviour is 1854 
harmful for their health or not. Education is a major predictor of smoking 1855 
status. The rate of smoking has been shown to decline with higher education, 1856 
a correlation that seems to have increased in recent times (301). Adolescents 1857 
with a lower socio-economic status have higher rates of marijuana use and 1858 
alcohol risk behaviour than adolescents with a higher socio-economic status 1859 
(302).  1860 
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Education can also influence what subjects choose to eat. Malnutrition 1861 
can contribute to obesity, cardiovascular disease, diabetes, cancer and dental 1862 
caries. In general, a healthy diet that contains vegetables and fruits is more 1863 
common among subjects with a higher education (303).  1864 
 1865 
 1866 
1.2.8. Workplace and job insecurity 1867 
 1868 
Many factors encountered in the workplace may influence an 1869 
individualʼs health. Men with a migratory background most often find jobs in 1870 
sectors such as mining, construction or agriculture, where they are more 1871 
prone to injuries and exposure to potentially toxic substances (236). Workers 1872 
may be exposed to lead (e.g. lead smelting) that can cause hematologic 1873 
abnormalities, neuropathy and nephropathy (304), or asbestos, with an 1874 
increased risk of developing lung cancer or mesothelioma (305, 306). Further, 1875 
there is a tendency for the labour market to be polarized according to 1876 
workersʼ qualifications. There is a demand for workers with high levels of 1877 
education and skills in new high-technology industries, whereas workers 1878 
without advanced education and training may be hired in so-called “Mac-jobs”  1879 
such as those in the service and sales industry (307).  1880 
Work may aggravate pre-existing disease. Psoriasis may worsen when 1881 
the skin is irritated by mechanical, chemical or physical agents. Asthma may 1882 
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be exacerbated when subjects are exposed to airway irritants such as dust, 1883 
fumes or cold air (308).  The workplace may offer easy access to potential 1884 
dangers, as reflected by an increased risk in liver cirrhosis in innkeepers and 1885 
bartenders (309), or suicide due to drug overdoses in medical personnel, 1886 
such as pathologists (310). More recently, the social organization of work, 1887 
management styles and social relationships in the workplace have been 1888 
identified as predictors for health, sick leave and premature mortality (260). It 1889 
has been shown that men and women with a low level of job control do have 1890 
higher risks for coronary heart disease compared to those with a high level of 1891 
job control (311).  1892 
Having a secure job can increase the subjectʼs health, well-being and 1893 
job satisfaction. In a large population study in Denmark consisting of subjects 1894 
aged 20-64 years, those who were unemployed had a significantly increased 1895 
death rate after adjusting for occupation, housing category, geographical 1896 
region and marital status. Specific relative death rates were elevated for all 1897 
causes, but especially for accidents and suicide (312). The increased 1898 
mortality rate was interpreted by the authors as being the result of a selection 1899 
of unhealthy workers who lost their jobs and increased susceptibility 1900 
associated with the psychosocial stress of unemployment (312). 1901 
Subjects who are unemployed or insecurely employed are at increased 1902 
risk for physical disease and premature death (307). Many studies show that 1903 
individualsʼ psychological health can be impaired, leading to a less integrated 1904 
and active life, and that this effect takes place regardless of pre-existing 1905 
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mental illness (313). Support in the workplace by colleagues and supervisors 1906 
has been shown to be associated with less frequent short-duration medical 1907 
leaves in general, and this applies even in individuals with high levels of 1908 
negative aspects in close relationships away from the workplace (266, 287). 1909 
However, psychological distress can go down again when the individual is re- 1910 
employed (307, 314). Increased levels of psychological distress or mental 1911 
illness increase the risk of job loss and impair the personʼs chances of 1912 
subsequent re-employment (315-317). 1913 
The development of psychiatric disease is frequently associated with 1914 
recent job loss. Studies suggest that the decline in psychological well-being is 1915 
greatest in the first 12 months after leaving the workplace and plateaus 1916 
afterwards, suggesting that intervention programs designed to address the 1917 
development of psychiatric disease need to be implemented early for those 1918 
who become unemployed (307, 318-320).  1919 
Work per se has a beneficial effect on health, and the loss of work 1920 
must be considered a highly stressful life event. Being unemployed creates 1921 
heightened vulnerability to other stressful life events (307, 321).The beneficial 1922 
effects of regular work have been summarized by Bartley and co-workers 1923 
(307), as reported in Table 7. 1924 
1925 
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 1925 
Structure of the day 
Self-esteem 
Respect of others 
Stimulates physical and mental activity 
Allows use of personal skills  
Decision latitude 
Interpersonal contact 
Social status 
Table 7: The beneficial effects of regular work 1926 
 1927 
Prolonged job loss is associated with a loss in income if no 1928 
compensation is received, which leads to significant financial strain for 1929 
individuals and their families. Individuals may run up debts to cover expenses 1930 
and care for their family. Meltzer and co-workers have shown that poor job 1931 
security and being in debt were independently associated with depression 1932 
even after controlling for age and sex (322). Jackson and Warr also found a 1933 
strong association in working-class men between household income and 1934 
scores indicating more distress on a common assessment of mental well- 1935 
being, the general health questionnaire (GHQ) (323). In several studies, 1936 
financial hardship was found to be an important intermediary between 1937 
unemployment and psychiatric illness or self-reported health status (324, 1938 
325). Furthermore, longer unemployment increases the risk of getting 1939 
divorced and losing the home (326-328). In Australia, women who were 1940 
currently unemployed described themselves more often as being isolated 1941 
than women engaged in household duties or those who were currently 1942 
employed (329). There is evidence that employment status in workers with 1943 
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long-term medical leave differs according to socio-economic position: the 1944 
employment rate of groups of managers and professionals was about 75%, 1945 
while it was less than 50% in groups of semi- or unskilled workers (330).  1946 
The feeling of job insecurity can cause health status to decline: Ferrie 1947 
and co-workers investigated civil servants in a state department that was sold 1948 
to the private sector. Subjects who reported feeling that their jobs were 1949 
insecure or had lost their jobs had increased minor psychiatric morbidity and 1950 
more health-care visits to their general practitioner than securely employed 1951 
subjects (331). But this does not only apply to the affected workers, as 1952 
demonstrated by Beale and Nethercott, who studied health-care use in 1953 
families of workers who lost their jobs when a factory was closed. Health-care 1954 
resource use had already risen before the factory closing, when management 1955 
announced that production might have to stop, but increased significantly in 1956 
the four years after production stopped and the factory was shut down (332).  1957 
Several studies have indicated that being dissatisfied with the current 1958 
workplace has a negative effect on mental health (333, 334).It has been 1959 
shown that workers who were forced to agree to work in lower-status jobs had 1960 
scores similar to unemployed individuals in the general health questionnaire 1961 
(GHQ) designed to assess psychological well-being (307). Even an 1962 
unintended job interruption despite continuing to receive full salary can lead to 1963 
increased psychological distress, as shown in Italian workers (330, 335).  1964 
As outlined in this chapter, some professional activities can be harmful 1965 
to an individualʼs health if they are associated with risky exposures, especially 1966 
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if individuals are more susceptible due to pre-existing disease. Regular work 1967 
has several beneficial effects, while unemployment may lead to financial 1968 
hardship and loss of socio-economic position, putting people at risk for 1969 
physical or mental illness.  1970 
 1971 
 1972 
1.2.9. Labour union affiliation 1973 
 1974 
A labour union is an organization of workers who band together to 1975 
achieve common goals such as better working conditions, wages and 1976 
benefits. In the United States, the Economic Policy Institute has estimated 1977 
that union membership raises wages by about 20% (336). Unionized workers 1978 
have been shown to receive better health-care coverage and pensions than 1979 
their non-unionized co-workers. In Canada, it has been shown that 70% of 1980 
unionized workers, but only 40% of non-unionized workers, have health-care 1981 
coverage (337). Coverage is even lower for workers in small companies with 1982 
fewer than 20 employees, and for those working part-time or with temporary 1983 
jobs (337). Labour unions try to improve health and safety protection in the 1984 
workplace (338). Some unions even ensure the rights of their most senior 1985 
members to make sure that they remain employed once they get older and 1986 
could be replaced by a younger worker with a lower salary (339). They defend 1987 
their members against unjust firing, offering better job security. When 1988 
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employers decide to cut wages, unions require them to partake in collective 1989 
bargaining with the labour force. In collective bargaining, the union will 1990 
represent the workers for the negotiations. Collective bargaining can also be 1991 
used to advocate for changes in the workersʼ favour (339).  1992 
Grievances are concerns, problems or complaints that workers raise 1993 
with their employer. Labour unions can present a formal means to 1994 
communicate with the employer and institute the grievance process. If a 1995 
worker is punished for the complaint, the union will protect the worker and 1996 
punishment can be handled through the union (339). 1997 
 1998 
 1999 
1.2.10. Stress 2000 
 2001 
According to Hans Selye (340), stress is a physiological response of 2002 
the human body to the challenges of everyday life (which may be called 2003 
“stressors”)(340). It involves the neuroendocrine pathways, which can be 2004 
divided into two systems. The body immediately acts over the sympathetic 2005 
branch of the autonomic nervous system by releasing noradrenaline and 2006 
adrenaline, whereas action via the hypothalamic-pituitary-adrenal axis usually 2007 
takes minutes to hours and releases cortisol and other steroid hormones 2008 
(195). The action of the neuroendocrine pathways will trigger the “fight or 2009 
flight” response by causing the heart rate to rise, mobilizing stored energy, 2010 
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diverting blood to muscles and increasing alertness (260). Living in social 2011 
hardship with financial strain, less social support and having a high-intensity 2012 
job with low job control can produce constant psychosocial stress. As shown 2013 
by Bosma et al., workers in government offices with low control over their 2014 
work environment are at increased risk of future coronary heart disease (341). 2015 
 2016 
 2017 
1.2.11. Substance abuse and addiction 2018 
 2019 
Substance abuse is common among subjects with low socio-economic 2020 
status (342). Consuming substances may be seen as a way to escape 2021 
hardship and stress, particularly among men. This behaviour can lead to 2022 
deprivation when an individualʼs daily routine is controlled by the desire to 2023 
consume and procure the substance. Healthy habits as well as social 2024 
contacts are neglected. Consumption of the substance may have a direct 2025 
impact on the individualʼs health. Alcohol abuse may put the individual at risk 2026 
of injuries and may cause diseases such as liver cirrhosis, while intravenous 2027 
administration of substances increases the risk of acquiring hepatitis or 2028 
human immunodeficiency viruses. Smoking cigarettes is known to be a major 2029 
cause of lung cancer and COPD (343). Adolescent and adult smokers have 2030 
been shown to be at increased risk for the development of asthma (344, 345). 2031 
Asthmatics who smoke are more likely to have poorer asthma control 2032 
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compared with non-smokers, and smoking cigarettes decreases the 2033 
effectiveness of steroid therapy (346). There is a known gradient in the 2034 
prevalence of cigarette smoking by occupational class, with higher rates of 2035 
smoking among single parents, the unemployed and mentally ill individuals, 2036 
as reflected in higher death rates among these smoking populations (347). 2037 
Poor people have been shown to have higher nicotine dependency, to be 2038 
more likely to have a partner who smokes, and to have less money to spend 2039 
for nicotine replacement medication (347). 2040 
 2041 
 2042 
2043 
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1.3. Asthma in the workplace and its association with socio- 2043 
economic factors 2044 
 2045 
1.3.1. The socio-economic and psychological consequences of having 2046 
asthma while in the workforce 2047 
 2048 
Asthma is an extremely common condition among working-age adults. 2049 
The median prevalence of asthma in the working population 20-44 years of 2050 
age in 22 countries in Europe has been estimated to be 4.5% (348), and 2051 
about 5.2% in the 1994 US National Health Interview Survey (NHIS) (349). 2052 
More or less severe exacerbations can reduce the workerʼs productivity and 2053 
lead to more  days off work due to sick leave and finally, work loss. Further, 2054 
asthma is influenced by various environmental stimuli that may be present in 2055 
the workplace, leading to a deterioration of asthma control.  2056 
Several studies have investigated the impact of asthma on work. In the 2057 
US, Collins reported that among individuals with asthma included in the NHIS 2058 
census, 21% reported some limitation of routine activities in their daily life, 2059 
and 22% had at least one hospitalization for asthma per year (350). The rates 2060 
were significantly higher when compared to individuals with hypertension 2061 
(11% reporting activity limitation and 8% hospitalization) (350). In the census, 2062 
work limitation was reported by 7.1% of asthmatics between 18-44 years of 2063 
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age and ranked among the most common medical conditions associated with 2064 
working-age disability (349, 350). 2065 
Sibbald and co-workers reported that young adults working in the UK 2066 
with a current or past history of asthma do have a higher risk of 2067 
unemployment and tend to have more job changes and less recent full-time 2068 
employment than subjects without a history of asthma (351). In a study by 2069 
Blanc et al. of 550 study subjects with a history of labour force participation, 2070 
about 17% reported asthma-attributed work disability, and the prevalence of 2071 
complete work cessation was 7% (352). Yelin and co-workers showed that in 2072 
a follow-up study over almost five years, only 66% of asthmatics were 2073 
continuously employed. Interestingly, the strongest predictors for continuity of 2074 
employment over the follow-up period were demographic and employment 2075 
characteristics, not asthma severity (353).  2076 
In New Zealand, almost half of the asthmatic participants in a study by 2077 
McClellan and co-workers indicated that asthma had affected their working 2078 
activities. About 14% of the asthmatics indicated that the disease was a 2079 
reason for employer discrimination, job dismissal and lack of career 2080 
advancement; 77% of asthmatics had not informed their employers of their 2081 
asthma, which further emphasizes the stigmatizing nature of the disease 2082 
(354).  2083 
In Spain, patients with asthma seen in an outpatient clinic reported a 2084 
mean of over 22 lost work days in the previous six months due to asthma, 2085 
while in Singapore, about 62% reported work or school absences of at least 2086 
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one day, with 21% reporting absences longer than one week due to asthma 2087 
(355, 356). 2088 
While absenteeism represents days/hours missed from work 2089 
attributable to the illness, presenteeism refers to illness/condition-related 2090 
reductions in productivity while the person is at work. It has been shown that 2091 
workers with asthma can see a major decline in self-rated work-effectiveness 2092 
(354, 357, 358) as well as limitations in quality of life and work ability (359).  2093 
Several asthma-triggering or aggravating factors present in a military 2094 
environment can impair work performance in individuals with asthma. In the 2095 
Israeli armed forces, it was shown that soldiers with new-onset asthma were 2096 
more often transferred to a new job when they had more severe asthma than 2097 
soldiers with mild asthma (360). 2098 
A change of job duties, a reduction in salary or a change in job or 2099 
employment status attributed to asthma can be seen as surrogate markers of 2100 
work disability. Using these criteria, Blanc and co-workers reported that 36% 2101 
of outpatients with asthma had had  a work disability due to asthma in the 2102 
previous five years (361).   2103 
The impact of asthma on absenteeism is reflected in indirect disease 2104 
costs, which have important implications for the economy (362). In Canada, 2105 
Krahn and co-workers estimated the costs for asthma out- and inpatient care 2106 
in the year 1990 at between $504 and $648 million CAD$. Their assumption 2107 
for indirect costs ranged from $76 to $98 million CAD$ for lost work outside 2108 
and inside the home, and $21 million CAD$ for workersʼ compensation and 2109 
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disability insurance payments (363). In the US, Birnbaum and co-workers 2110 
estimated the costs of asthma for a major employer. In employees who 2111 
claimed for illness, total costs for claimants with asthma were approximately 3 2112 
times higher than for disability claimants for conditions other than asthma 2113 
(364). In the claimants with asthma, wage-replacement costs for lost work 2114 
days were almost as high as costs for medical care (364).  2115 
 2116 
 2117 
Work factors 2118 
 2119 
Many factors in the working environment affect asthma in a complex 2120 
manner, as reported by Blanc and co-workers (349) and shown in Figure 8.  2121 
2122 
110 
 2122 
 2123 
Figure 8: The working environment can interact with asthma in a complex 2124 
manner 2125 
 2126 
Workplace sensitizers such as LMW or HMW agents that may be 2127 
present in an individualʼs workplace can lead to sensitization. Eventually, the 2128 
workers develop symptoms and overt OA. However, besides substances that 2129 
are known to cause OA, asthma-exacerbating factors such as exposure to 2130 
frequent temperature changes, exposure to vapours, gases, dust and fumes 2131 
may be present in the workplace and lead to a deterioration in asthma control. 2132 
Asthma exacerbations may occur, for example, in a shopkeeper with asthma 2133 
who needs to enter a refrigerated warehouse many times each day, where he 2134 
may be performing work tasks with high physical demands. High physical job 2135 
demands may exceed the respiratory capacity of an asthmatic subject. For 2136 
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example, firefighters face high physical demands, especially when working 2137 
with respiratory protection provided by a self-contained breathing apparatus 2138 
(126). 2139 
The social characteristics of workplace personnel may affect an 2140 
individualʼs ability to maintain employment by controlling the pace and 2141 
schedule of work activities (365). Karasek and co-workers showed in a 2142 
sample of the Swedish male working population that hectic and 2143 
psychologically demanding jobs were associated with coronary heart disease 2144 
symptoms and death. Low decision-making latitude, low intellectual discretion 2145 
and a low personal schedule of freedom at work  were also associated with 2146 
coronary heart disease symptoms or mortality (366). 2147 
In patients with various chronic diseases, those who had greater 2148 
autonomy and flexibility in the workplace were much less likely to stop 2149 
working than those who had less control over their working schedule (349). 2150 
Lack of flexibility may lead to work disability, for example when a worker who 2151 
is having a more “symptomatic” day is not allowed to see a physician for 2152 
medical care or to avoid certain exacerbating exposures in the workplace. 2153 
There is evidence that lower socio-economic status and educational level are 2154 
associated with less job autonomy and flexibility and workplaces at higher risk 2155 
for sensitization to occupational agents (349).  2156 
As mentioned above, the individualʼs impairment in work capacity is 2157 
unique to each job environment. An individual with asthma may be unable to 2158 
work as a wild land firefighter with high physical work demands and airway 2159 
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irritant exposure, but may work as an operator in a call centre, where he or 2160 
she can work in a sitting position without exposure to irritants and be able to 2161 
adapt the work schedule to suit his or her current state of health. Therefore, 2162 
work disability in asthma must be considered multifactorial, as suggested by 2163 
Blanc and co-workers (349) and shown in Figure 9: 2164 
 2165 
 2166 
Figure 9:  Predictive model of work disability among adults with asthma 2167 
 2168 
This theoretical model was tested by the authors in a sample of adult 2169 
asthma patients in the US. Among individuals with any history of labour force 2170 
participation, work factors such as exposure to chemicals or dust, 2171 
temperature changes and physical demands were all associated with partial 2172 
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or complete work disability. In this sample, the strength of association 2173 
between severity of asthma (incorporating symptoms, hospitalization and 2174 
medication use) or general health status measured with the general quality of 2175 
life SF-36 questionnaire was roughly the same (352). In Sweden, Balder and 2176 
co-workers investigated asthmatics with new-onset asthma in the Göteborg 2177 
area. In multivariate analysis, having respiratory symptoms in the workplace 2178 
was significantly associated with asthma-related work disability, while having 2179 
a physically demanding occupation and having exposure to respiratory 2180 
irritants at work showed a borderline association when the model was 2181 
controlled for asthma severity, bronchial hyperresponsiveness to 2182 
methacholine and atopy (357). In the validation study of the Perceived Control 2183 
of Asthma Questionnaire (PCAQ), asthma control status was associated with 2184 
asthma severity, health-care use and work disability (367).  2185 
 2186 
 2187 
Psychological Impact 2188 
 2189 
There is a link between asthma and psychiatric disorders: Anxiety 2190 
disorders (e.g. panic disorder, generalized anxiety disorder and social phobia) 2191 
have been shown to affect 16% to 52% of asthmatics, and mood disorders 2192 
(e.g. depression) have been shown to affect 14-41% of asthmatics (368, 369). 2193 
By comparison, the one-year prevalence rate for depression in the French- 2194 
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speaking population of Quebec has been estimated at 4.6%, and for anxiety 2195 
disorders, 3.9% (370).  2196 
 There is increasing evidence on how emotional factors and 2197 
psychological distress affect airway function in healthy and asthmatic adults. 2198 
Several studies by Ritz and co-workers indicate that respiratory resistance 2199 
measured with forced oscillation technique rises in asthmatic and non- 2200 
asthmatic individuals during laboratory sessions when shown films that are 2201 
known to induce various emotions (anxiety, anger, depression, happiness, 2202 
elation, contentment and neutrality) (371-373), whereas the increased 2203 
resistance mainly affects the expiratory portion of the breathing cycle, 2204 
suggesting that the upper airways contribute to this response (374). These 2205 
reactions seem to be stronger in asthmatics in response to specific stimuli 2206 
with medical slides depicting injuries, mutilation and corpses compared to 2207 
non-asthmatics (375). In asthmatics investigated over three weeks with self- 2208 
assessments of spirometry and mood, an association between negative and, 2209 
to a lesser extent, positive mood states with FEV1 values was reported (372). 2210 
There is, however, a study in which active psychological laboratory tasks 2211 
produced a decrease in airway impedance in asthmatic and non-asthmatic 2212 
participants, while passive response to watching films depicting accidents and 2213 
thoracic surgery procedures did not change respiratory impedance (376).  2214 
 Further data are accumulating to indicate that mood states and 2215 
psychological distress can influence the allergic reaction of the human body 2216 
to an allergen challenge. Liu and co-workers investigated college students 2217 
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with mild asthma during a low-stress phase and during a stress phase during 2218 
final school examination week. The studentsʼ anxiety and depression scores 2219 
were significantly increased during the stress phase compared to the low- 2220 
stress phase. Interestingly, an allergen challenge during the stress phase led 2221 
to significantly increased sputum eosinophils and eosinophil-derived 2222 
neurotoxin levels reflecting increased allergic airway inflammation when these 2223 
markers were obtained after a challenge during the low-stress phase (377). In 2224 
another study investigating asthmatic individuals with bronchial challenge 2225 
tests, Rosenkranz and co-workers performed functional magnetic resonance 2226 
imaging of the anterior cingulated cortex and insula to determine the effect of 2227 
asthma-relevant emotion, compared with neutral stimuli presented during 2228 
measurement of activity in that brain region. Further, they measured several 2229 
inflammation markers in the blood of participants. In multivariate analysis, 2230 
they reported that activation of these brain regions due to emotional stimuli 2231 
accounted for ≥40% of variance in the peripheral inflammation markers, 2232 
suggesting a neural basis for emotion-induced modulation of airway disease 2233 
in asthma (378).  2234 
Lavoie and co-workers investigated 504 outpatients with asthma seen 2235 
in a consecutive manner in a tertiary-care asthma clinic with a brief structured 2236 
psychiatric interview using the Primary Care Evaluation of Mental Disorders 2237 
Questionnaire (Prime-MD). The authors found that 31% met Diagnostic and 2238 
Statistical Manual of Mental Disorders (DSM-IV) diagnostic criteria for one or 2239 
more psychiatric disorders. In the same sample, 20% met criteria for a current 2240 
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mood disorder and 23% met criteria for a current anxiety disorder (379). In 2241 
the ECRHS, Janson and co-workers investigated a sampling of subjects 2242 
between the ages of 22 and 44 using the Hospital Anxiety and Depression 2243 
Scale questionnaire (HADS) (380).  They found a significant correlation 2244 
between anxiety and depression on the one hand and reports of asthma- 2245 
related symptoms, such as attacks of breathlessness after activity and waking 2246 
with attacks of breathlessness, on the other hand. However, there was no 2247 
evidence that patients with diagnosed bronchial asthma had more anxiety and 2248 
depression than those who did not have asthma (380). In Dutch patients, the 2249 
length of hospitalization was significantly correlated with anxiety symptoms, 2250 
as reported by Kaptein (381). Subjects with asthma and comorbid anxiety 2251 
showed marked differences in their asthma self-management knowledge and 2252 
their actual behaviour compared to asthmatics without anxiety, particularly in 2253 
terms of potentially life-saving actions such as medication use and seeking 2254 
help (e.g. calling an ambulance) (382). In the same study, asthmatics 2255 
identified as having a psychiatric disorder were more likely to have poorly 2256 
controlled asthma and higher drop-out rates from asthma management 2257 
programs (382). Goldney and co-workers investigated a representative 2258 
sample of the South Australian population in respect to doctor-diagnosed 2259 
asthma and assessed depression using the Primary Care Evaluation of 2260 
Mental Disorders Questionnaire (PRIME-MD) self-report questionnaire. In this 2261 
sample, major depressive disorders were associated with worse nocturnal 2262 
and waking asthma symptoms, as well as worse asthma-related quality of life 2263 
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(383). Lavoie and co-workers evaluated the prevalence of psychiatric 2264 
disorders in 406 adult asthma patients seen in an asthma outpatient clinic 2265 
using the PRIME-MD brief structured psychiatric interview and found 2266 
evidence of an association between psychiatric disorders and higher asthma 2267 
morbidity, such as worse asthma control and quality of life (384). High job- 2268 
specific stress is common and associated with worse health outcomes in 2269 
patients with several chronic illnesses: job stress is positively associated with 2270 
cardiovascular risk factors (385-387) and non-fatal myocardial infarction 2271 
(388). Subjects with chronic illnesses (e.g. musculoskeletal diseases, cancer) 2272 
but who had greater autonomy and flexibility in the workplace were much less 2273 
likely to stop working (365, 389-391).  2274 
 2275 
 2276 
1.3.2. Socio-economic consequences of work-related asthma 2277 
 2278 
The workplace can trigger or induce asthma. Therefore, individualsʼ 2279 
asthma must be considered work-related if asthma control or symptoms are 2280 
influenced by the workplace. In work-exacerbated asthma, workplace 2281 
exposure leads to a worsening of pre-existing or coincident asthma. If asthma 2282 
is caused by a specific agent encountered only or mainly in the workplace, it 2283 
is called OA.  2284 
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In order to prevent further deterioration of OA, it is essential to remove 2285 
the person from exposure to the offending agent. Individuals with OA have 2286 
worse outcomes, such as increased respiratory symptoms, airway obstruction 2287 
and non-specific AHR, when they remain in their workplace by comparison 2288 
with workers who leave exposed workplaces (122). Lemière and co-workers 2289 
have shown that health-care use such as seeing a physician, visiting the 2290 
emergency room and being hospitalized for asthma were more frequent 2291 
compared to individuals without work-related symptoms (392). However, this 2292 
finding contradicts the results of an earlier study by Liss and coworkers in 2293 
Ontario, in which workers with OA were shown to have a lower rate of 2294 
hospitalizations for asthma than those with asthma not related to the 2295 
workplace (393). 2296 
Workers with OA are more likely to change their workplace compared 2297 
with workers who have asthma that is not worsened at work (394). 2298 
Unfortunately, many studies in various countries have shown a relatively high 2299 
proportion of workers with OA who were not working and who had significant 2300 
loss of income at the time of evaluation (Table 9), as reviewed in a book 2301 
chapter by Vandenplas and DʼAlpaos on the social consequences of WRA 2302 
(395). 2303 
 2304 
2305 
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 2305 
Country Number of 
subjects 
Duration of 
follow-up 
(years) 
Rate of 
unemployment 
(%) 
Loss of 
income (% of 
workers) 
UK (396) 112 Median 1.4 35% Exposed: 44% 
Unexposed: 
74% 
British 
Columbia/Canada 
(180) 
128 Mean: 4.8 41%  
Quebec/Canada 
(397) 
134 Range: 2-5 25%  
UK (398) 87 5 39% 55% 
France (399) 209 Mean: 3.1 34% 46% 
USA (400) 55 Mean: 2.6 69%  
UK (401) 770 Range 1.5-
5.5 
37%  
Belgium (160) 86 Median 3.3 38% 62% 
Norway (402) 496 Range 2-6 49% 51% 
Finland (403) 213 Mean: 10 14%  
Table 8: Impact of OA on major socio-economic outcomes 2306 
 2307 
Workers who avoid exposure to the offending agent suffer from more 2308 
pronounced loss of income compared to those who remain exposed. In the 2309 
UK, Gannon reported that 74% of workers who had changed their jobs 2310 
reported reduced income as opposed to 44% of those who kept their jobs 2311 
(396). In France, Ameille and co-workers reported that 84% of workers who 2312 
left their employers saw a loss of income compared to 19% of those who 2313 
remained exposed (399). In Belgium, 20% of workers who continued to work 2314 
suffered a loss in income, compared to 32% of workers who experienced a 2315 
reduced exposure and 78% of workers who were not exposed any more, as 2316 
reported by Larbanois and co-workers (160). This may be one reason why 2317 
workers choose to continue working without seeking medical advice or 2318 
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choose to remain exposed if a diagnosis has been assigned. Moscato and co- 2319 
workers prospectively studied the clinical and socio-economic outcomes of 2320 
workers with a diagnosis of immunological OA. After one year, the patients 2321 
with more severe asthma had stopped their exposure, probably because their 2322 
asthma was too severe to continue with the exposure. In all the subjects who 2323 
stopped exposure, the severity of asthma declined, as did their monthly 2324 
expenses for asthma medication. Nevertheless, 69% of those who had 2325 
stopped their exposure, compared to 17% of those who remained exposed, 2326 
reported a deterioration in their financial condition. Those who had to stop 2327 
working had a mean decline in annual income of 27% (range 12-50 %) (178). 2328 
Vandenplas and co-workers have shown that complete cessation of exposure 2329 
as well as reduction of exposure to latex can lead to a similar improvement in 2330 
lung function and bronchial hyperresponsiveness, but with fewer socio- 2331 
economic consequences such as work disruption due to OA and loss of 2332 
income in those with reduced exposure (183). 2333 
Studies of workers in the UK, Belgium and Quebec/Canada indicate 2334 
that workers with a work exacerbation of asthma had similar adverse socio- 2335 
economic outcomes to individuals with OA (160, 164, 398).  2336 
As discussed above, gender may be a risk factor for OA and there is 2337 
evidence that women – due to less job security and lower salaries – may 2338 
remain exposed for a longer time even when they are having respiratory 2339 
symptoms and may have more difficulty qualifying for compensation, since 2340 
they are hired in temporary or part-time contracts or work in jobs without 2341 
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workersʼ compensation coverage. In the UK, where a surveillance scheme for 2342 
OA is in place (Surveillance of Work-related and Occupational Respiratory 2343 
Disease (SWORD)), reported medico-legal cases are more common in men 2344 
than in women (401).  Dimich-Ward and co-workers have shown that the 2345 
perception of respiratory symptoms is different in men and women in various 2346 
occupations, such as hospitality workers, radiographers and respiratory 2347 
therapists, and that women are more likely to report shortness of breath while 2348 
men report more phlegm (404). 2349 
In Quebec, when the Workersʼ Compensation Board accepts claims for 2350 
OA, individuals with asthma can receive compensation not only for medical 2351 
expenses but also for loss of income. If a worker who had to leave the 2352 
workplace because of asthma now earns less than he or she was earning in 2353 
the workplace at the time the diagnosis was made, the worker can claim for a 2354 
compensation payment to boost that income back to what he or she was 2355 
earning at the time of diagnosis. The Quebec Workersʼ Compensation 2356 
System provides at the current time income replacement for up to 90% of net 2357 
salary for insurable earnings of up to CAD$ 60,500/year. 2358 
Nevertheless, the proportion of individuals who receive some kind of 2359 
compensation for OA varies significantly in studies conducted in Europe and 2360 
Canada (395). The reported median loss of salary compared to the income 2361 
the individual earned in the causing workplace was 22% and 41% in workers 2362 
in Belgium and France respectively (160, 399).  2363 
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It has been estimated that about one-third of workers in studies 2364 
conducted in the United Kingdom, British Columbia/Canada, France and 2365 
Belgium remain exposed at the workplace after a diagnosis of OA (177). 2366 
Studies show that the loss of income is more pronounced when an individual 2367 
has to leave the workplace even when she/he is hired by another employer 2368 
(399). Many studies, however, indicate that relocation to a workplace without 2369 
exposure can be achieved in fewer than 20% of workers with OA (395). It is 2370 
more difficult to relocate a worker in a small-sized company where job 2371 
opportunities are limited and where the workers are confined to small 2372 
premises, increasing the risk of job change or unemployment (399).  2373 
Effective retraining and re-integration programs, as offered in 2374 
Quebec/Canada and Finland, are considered an important tool for bringing 2375 
down rates of unemployment in individuals with OA (395). 2376 
For health-care workers in Belgium, harm reduction by providing 2377 
personal respiratory equipment or reducing exposure – as discussed above - 2378 
has been shown to have a similar short-term impact on health outcomes with 2379 
less adverse socio-economic impact (183). However, this management 2380 
approach is not considered standard care for patients with OA (3, 172).  2381 
Individuals with OA hired in unskilled jobs or with lower levels of 2382 
education have been shown to be at higher risk of becoming unemployed 2383 
after the diagnosis (160, 396, 399). It seems likely that subjects with lower 2384 
education levels are more limited in their job selection, and it is therefore 2385 
more difficult for them to find a new job without the risk of exposure to the 2386 
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offending agent or to irritating substances. In workers who process Western 2387 
red cedar, Marabini et al. reported that workers with a higher number of 2388 
dependent family members were less likely to be unemployed compared to 2389 
those with smaller families and fewer dependent individuals in the household 2390 
(180).  2391 
 In order to avoid financial hardship, workers with OA who have to take 2392 
care of family members without income are forced to continue to work and to 2393 
be exposed. Younger age has been associated with unemployment in 2394 
France; this is suggested to be the result of poor and limited possibilities for 2395 
re-training in individuals under 40 years of age (399). However, in Belgium 2396 
and British Columbia/Canada, the findings were contrary, with unemployment 2397 
associated with older age (160, 180). While Piirilä and co-workers reported an 2398 
association between asthma severity and employment status, suggesting that 2399 
those with night-time asthma symptoms and increased peak-flow variability 2400 
were more likely to be unemployed (403), most other studies have not shown 2401 
such strong and significant associations (160, 178, 180, 396-399, 405).   2402 
 In a cross-sectional study carried out by Caldeira and co-workers in 2403 
1,922 subjects who were randomly selected from a birth cohort in1978/79 in 2404 
Brazil, individuals 23 to 25 years of age had a prevalence of work- related 2405 
asthma of 4.2%. Work-related asthma was associated with low education 2406 
level after adjusting for gender, smoking, atopy and rhinitis. The adjusted OR 2407 
for work-related asthma in the entire population was 6.82 (95% CI 2.99 to 2408 
15.57) for those individuals with one to eight years of education compared to 2409 
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those with more than 12 years. When analyzing the data only in those with 2410 
hyperresponsiveness to methacholine, the OR was 2.99 (95% CI 1.32 to 2411 
6.76) (406). It is likely that individuals with lower education levels are more 2412 
limited in choosing a profession and therefore are diverted towards lower-paid 2413 
manual working professions with more risk of exposure to asthma-causing 2414 
substances. Their lack of education may have prevented participants from 2415 
being aware of the danger to their health and how to effectively limit 2416 
exposure, for example by using respiratory protection. However, the duration 2417 
of exposure to asthma-causing substances may differ as well. The authors 2418 
did not provide data on exposure duration, and it is likely that individuals with 2419 
one to eight years of education had started to work earlier than individuals 2420 
with more than 12 years of education, who had probably just finished their 2421 
university studies. It is also possible that exposure may be limited during job 2422 
training as respiratory protection is applied or individuals spend more time in 2423 
the classroom than in their workplace.  2424 
 2425 
 2426 
2427 
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1.3.3. Quality of life, psychological distress and psychiatric disease in 2427 
individuals with work-related asthma 2428 
 2429 
1.3.3.1. Impact on quality of life 2430 
 2431 
Once OA is confirmed, subjects should perhaps avoid contact with the 2432 
causing allergen and stop working at their workplace. However, up to 70% of 2433 
subjects with OA experience persistent respiratory symptoms and non- 2434 
specific AHR when evaluated years after cessation of exposure (154). This 2435 
directly influences patientsʼ quality of life, as shown by Malo and co-workers 2436 
in subjects with OA who had been off exposure for more than two years 2437 
(407). In this study, subjects were investigated by using a disease-specific 2438 
QOL questionnaire originally developed by Juniper and co-workers (408). The 2439 
authors found that subjects had significantly reduced quality of life in the four 2440 
domains of activity limitations, asthma symptoms, management of 2441 
environmental triggers and emotional distress (407). Interestingly, quality of 2442 
life of subjects with OA was even more affected than in the control population 2443 
of subjects with asthma not related to the workplace, matched for disease 2444 
severity. Al-Otiaibi evaluated a small group of health-care workers with 2445 
different types of natural rubber latex allergies at a mean interval of 24.4 2446 
months (SD ±11.1 months) post-diagnosis and found only marginally impaired 2447 
disease-specific quality of life, despite the fact that some of the subjects had 2448 
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not changed their workplace. However, most of the subjects avoided wearing 2449 
latex gloves and their co-workers mainly used non-powdered latex gloves 2450 
(409).  2451 
Satisfaction with life and perception of asthma symptoms are related to 2452 
employment status and asthma control, as shown by Piirila and co-workers: 2453 
Those who indicate more impairment in quality of life are more likely to be 2454 
unemployed and have greater PEF variability and a greater need for 2455 
medication to control asthma (403). In a retrospective study, Vandenplas and 2456 
co-workers compared asthma-specific quality of life impairment in health-care 2457 
workers who completely avoided exposure to latex with those who reported 2458 
reduced ongoing exposure. Individuals who reported having reduced ongoing 2459 
exposure tended to have more impairment in QOL than those who were no 2460 
longer exposed to latex, although the difference was not statistically 2461 
significant (183). Henneberger and co-workers have shown that individuals 2462 
with WEA report more impairment of quality of life, measured with the Marksʼ 2463 
asthma quality of life questionnaire, than control subjects whose asthma is 2464 
unrelated to the workplace (166). It has recently been reported that quality of 2465 
life impairment was in the same range for workers with OA and WEA who had 2466 
left their workplace and were evaluated approximately three years after 2467 
diagnosis (164). 2468 
 2469 
 2470 
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1.3.3.2. Psychological distress and Psychiatric disease in individuals 2471 
with work-related asthma 2472 
 2473 
Psychological distress may persist after withdrawal from the 2474 
workplace, as demonstrated by Yacoub and co-workers, who evaluated 2475 
subjects with OA two years after the diagnosis. They found a prevalence of 2476 
35% for anxiety disorders and 22.5% for dysthymia (410). Interestingly, that is 2477 
higher than the rate of 25% for anxiety disorders and 4% for dysthymia found 2478 
in subjects with confirmed non-OA, as shown by Lavoie and co-workers for 2479 
asthma outpatients (384). The difference can be explained in part by the fact 2480 
that Lavoie and co-workers used a standardized psychiatric interview to 2481 
assess psychiatric disorders, while in the study by Yacoub and co-workers, a 2482 
self-report questionnaire was used, which may overestimate the true rate of 2483 
psychiatric illness (410).  2484 
There is an important knowledge gap regarding the prevalence of 2485 
psychological distress and psychiatric disease in the population of patients 2486 
with OA. Currently, the prevalence of these conditions is unknown at the time 2487 
individuals develop asthma-like symptoms in the workplace and at the time a 2488 
diagnosis of OA is made (167). 2489 
 2490 
 2491 
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1.3.4. Possible interactions between socio-economic factors and 2492 
objective measures of asthma 2493 
 2494 
Questionnaires 2495 
 2496 
One of the main obstacles in patient–health care worker 2497 
communication is linguistic differences, especially when the patientʼs native 2498 
language is not the language spoken in the health care system at which 2499 
he/she is consulting (411, 412). Therefore, whenever possible, health care 2500 
providers should try to use questionnaires that are translated and validated in 2501 
the patientʼs native language (413).  2502 
Individuals with illiteracy have never learned or cannot read and write 2503 
in their native language, whereas those with functional illiteracy have reading 2504 
and writing skills that are inadequate to cope with the demands of everyday 2505 
life. The Expert Panel on Health Literacy of the Canadian Public Health 2506 
Association (414) defined health literacy as the ability to access, understand, 2507 
evaluate, and communicate information in such as way so as to promote, 2508 
maintain, and improve health in a variety of settings during the course of life.  2509 
Various questionnaires have been developed to measure health 2510 
literacy and numeracy (415). Although health illiteracy is more prevalent 2511 
among minority groups, such as the poor, ethnic minorities, immigrants, 2512 
elderly, and those with limited education, it is a common problem even in 2513 
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industrialized countries (416). In a study of working age Canadians, 2514 
approximately 55% of the participants had low health literacy by scoring 2515 
below the threshold of skills needed to manage oneʼs health without 2516 
compensatory help (414). Importantly, health illiteracy often coincides with 2517 
asthma in poor urban communities and certain minority groups (415, 416). 2518 
Furthermore, a study conducted in the US showed that physicians commonly 2519 
overestimate literacy levels of patients; this apparently occurs more often with 2520 
minority patients, particularly, African Americans (417).  2521 
 Low health literacy and low numeric skills have been shown to be 2522 
associated with adverse asthma-related quality of life. Apter et al. examined 2523 
individuals with asthma using the Asthma Numeracy Questionnaire and Mini- 2524 
Asthma Quality of Life Questionnaire. They found that low numeracy was 2525 
associated with decreased levels of asthma-specific quality of life (418). 2526 
Mancuso and Rincon studied adults with asthma who were seen in primary 2527 
care practices in New York City. They reported that low health literacy was 2528 
associated with less satisfaction with asthma status, worse results from 2529 
asthma care, and a lower likelihood of participating in asthma management 2530 
programs, even after adjustments were made in a multivariate model for 2531 
asthma and demographic characteristics (419). In their longitudinal follow-up 2532 
study, low health literacy was associated with worse asthma-related quality of 2533 
life, although associations became statistically insignificant after adjustments 2534 
were made to their model (420). 2535 
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The Australian Health Omnibus Survey investigated individuals ≥15 2536 
years of age, and found that those who had inadequate health literacy more 2537 
often reported nighttime awakenings, hospitalizations, and days lost from 2538 
usual daily activities than those with better health literacy (421).  2539 
 One method to overcome health illiteracy might be to offer short, easy 2540 
to administer questionnaires that use pictures rather than words. Ghiassi et 2541 
al. translated a questionnaire to measure daytime sleepiness, the Epworth 2542 
Sleepiness Scale, into a pictorial version for use with those with normal or 2543 
diminished literacy skills. They showed that this new questionnaire provided 2544 
similar results but was rated as more easy to fill than the traditional 2545 
questionnaire (422). 2546 
 2547 
 2548 
Lung function assessments 2549 
 2550 
To perform lung function measurements, an individual must perform 2551 
respiratory maneuvers according to the instructions given by a lung function 2552 
technician. It might be difficult to follow these instructions if they are given in a 2553 
foreign language. To have reliable spirometry results, acceptability and 2554 
reproducibility criteria formulated by the American Thoracic Society must be 2555 
fulfilled (111). Individual spirograms are considered acceptable if they are free 2556 
from artifacts, such as cough or glottis closure during the first second of 2557 
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exhalation, early termination, variable effort, leakage, or obstructed 2558 
mouthpieces. The spirograms must show a good test start and have a 2559 
satisfactory exhalation time. Regarding criteria for reproducibility, the two 2560 
highest FVC and FEV1 values should have measured values within 200 ml of 2561 
each other.  2562 
Lung volumes are gender dependent. Adult males have greater lung 2563 
volumes than females (423). Lung function increases with body size and 2564 
declines at both the high and low extremes of weight (423). Race has also 2565 
been shown to be an important determinant of lung volume (423). Normal 2566 
lung development is characterized by an increase in lung function (expressed 2567 
as FEV1) during childhood and adolescence until peak lung function is 2568 
reached by 18–20 years of age. Subsequently, lung function plateaus before 2569 
it begins to decline due to normal aging (424). Several factors can influence 2570 
the growth and plateau phases or lead to an accelerated decline in lung 2571 
function Figure 10.  2572 
 2573 
132 
 2574 
Figure 10: Theoretical model of how exposures affect lung function 2575 
throughout the life 2576 
(Reprinted with permission of The American Thoracic Society. Copyright © 2577 
2012 American Thoracic Society.) 2578 
 2579 
Therefore, lung function at any one point in time not only reflects the 2580 
health of the individual at that time but also is a result of insults and injuries 2581 
and how the body dealt with exposures in the past.  2582 
Social and environmental factors may influence the development of 2583 
peak lung function and influence its rate of decline. There is evidence that 2584 
children with lower socio-economic status attain lower peak levels of 2585 
pulmonary function in early adulthood, and they experience earlier, faster 2586 
declines compared to children with higher socio-economic status (425). 2587 
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Socio-economic factors such as education level and poverty have been 2588 
shown to explain only a small proportion of the racial differences in lung 2589 
function as suggested by an analysis of data from the Third National Health 2590 
and Nutrition Examination Survey (426). In this same cohort, Van Sickle et al. 2591 
showed that completing high school was associated with improved FEV1 in 2592 
men and women and that there was a significant interaction based on racial 2593 
differences in the effects of completing high school on FEV1 (427). 2594 
 2595 
 2596 
Peak Flow measures 2597 
 2598 
The availability of portable, inexpensive devices allows physicians to 2599 
monitor and record PEF when at and away from work. There are 2600 
physiological diurnal variations in PEF values for most healthy individuals and 2601 
these rhythms are exaggerated in those with asthma. The lowest PEF values 2602 
are usually recorded around the time of waking. Then, there is an 2603 
improvement for 6–8 h, followed by a subsequent decline until going to sleep, 2604 
with a further decline overnight (428). This relationship can be substantially 2605 
altered by shift work. The effects of an intermediate reaction can dampen the 2606 
increase in peak flow rather than causing any decline, and thus renders PEF 2607 
recordings less sensitive for diagnosis of asthma (428).  2608 
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Workers should record their PEF at least four times daily and the 2609 
minimum period of recording should be at least 2 weeks both at and away 2610 
from work to be able to draw any conclusions (428). It is very important to 2611 
instruct the worker on when and how PEF measurements need to be 2612 
performed. This is best demonstrated by personal instructions from a health 2613 
care worker with experience in PEF measurements. Huggins et al. noted that 2614 
after sending written instruction by post, only 56% of patients investigated in a 2615 
specialized occupational lung clinic returned their PEF diary compared to 2616 
85% of those who were personally instructed (429). 2617 
 However, there are some limitations to this method of investigation. 2618 
Records from less compliant workers are more difficult to interpret and 2619 
sensitivity and specificity decline with less frequent readings (430). In a study 2620 
of 12 workers who were investigated for OA with an electronic PEF meter, 2621 
Gannon et al. showed that peak flow readings taken when unsupervised were 2622 
lower and that a learning curve was needed for PEF values to increase in the 2623 
first few days of a recording period (428, 431). Additional evidence suggests 2624 
that electronic PEF meters should be used instead of mechanical PEF meters 2625 
and written diaries. Quirce et al. studied individuals who used electronic PEF 2626 
meters and asked the study participants to record their measured PEF values 2627 
in a diary. They found that only 55% of the PEF records were completely 2628 
accurate in terms of the recorded values and the timing of measurements. 2629 
About 23% of the results were inaccurate either in terms of the recorded 2630 
values or the timing of measurements. The remainder of the recorded 2631 
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readings were fabricated results because no such measurements were stored 2632 
in these electronic devices (432). Similar findings were reported by Malo et al. 2633 
in which only 80% of the requested measurements were either recorded in 2634 
the electronic peak flow monitor memory or in the written diary. Only 52% of 2635 
the recordings corresponded accurately with the stored values, and only 71% 2636 
of the recordings were made within 1 h of the requested time slot for 2637 
measurement. Interestingly, PEF recording compliance was the worst among 2638 
those individuals who were referred for investigations by the Workersʼ 2639 
Compensation Board (121).  2640 
Even when PEF measurements are performed with electronic devices, 2641 
varying treatments, intermittent use of bronchodilatators, or non-compliance 2642 
with treatments can result in variations in PEF recordings that are difficult to 2643 
interpret (428). Individuals who are unable to keep an adequate manually 2644 
transcribed record often fail to produce adequate recordings with an electronic 2645 
device (428). In some workplaces where the use of complete respiratory 2646 
protection is required, it might be difficult to measure peak flow because the 2647 
worker will need to leave his workplace to remove the personal protective 2648 
device and perform measurements. 2649 
2650 
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Exhaled biomarkers 2650 
 2651 
Several factors can influence exhaled biomarker values like ENO. For 2652 
example, relationships exist among ENO values, age, and sex (433). In 2653 
females, ENO is associated with the menstrual cycle and pregnancy (434, 2654 
435). Smoking has been found to acutely and chronically reduce ENO levels 2655 
in adults (433). In addition, upper and lower respiratory tract infections may 2656 
lead to higher ENO levels (436, 437).  2657 
In a clinic study population, Dressler et al. derived predicted values for 2658 
ENO considering smoking status, respiratory tract infections during the last 4 2659 
weeks, allergic rhinitis, height, and sex (438). 2660 
 2661 
 2662 
Specific Inhalation Challenge 2663 
 2664 
SIC is considered to be the gold standard for diagnosis of OA. 2665 
However, if some substances are used in high concentrations during SIC 2666 
determinations, they can provoke irritating reactions and give false-positive 2667 
results (439). In addition, SIC determinations can have false-negative results 2668 
for individuals in whom the wrong substance is tested. Therefore, knowledge 2669 
of work conditions and the ability to report exposures at the workplace can be 2670 
influenced by education and language skills of the individual worker.  2671 
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There are reports of workers with asthma who became sensitized to a 2672 
product that was used in a different factory and not to products used in their 2673 
workplace (440). Thus, proximity to other workplaces and company size can 2674 
be factors that need to be considered when workers are scheduled for SIC 2675 
and in decisions on what substances should be tested.  2676 
Individuals frequently suffer from respiratory symptoms for years 2677 
before they present to a physician or a diagnosis is finally made (397, 441). 2678 
Often, when these individuals are scheduled for specialist investigations they 2679 
are no longer employed at the workplace that caused their problems or have 2680 
been away from work for a prolonged period of time. Several studies have 2681 
shown decline in specific AHR after being removed from exposure for a long 2682 
time (59, 442). Nevertheless, most individuals with OA retain their specific 2683 
bronchial reactivity despite being removed from the causative workplace for a 2684 
long time (175). When these individuals are examined, one also needs to 2685 
consider the changes in NSBH levels or inflammation markers in sputum after 2686 
exposure to the allergen during SIC (443, 444).  2687 
2688 
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1.4. The medico-legal system for workersʼ compensation in 2688 
Quebec 2689 
 2690 
The CSST is entirely funded by employersʼ contributions to insurance 2691 
rates. The amount of the insurance rate is set by the CSST and depends on 2692 
the risk of the workplace, the number of employees and workersʼ salaries.  2693 
In 2007, $1,700 million CAD$ was paid by the CSST in benefits for 2694 
occupational injuries. That includes such costs as the income replacement 2695 
indemnity (IRR) and rehabilitation (medical expenses, expenses for 2696 
rehabilitation, benefits for death) and permanent disability indemnity (DAP). 2697 
$1,062.5 million CAD$ was allocated for the IRR; of that amount, $565.4 2698 
million CAD$ was paid to workers during the period of consolidation and 2699 
rehabilitation and $497.1 million CAD$ in the post-rehabilitation period (445). 2700 
OA is currently among the most frequently compensated occupational 2701 
respiratory diseases in Quebec, after diseases related to exposure to 2702 
asbestos dust, including pleural and bronchial cancers. The number of 2703 
accepted claims for some occupational respiratory diseases in Quebec is 2704 
shown in Figure 11. 2705 
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 2706 
Figure 11: Number of cases of compensated occupational lung diseases in 2707 
the province of Quebec from 1988-2003   2708 
 2709 
 2710 
1.4.1. The claims process  2711 
 2712 
In Quebec, workers who are insured with the CSST through their 2713 
employer are eligible for compensation for OA. There are several possible 2714 
ways of filing  claims for compensation. A worker who suspects that he or she 2715 
suffers from OA can file a claim for compensation at the regional office of the 2716 
CSST. Alternatively, the employer can file a claim for compensation. Also, 2717 
when a link between the health symptoms and the workplace is suspected or 2718 
established, a physician can issue a medical leave certificate and advise the 2719 
worker to go to the regional CSST office to file a claim for compensation. The 2720 
claim is then handled by the central medical department of the CSST. All 2721 
claims for respiratory diseases are sent for evaluation to one of the four 2722 
provincial committees responsible for assessing occupational pulmonary 2723 
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diseases (the comité des maladies pulmonaires professionnelles or CMPP). 2724 
Three respiratory specialists sit on each of these committees. There are two 2725 
committees in Montreal (McGill University and the Université de Montréal), 2726 
one in Quebec City (Université Laval), and one in Sherbrooke (Université de 2727 
Sherbrooke). The committees assess each worker by collecting a structured 2728 
history, performing medical examinations and pulmonary function and 2729 
biological testing. If OA is suspected, the committee refers the claimant for a 2730 
specialist investigation of OA to one of the two centres in Quebec (Hôpital du 2731 
Sacré-Coeur de Montréal and Hôpital Laval) where experienced physicians 2732 
and trained personnel offer specific expertise and where specific inhalation 2733 
challenges can be performed. In order to be accepted by the CSST, OA must 2734 
be confirmed by objective means. The dossier is then re-evaluated by the 2735 
CMPP, at which the results of specific tests are appraised and a suggestion 2736 
for the acceptance or rejection of OA is formulated. That suggestion is then 2737 
reviewed by the chairperson of one of the four medical committees (Comité 2738 
des présidents) and a decision is made to accept or reject the suggestions 2739 
made by the CMPP. Finally, in case of a dispute, the decision of the Comité 2740 
des présidents can be appealed by the claimant or the employer. If this is the 2741 
case, a medico-legal court, the commission des lésions professionnelles 2742 
(CLP), is required to make the final decision that is mandatory for all the 2743 
parties involved. 2744 
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Compensation for accepted claims includes income and the cost of 2745 
rehabilitation, such as expenses for medical treatment and the permanent 2746 
disability indemnity.  2747 
 2748 
 2749 
1.4.2. Income replacement indemnity and rehabilitation 2750 
 2751 
In general, workers whose OA is confirmed by objective means and 2752 
whose  claim is accepted will stop working at their workplace if the offending 2753 
agent cannot be removed. The IRR covers a maximum of 90% of net annual 2754 
income for the previous year. An IRR is usually paid for one to two years, until 2755 
the worker has found a new job, but there is no time limit and it is theoretically 2756 
possible to receive the IRR up to the age of retirement (65). If a worker whose 2757 
claim is accepted is over 55 years of age, he or she is eligible to receive the 2758 
IRR until the age of 65. All costs for diagnostic evaluation or re-evaluation, if 2759 
the condition worsens, as well as medical treatment, are reimbursed by the 2760 
CSST. Rehabilitation costs also include  the cost of counselling to find a new 2761 
job and the cost of retraining (studies to complete another degree and studies 2762 
at vocational schools).  2763 
 2764 
 2765 
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1.4.3. Permanent disability indemnity 2766 
 2767 
Impairment is defined by the WHO as a weakening, damage or 2768 
deterioration of a body function, especially as a result of injury or a 2769 
physiological disorder. A disability is an inability to execute some class of 2770 
movements, or pick up sensory information of some sort, or perform some 2771 
cognitive function, that typical unimpaired humans are able to execute or pick 2772 
up or perform. A handicap is an inability to accomplish something one might 2773 
want to do, that most others around one are able to accomplish 2774 
(http://www.who.int/classifications/icf/en/). 2775 
In the case of OA a loss in FEV1 measured by lung function can be 2776 
considered as impairment. If the loss in FEV1 causes some exercise 2777 
limitation it can be considered a disability. If individuals with loss of FEV1 are 2778 
unable to climb more than one fleet of stairs the individual can be considered 2779 
handicapped due to the loss of lung function. 2780 
In subjects with OA, the rate of improvement in lung function and 2781 
decline in bronchial hyperresponsiveness declines significantly two years 2782 
after exposure has ended (152). In Quebec, all claimants are re-evaluated by 2783 
the CSST two years after the initial assessment in order to determine the 2784 
DAP. The criteria used are: the level of bronchial obstruction, measured as 2785 
the FEV1 in %predicted and the ratio FEV1/FVC in %predicted, the level of 2786 
bronchial responsiveness determined by the concentration that causes a drop 2787 
in FEV1 of 20% (PC20) and the need for medication to treat asthma. 2788 
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Sensitization to the agent, as well as impairment of quality of life, increases 2789 
the percentage of impairment. The evaluation scheme that is currently used is 2790 
shown in Figure 12.  2791 
 2792 
 2793 
Figure 12: Table for calculation of permanent disability indemnity used by the 2794 
“CSST” in Quebec/Canada 2795 
 2796 
Before this scale was used, determination of impairment and disability 2797 
for individuals with asthma was performed according to the method 2798 
suggested by the American Medical Association (AMA), which incorporated 2799 
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information on dyspnoea severity, spirometry (FEV1, FVC and the ratio 2800 
FEV1/FVC), as well as exercise capacity, expressed as maximal oxygen 2801 
consumption during exercise (446). Unlike other occupational respiratory 2802 
diseases, occupational asthma does not typically present with radiological 2803 
changes, and airflow obstruction is variable. The guidelines suggested that 2804 
due to the variability of airflow obstruction, periodic evaluation should be 2805 
considered and the degree of impairment should be determined by recording 2806 
post-exercise spirometry (446). However, the prevalence of post-exercise 2807 
airway obstruction or exercise-induced AHR in individuals with OA is 2808 
unknown, and so these guidelines were considered insufficient and even 2809 
inappropriate for the evaluation of impairment/disability in individuals with OA 2810 
(447). Subsequently, scales incorporating information on spirometry, non- 2811 
specific AHR to BPTs and medication needed to control symptoms of asthma 2812 
were suggested or introduced (447-449). This led to a new scale for the 2813 
evaluation of patients with asthma in the AMAʼs fifth edition of the Guides to 2814 
the Evaluation of Permanent Impairment (450). 2815 
 2816 
 2817 
2818 
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1.4.4. Costs of occupational asthma and effectiveness of the 2818 
compensation system  2819 
 2820 
Leigh and co-workers attempted to estimate the costs of OA in the 2821 
USA. For this analysis, the population-attributable risk for an occupational 2822 
case of asthma was set at 15% and the lower age limit at 20. To calculate 2823 
costs, the authors used the human capital method, which separates costs into 2824 
direct categories, such as medical expenses, as well as indirect categories, 2825 
such as lost earnings and lost home production. The proposed model 2826 
suggested that this PAR leads to costs of USD $1.6 billion and that the major 2827 
contributor to that sum is direct costs (74% direct and 26% indirect costs) 2828 
(451). 2829 
Malo and co-workers evaluated the direct costs of OA in Quebec by 2830 
evaluating a sample of claims that were filed between 1988 and 2002. They 2831 
estimated the median costs of compensation for IRR, DAP and total direct 2832 
costs at $40,700, $7,600 and $ 61,300 respectively. In their study, direct 2833 
costs were higher for older subjects, men, workers exposed to LMW allergens 2834 
and workers with more severe asthma reflected by use of steroids, lung 2835 
function impairment and bronchial hyperresponsiveness (162). In a 2836 
subsequent analysis, using socio-economic factors as predictors of cost for 2837 
compensation, the authors showed that IRR was directly and positively 2838 
related to the length of time for which compensation was received. Again, the 2839 
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IRR was shown to be higher in older, married individuals and those to whom 2840 
early retirement was offered. Older individuals whose claim is accepted are 2841 
eligible to get the IRR until the age of 65. These workers are often earning 2842 
higher salaries due to their seniority and experience in the workplace. 2843 
Individuals with OA to low-molecular-weight agents also had higher IRR 2844 
costs, which were only associated with the duration of compensation but not 2845 
with other socio-economic factors in multivariate analysis (452).  2846 
Although this compensation program is among the most extensive for 2847 
workers affected by OA, it seems that a significant proportion of subjects with 2848 
probable OA do not receive compensation. In the PROPULSE sentinel 2849 
physician-based study by Provencher and co-workers, 121 highly likely cases 2850 
of OA asthma were reported by sentinel physicians during the one-year study 2851 
period in 1992-1993 (453). However, in the 1991-1994 period, only a mean of 2852 
60 cases were compensated for OA, suggesting that a significant proportion 2853 
of subjects with highly probable OA do not submit a claim to the CSST and do 2854 
not receive compensation. To get compensation from the CSST for 2855 
immunological OA, a worker needs to be exposed to a product that is specific 2856 
to the workplace and does not aggravate pre-existing asthma through a non- 2857 
specific (irritant) mechanism, which is considered to be WEA (397). 2858 
Occasionally, workers with WEA may be compensated if they had to be away 2859 
from work due to the unusual presence of ubiquitous allergens (moulds in the 2860 
case of water leaks) or irritants (renovation with dusts at work). The IRR 2861 
allocation is offered for a short interval in these circumstances.  2862 
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It is possible that workers do not file a claim. Some workers may 2863 
change their workplace, stop being exposed, and have fewer symptoms or 2864 
even become asymptomatic; they therefore feel it unnecessary to file a claim, 2865 
whereas others continue to work in order to avoid stigmatization, loss of 2866 
income or diminished personal status.   2867 
Subjects with OA who have left the workplace do have persistent 2868 
sequelae, measured as lung function impairment, bronchial 2869 
hyperresponsiveness, inflammatory cells in the sputum or quality of life, as 2870 
demonstrated by Yacoub and co-workers (410). One reason for this 2871 
unfavourable outcome is that individuals remain exposed to the causal agent 2872 
despite having respiratory symptoms for too long a time. Assigning a 2873 
diagnosis of OA has significant consequences for the worker and the 2874 
compensation system. Therefore, it needs to be precise. Specialized centres 2875 
with experience in the diagnosis and treatment of subjects with OA are 2876 
needed.  Moreover, the wait for referral should be reasonably short. In 2877 
Quebec, once a claim is submitted to the CSST, there is a delay of 2-3 2878 
months for the claimant to be assessed by a CMPP. It has been estimated 2879 
that the medico-legal process for examining claims and making an initial 2880 
decision takes an average of eight months, including the 2-3 monthsʼ interval 2881 
for referral to the CMPP (397).  2882 
The cause of the delay in diagnosing OA was investigated in 2883 
Ontario/Canada by reviewing charts of patients referred to a tertiary asthma 2884 
centre for a diagnosis of WRA. In a sample of 42 patients, it was found that 2885 
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common reasons for a delay in investigation and referral to a specialist centre 2886 
were that the physician did not inquire about workplace association and that 2887 
workers feared losing their job. The mean interval to diagnosis was longer for 2888 
those with a lower level of education: for those with primary education, it was 2889 
7.4 years ± 6.7 years, versus 3.1 years ±1.6 years for those with post- 2890 
secondary education.  Patients whose household income before diagnosis 2891 
was less than $30,000 CAD$ had a mean interval to diagnosis of 6.4 years 2892 
±6.5 years, compared to 2.7 years ±1.8 years for those with a household 2893 
income of $80,000 CAD$ or more (441, 454).  2894 
2895 
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1.5. Measuring health with questionnaires 2895 
 2896 
Measurement is an essential component of scientific research, and 2897 
measurements in the laboratory disciplines present no inherent difficulties. It 2898 
is relatively easy for intervention studies to measure clear endpoints such as 2899 
death. However, there is an increasing awareness of the impact of health and 2900 
health care on the quality of human life. Many interventions in the various 2901 
fields of medicine are directed equally, if not primarily, to improving the quality 2902 
and not the “quantity” of life (455).  2903 
As in the laboratory disciplines, there is need for reliable and valid 2904 
quality of life measures. In the field of psychiatry, it has been shown that 2905 
when unpublished measurement scales are used, studies are more likely to 2906 
report that treatments are effective compared to those in which validated 2907 
instruments are used (456).  2908 
The impact of disease on a patientʼs health and well-being differs 2909 
among individuals. According to Paul Jones, “A patientʼs health-related quality 2910 
of life is the result of a generic disturbance to health common to all patients 2911 
with the disease, modulated by factors that are internal and unique to the 2912 
individual.” (457). Health-related quality of life questionnaires should include 2913 
items that evaluate the physical, psychological, and social domains; in 2914 
general, the items of a questionnaire should be derived from patients rather 2915 
than health care professionals (458). 2916 
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Questionnaires can use open-ended questions for which respondents 2917 
can record what they have to say in their own words. These types of 2918 
questions are often used in the exploratory phases of question design and 2919 
allow researchers to formulate more structured and perhaps more closed- 2920 
ended questions at a later phase. These require qualitative methods for 2921 
coding and analyzing data (459).  2922 
Closed-ended questions are much more common in questionnaires, 2923 
which ask respondents to choose from one or more preselected answers. 2924 
Closed-ended questions are generally faster to answer and data are easier to 2925 
manage and analyze (459). However, there are disadvantages. The 2926 
questions may lead respondents in certain directions and the answers that 2927 
can be chosen may not be the most appropriate for a particular respondent 2928 
because the set of answers is not exhaustive (459).  2929 
A variation in the option to answer closed-ended questions is to 2930 
provide respondents with visual analog scales. The individual is asked to 2931 
mark a line at a spot along a continuum from one extreme to the other that 2932 
best represents his characteristics. The ends of these scales are anchored 2933 
with words that describe the most extreme responses (e.g. “none” and 2934 
“unbearable”). The advantage of these answering options is that individuals 2935 
can create their characteristics on a continuous scale, which has a higher 2936 
sensitivity to detect changes. 2937 
Questionnaires can be administered either by the respondent or by an 2938 
interviewer. Often, questionnaires are self-administered because this option is 2939 
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cheaper and there is no risk of introducing bias in such a way that the 2940 
response might be influenced by the relationship between the interviewer and 2941 
respondent. However, interviews are considered to be the better option if 2942 
long, complicated questions that require explanation or guidance are asked. 2943 
Further, an interviewer can assure that the respondent answers all the 2944 
questions in the questionnaire. 2945 
 2946 
 2947 
Validation and testing  2948 
 2949 
Questionnaires should be assessed for their validity (i.e., accuracy) 2950 
and reproducibility/reliability, which is the same as precision. This is 2951 
analogous to validating laboratory tests. Questionnaires should have face 2952 
validity, which is a subjective judgment that the items in the instrument seem 2953 
to measure the desired characteristics. Validity can be assessed by 2954 
comparing measurements of the questionnaire with a reference or gold 2955 
standard measure. Predictive validity can be assessed by examining the 2956 
correlations of the questionnaire measurements with the future outcomes of 2957 
interest. If the questionnaire is intended to measure change, its 2958 
responsiveness should be examined by using it for patients both before and 2959 
after receiving known effective treatments (459). Reliability, or the degree to 2960 
which an instrument is free from random error, is assessed by evaluating the 2961 
152 
homogeneity of the scaleʼs items at one point in time, whereas test–retest 2962 
reliability assesses the stability of an instrument over time (460).  2963 
 2964 
 2965 
Generic versus disease-specific health measurement scales  2966 
 2967 
Generic instruments are broad-based instruments that can measure 2968 
quality of life with regard to different disease states and conditions, treatment 2969 
interventions, and populations (460). These measures are specifically 2970 
designed to detect differences between individuals and a general population 2971 
(461). One of the most widely used generic health measurement scales is the 2972 
Short Form Health Survey (SF-36) (94). This questionnaire incorporates eight 2973 
domains. Each domain explores a different aspect of health-related quality of 2974 
life: physical functioning; physical role; bodily pain; general health; vitality; 2975 
social functioning, emotional role; and mental health.  2976 
Disease-specific instruments include items that are more relevant to a 2977 
particular condition and have been shown to be more sensitive for assessing 2978 
changes within patients (460-462). When most of the marks are clustered in 2979 
only a few boxes at one extreme, the scores are very close to the top of the 2980 
scale. In population studies that might include many individuals with mild 2981 
forms of disease, this effect can occur and is called a ceiling effect. For 2982 
asthma studies, Puhan reported that general health measures like the SF-36 2983 
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are less influenced by this phenomenon compared to disease-specific 2984 
measures like AQLQ. Thus, SF-36 should be considered a more valid 2985 
measure of HRQL than AQLQ in cross-sectional studies in general 2986 
populations (463).  2987 
Most of the currently available asthma-specific quality of life 2988 
questionnaires were developed in the 1990s. Some of these can be used for 2989 
different age groups, for individuals with asthma or COPD, and one was 2990 
developed specifically for individuals with asthma and concomitant rhinitis 2991 
(Table 9) (460). 2992 
2993 
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 2993 
 AQLQ-Juniper AQLQ-Sydney LWAQ SGRQ QOL-RIQ Rhinasthma 
Country of 
origin 
Canada Australia United Kingdom United Kingdom Netherlands Italy 
Target group Adults with asthma Adults with asthma Adults with 
asthma 
Adults with 
chronic airflow 
obstruction 
Adults with mild to 
moderate chronic 
nonspecific lung 
disease 
Adults with rhinitis 
and/or asthma 
Items 32 20 68 50 55 30 
Domains -Activity limitation 
-Symptoms 
-Emotional functioning 
-Exposure to 
environmental stimuli 
-Breathlessness 
-Concerns 
-Mood 
-Social 
-Social/leisure 
-Sport 
-Holidays 
-Sleep 
-Work & other 
activities 
-Colds 
-Mobility 
-Effects on others 
-Medication 
usage 
-Sex 
-Dysphoric states 
& attitudes 
-Symptoms 
-Activities 
-Impacts 
-Breathing problems 
-Physical problems 
related to chest 
problems 
-Emotions related to 
chest problems 
-Problems with 
general activities 
-Situations that might 
trigger or enhance 
breathing problems 
-Daily & domestic 
activities 
-Social activities, 
relationships & 
sexuality 
-Upper airways 
symptoms 
-Lower airways 
symptoms 
-Respiratory allergy 
impact 
Recall period 2 weeks 4 weeks Current time point Past 12 months, 
past 3 months, 
“these days” 
12 months 2 weeks 
Response 
format 
7-point Likert scale 5-point Likert scale 3-point Likert 
scale, Not 
applicable option 
Mostly binary or 
up to five 
response options 
7-point Likert scale. 
Not applicable option 
5 point Likert scale 
Burden of 
administration 
10-15 min 5 min 15-20 min 10 min Not reported 5-10 min 
Cultural and 
language 
adaptations 
79 languages 4 languages 3 languages 73 languages 2 languages 2 languages 
Table 9: Comparison of different asthma-specific quality of life questionnaires 2994 
 2995 
For this study, we selected AQLQ developed by Juniper et al. The 2996 
English version of this questionnaire was developed in Canada. Malo et al. 2997 
conducted a formal validation study of the French version of this 2998 
questionnaire at the Sacré-Coeur Hospital in Montreal (407). It is the most 2999 
widely used asthma-specific quality of life questionnaire with the most 3000 
available validated translations. This questionnaire was routinely used by our 3001 
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research group in previous studies of individuals with OA, which allowed easy 3002 
comparison with results of prior studies conducted by us and researchers 3003 
worldwide.  3004 
This questionnaire was originally developed at McMaster University in 3005 
Hamilton, Canada in 1991 (408, 464). After generating 152 items from a wide 3006 
range of sources, Juniper et al. reduced it to 32 items. Patients rated the 3007 
importance of each item and those items with the greatest importance were 3008 
selected. The items can be grouped into four domains: activity limitation; 3009 
symptoms; emotional function; and exposure to environmental stimuli. Each 3010 
question is scored from one (extremely severe impairment of quality of life) to 3011 
seven (no impairment). The total score is the mean of the four domain scores. 3012 
AQLQ(S) used in our study and the original questionnaire distinguish 3013 
themselves on one point: in AQLQ(S), five generic activities (strenuous 3014 
exercise, moderate exercise, work-related activities, social activities, and 3015 
sleep) replaced specific activities that could be chosen by the patient in the 3016 
original questionnaire (465).  3017 
Construct validity was investigated and reported by correlating the 3018 
questionnaire scores with lung function test results and generic health- 3019 
specific quality of life questionnaires, such as the Sickness Impact Profile and 3020 
the shortened version of the Rand General Health Survey (408). The 3021 
questionnaireʼs responsiveness was shown by comparing asthmatics with 3022 
stable disease and asthmatics in which asthma had changed. A change in 3023 
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score of around 0.5 has been reported as being the minimal important 3024 
difference for the sub-scores and the total score (466).  3025 
Therefore, we selected the AQLQ(S) questionnaire developed by 3026 
Juniper et al. for the following reasons: 3027 
1. It is the best validated questionnaire currently available to measure 3028 
asthma-specific quality of life; 3029 
2. The French translation has been validated in Quebec;  3030 
3. It is the most widely used asthma-specific quality of life questionnaire 3031 
worldwide; 3032 
4. It has often been used in various studies conducted at our laboratory; 3033 
5. The administration burden is only about 10 min. 3034 
 3035 
 3036 
St. Georges Respiratory Questionnaire (SGRQ) 3037 
 3038 
In our study, we used the symptoms domain of SGRQ only. SGRQ 3039 
was developed in the United Kingdom in 1991 by Jones et al. It was intended 3040 
to be used for adults older than 20 years of age who had chronic airflow 3041 
obstruction (467, 468). The unabridged measure consists of 76 items, and 3042 
each item has an empirically-derived weight (range: 0–100). The scores are 3043 
calculated as the percentage of the summed weights of positive items relative 3044 
to the summed weights of all items for each component, and in total (460). In 3045 
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the symptoms domain, respondents are asked to report the intensity of their 3046 
symptoms during the last 12 months, for which they respond to eight items 3047 
(Figure 13).  3048 
 3049 
 3050 
Figure 13: Symptoms domain of the SGRQ questionnaire 3051 
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Psychiatric diseases 3052 
 3053 
The concept of a syndrome is fundamental to the diagnostic 3054 
classifications used for mental disorders. Without the concept of a syndrome, 3055 
a disorder would be defined by a single symptom or a simple symptom count. 3056 
A syndrome is a special collection of symptoms that cluster in a peculiar 3057 
manner, which is determined by the underlying pathophysiology (469). For 3058 
this, we rely on certain essential or core symptoms that commonly occur in 3059 
individuals with the disease, but rarely occur in those without the disease.  3060 
Some symptoms are diagnostically more important than others. In 3061 
mental disorders, there are rarely any symptoms that are entirely unique only 3062 
to a specific disorder and not to another (469). Diagnostic checklists can be 3063 
used to define psychiatric disorders. Some of these have been developed by 3064 
the World Health Organization in the form of the International Classification of 3065 
Diseases or by the American Psychiatric Association Committee on 3066 
Nomenclature and Statistics in the form of the Diagnostic and Statistical 3067 
Manual: Mental Disorders (DSM).  3068 
Despite the availability of these checklists, there is no universally 3069 
accepted gold standard for diagnosis of mental disorders. As with asthma, 3070 
clinically-based assessment is purportedly a reference standard in psychiatry 3071 
if the clinician has adequate time and resources available for diagnosis (469). 3072 
Longitudinal evaluation performed by Expert Clinicians who utilize All 3073 
available Data (LEAD) approach was proposed by Spitzer (470). In this 3074 
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approach, physicians have to incorporate information on collateral history, 3075 
hospital records, psychological evaluations, and laboratory results to make a 3076 
diagnosis. Semi-structured diagnostic interviews were developed to allow lay 3077 
interviewers to obtain a diagnosis in mental disorders. However, they are 3078 
considered time-consuming and are often not well accepted by patients and 3079 
interviewers (471). 3080 
It is estimated that about one-third of patients in a primary care setting 3081 
suffer from relevant psychiatric disorders, but only a small proportion of these 3082 
are recognized and subsequently receive treatment (472, 473). It has been 3083 
shown that primary care physicians encounter difficulties with accurately 3084 
diagnosing mental disorders in their practices (474, 475).  3085 
 3086 
 3087 
Questionnaires to screen for depression and anxiety 3088 
 3089 
The American College of Psychology Consultants lists 220 3090 
psychologically oriented scales with variable validation and reliability data 3091 
(http://www.mentaltests.com/cms/mentaltests_list). I will only discuss those 3092 
tests that have been previously used in the field of OA and that are available 3093 
at the Sacré-Coeur Hospital.  3094 
 3095 
 3096 
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Hospital Anxiety Depression Scale (HADS) 3097 
 3098 
HADS is a brief, self-administered rating scale of symptoms and 3099 
functioning. Anxiety and depression are assessed as separate components 3100 
(sub-scale HADS-A for anxiety and HADS-D for depression). Each of these 3101 
has seven items that are rated from 0 (no problem) to 3. Thus, a person can 3102 
score between 0 and 21 for either anxiety or depression. The scale used is a 3103 
Likert scale. A cut-off of >8 in the HADS-D and HADS-A sub-scales has been 3104 
suggested to provide an optimal balance between sensitivity and specificity 3105 
(476, 477). A limitation of this scale might be the reverse rating of some items 3106 
along with the random sorting of anxiety and depression questions, which can 3107 
create confusion. This questionnaire has not yet been used in studies that 3108 
investigated patients with OA, but it is one of the most frequently used 3109 
questionnaires in hospital settings in North America.  3110 
 3111 
 3112 
Psychiatric Symptom Index (PSI) 3113 
 3114 
PSI is a shortened version of the Hopkins Symptom Distress Checklist 3115 
that was constructed for use in a survey of stress and coping in 1972 in the 3116 
US (478). It is a 29-item questionnaire elaborated to assess the presence and 3117 
intensity of psychological distress during the 2 weeks preceding evaluation 3118 
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(479). Items are scored using a four-point Likert scale from 0 (never) to 3 3119 
(very often). Total and sub-scale scores (depression, anxiety, anger, and 3120 
cognitive disturbance) are calculated as a percentage of the total possible 3121 
score out of 100. Illfeld at al. considered a score of >20 as clinically significant 3122 
distress for all of the sub-scores (479). This questionnaire has been validated 3123 
using a large urban sample that included a significant subset of minority 3124 
inner-city residents (480). A total score on the PSI of ≥30 indicates a high 3125 
likelihood of major depression diagnosed by a structured psychiatric interview 3126 
(478).  3127 
 3128 
Therefore, for this study, we selected the PSI questionnaire for the following 3129 
reasons: 3130 
1. The administration burden is only about 10 min; 3131 
2. This questionnaire covers domains such as anger-related distress and 3132 
cognitive disturbances in addition to anxiety and depression related distress;  3133 
3. It has been validated with a large cohort that included individuals belonging 3134 
to minority groups;  3135 
4. It has often been used in various studies conducted at our laboratory; 3136 
5. A validated French version of the questionnaire is available. 3137 
 3138 
 3139 
3140 
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Millon Clinical Multiaxial Inventory I-III (MCMI-III) 3140 
 3141 
MCMI-III is a psychological assessment tool intended to provide 3142 
information on psychopathology, including specific disorders outlined in DSM- 3143 
IV. It is a 175-item, true–false inventory with 24 clinical scales designed to 3144 
assess personality disturbances (e.g. avoidant personality) and psychiatric 3145 
syndromes (e.g. anxiety disorders). Scores of <75 are considered to be within 3146 
the normal range, scores of 75–85 identify those with a possible psychiatric 3147 
syndrome, and scores of >85 identify those with a high probability of a 3148 
psychiatric syndrome (481). MCMI was developed and standardized 3149 
specifically with clinical populations (i.e. patients in psychiatric hospitals or 3150 
people with existing mental health problems). It is intended for adults (18 3151 
years and older ) with at least an 8th grade reading level who are currently 3152 
seeking mental health services (481). This questionnaire was used in the only 3153 
study to date at our clinic that investigated psychiatric disease in patients with 3154 
OA (410). 3155 
 3156 
 3157 
The Primary Care Evaluation of Mental Disorders (PRIME-MD) 3158 
 3159 
PRIME-MD is a validated, brief screening instrument that is designed 3160 
to detect some of the most common psychiatric disorders seen in community 3161 
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and medical settings. It assesses four domains of mental disorders that are 3162 
commonly observed in the general population: mood; anxiety; somatoform; 3163 
and alcohol disorders. It consists of a 27-item patient self-report section 3164 
followed by a structured clinical interview, which is used to follow-up on 3165 
patient responses. The structured clinical interview assists the physician in 3166 
either ruling in or ruling out psychiatric disorders and can be completed in 3167 
approximately 8 min. PRIME-MD has been shown to be an acceptable 3168 
surrogate for the reference standard in diagnosis by a structured psychiatric 3169 
interview with a sensitivity of 83%, a specificity of 88%, and an overall 3170 
accuracy of 86% for any mental disorder (482). 3171 
In this study, we selected the PRIME-MD questionnaire that diagnoses 3172 
mental disorders based on the diagnostic criteria from DSM-III-R. This 3173 
questionnaire was used in several ongoing studies at the Sacré-Coeur 3174 
Hospital. Therefore, the team administrating this questionnaire had already 3175 
gained experience with it. The administration time is much shorter, compared 3176 
to MCMI-III. Because other questionnaires on quality of life and socio- 3177 
economic factors were presented to study participants, we wanted to keep the 3178 
total number of questions to a certain limit.  3179 
By comparison, the HADS questionnaire is much shorter. However, it 3180 
only offers two dimensions (anxiety and depression) and, for depression, 3181 
seven of nine DSM criteria are not covered in HADS. Categorical 3182 
questionnaires, such as PRIME-MD, do not allow rating of disease severity. 3183 
This is better accomplished by using a dimensional approach with continuous 3184 
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measures, such as PSI. Using this approach, even “normal” individuals (no 3185 
mental disorder diagnosed with PRIME-MD) may have measureable levels of 3186 
depressive symptomatology. Those diagnosed with depression, for example, 3187 
can have depressive symptomatology and higher levels of anxiety in the PSI 3188 
questionnaire. 3189 
Therefore, for this study, we selected PRIME-MD for the following 3190 
reasons: 3191 
1. The administration burden is relatively short compared to other 3192 
investigational tools; 3193 
2. This instrument was developed for use by non-psychiatrists in a general 3194 
practice setting;  3195 
3. It diagnoses mental disorders based on criteria from DSM-III-R; 3196 
4. It evaluates a broad spectrum of mental disorders (mood, anxiety, 3197 
somatoform, alcohol, and eating); 3198 
5. It has often been used in various studies conducted at our laboratory; 3199 
6. A validated French version of this questionnaire is available. 3200 
3201 
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1.6. Study aims 3201 
 3202 
In this research study, we hoped to identify socio-economic factors that 3203 
can influence the delay in submitting a claim to a medico-legal agency with 3204 
removal from exposure after the onset of asthmatic symptoms. We wanted to 3205 
confirm that this delay is associated with worse respiratory prognosis and 3206 
examine whether the delay generates higher direct costs when combined with 3207 
others. Further, we wanted to examine the association between 3208 
anthropometric, clinical, functional and socio-economic variables, assessed at 3209 
the time of the OA diagnosis and two years later, on quality of life and 3210 
psychological outcomes in patients with OA. We also wanted to determine 3211 
whether quality of life and psychological distress assessed at follow-up were 3212 
associated with higher compensation costs for OA. Finally, we wanted to 3213 
assess the correlation between asthma-specific quality of life and both levels 3214 
of psychological distress and psychiatric disorders assessed by standardized 3215 
tools in patients with OA. Specifically, we examined the correlation between 3216 
general and different subscale scores on the Juniper Asthma Quality of Life 3217 
Questionnaire (AQLQ(S)) on the one hand and, on the other hand, levels of 3218 
psychological distress and rates of psychiatric disorders, and the extent to 3219 
which responses on the emotion subscale of the AQLQ(S) allowed for the 3220 
identification of individuals with significant psychological distress or 3221 
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psychiatric disorders (i.e. patients who met diagnostic criteria for depressive 3222 
and anxiety disorders).  3223 
2. Methods and Results 3224 
 3225 
2.1. Article 1: Factors influencing duration of exposure with 3226 
symptoms and costs of occupational asthma  3227 
 3228 
European Respiratory Journal 2010; 36(4): 728-734. 3229 
 3230 
3231 
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Lʼarticle peut être consulté en suivant le lien suivant: 3231 
http://www.ncbi.nlm.nih.gov/pubmed/20150200 3232 
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Abstract 3275 
 3276 
Objective 3277 
To examine the association between clinical and socioeconomic variables 3278 
and their influence on psychological and cost outcomes in patients with 3279 
occupational asthma (OA). 3280 
 3281 
Methods  3282 
Longitudinal study of 60 subjects who claimed compensation for OA in 3283 
Quebec. Beside clinical markers of asthma, quality of life (QOL), 3284 
psychological distress (PD) measures and an instrument to diagnose mental 3285 
disorders were used. 3286 
 3287 
Results 3288 
QOL and PD parameters had moderate correlations with clinical markers of 3289 
OA. Asthma severity, employment and marital status, income, and the length 3290 
of employment with the employer showed the strongest associations with 3291 
QOL and PD. More impaired QOL was associated with higher direct costs for 3292 
compensation.  3293 
 3294 
 3295 
 3296 
 3297 
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Conclusions 3298 
Impaired QOL and PD are frequent among subjects with OA receiving 3299 
compensation and are associated with clinical markers of OA and 3300 
socioeconomic factors.  3301 
3302 
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Introduction 3302 
Psychiatric disorders such as mood (depressive) and anxiety disorders are 3303 
frequently associated with asthma, and patients with depressive disorders 3304 
have been shown to have worse asthma control, impaired quality of life, and 3305 
tend to use more healthcare than patients without psychiatric comorbidity(1- 3306 
3).  3307 
 Only a handful of studies have attempted to assess quality of life 3308 
impacts and the prevalence of psychological and psychiatric disorders in 3309 
patients with OA as stated in a recent review article(2). One can hypothesize 3310 
that patients with OA would have a more impaired quality of life because of 3311 
being removed from their workplace, resulting in lost income and personal 3312 
status. We have shown that patients with OA have a significantly decreased 3313 
quality of life compared to asthma patients without OA(4).  3314 
In a study assessing participants with OA two years after removal from 3315 
exposure from the causal agent, we reported that 35% of patients with OA 3316 
had anxiety disorders and about 23% had dysthymia (a chronic form of 3317 
depression). We also found that patients with OA had elevated psychological 3318 
distress and moderately impaired disease-specific quality of life(5). However, 3319 
this study only examined psychological morbidity and disease-specific quality 3320 
of life two years post-diagnosis; therefore, we could not examine the risk 3321 
factors that might influence the psychosocial and quality of life outcomes of 3322 
OA. 3323 
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The aim of this study was to examine the association between 3324 
anthropometric, clinical, functional, and socio-economic variables assessed at 3325 
the time of the OA diagnosis and two years thereafter, on quality of life and 3326 
psychological outcomes in patients with OA. We expected that factors such 3327 
as sex, age, the time interval since diagnosis, asthma severity and being 3328 
employed at follow-up would be associated with worse psychological 3329 
outcomes, particularly the prevalence of mood and anxiety disorders. We also 3330 
wanted to determine whether or not quality of life and psychological distress 3331 
assessed at follow-up were associated with higher compensation costs for 3332 
OA. 3333 
3334 
176 
Methods 3334 
The interested reader will find a detailed account of all aspects of the 3335 
methodology used in this study by consulting the supplemental digital content 3336 
section. 3337 
Study design, setting and participants 3338 
This was a cross-sectional study investigating patients who claimed 3339 
compensation for occupational asthma (OA) at the Workersʼ Compensation 3340 
Agency of Quebec (Commission de la santé et sécurité du travail du Québec; 3341 
CSST) in the years 2004 to 2006. Patients who were no longer exposed to 3342 
the offending allergens causing OA for two years or more were evaluated by 3343 
two of the four Quebec CSST medical committees in Montreal (Montreal 3344 
Chest Institute and Hôpital du Sacré-Coeur) for a permanent disability 3345 
indemnity. In Quebec, all patients who claim compensation for OA undergo 3346 
specific inhalation testing to confirm a diagnosis of OA. The methods used for 3347 
specific challenge testing using different work related allergens have been 3348 
described before (6) and this method is considered to be the reference 3349 
standard for the diagnosis of OA (7). Therefore in all of the patients included 3350 
in this study showed a positive response to a specific inhalation test. In this 3351 
study the definition of asthma is therefore based on workplace associated 3352 
respiratory symptoms and a positive result in the specific inhalation test. All 3353 
claimants scheduled for evaluation by the committees were asked to 3354 
participate in this study on a voluntary basis.  3355 
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Patients were assessed on two occasions: when the initial OA 3356 
diagnosis was made and the claim filed with the Workersʼ Compensation 3357 
Board (WCB) (diagnosis), and when the participants were re-evaluated to 3358 
determine compensation for permanent disability approximately two years 3359 
later. Patients underwent the same testing protocol on both occasions, with 3360 
the exception of skin prick testing, which was only performed at diagnosis 3361 
(see details below). Further, questions regarding patientsʼ employment status 3362 
at the time, participation in rehabilitation programs, socio-economic factors as 3363 
well as validated psychological and quality-of-life questionnaires, were added 3364 
to their investigation at the two-year re-evaluation point.  3365 
Patients were assured that the medical committee would not be 3366 
informed of participation or decline of participation in this study nor of the test 3367 
results. They were given compensation for their study participation to cover 3368 
expenses like loss of salary and transportation or parking fees. All study 3369 
participants gave written consent for their participation. The research protocol 3370 
was approved by the Research Ethical Committee of our hospital (CER de 3371 
lʼHôpital Sacré-Coeur, Montreal).  3372 
Measures at diagnosis 3373 
All patients investigated underwent standard spirometry, methacholine 3374 
challenge testing and induced sputum analysis. The type of agent causing 3375 
OA, medication use, smoking status, and data on socio-economic status such 3376 
as income, employment status, and company size were recorded from the 3377 
WCBʼs report (Figure 1). 3378 
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Measures at re-evaluation 3379 
Approximately two years after receiving their initial diagnosis, all patients 3380 
investigated underwent standard spirometry, methacholine challenge testing 3381 
and if patients could produce sputum on induction examination, induced 3382 
sputum analysis (Figure 1). All patients completed a questionnaire on chest 3383 
and upper airway symptoms, medication use, home allergen exposure, and 3384 
smoking status. Patients also completed a questionnaire assessing whether 3385 
they were still exposed to the offending agent, as well as a questionnaire 3386 
assessing socio-economic factors including their employment at time, salary, 3387 
education history, country of origin, number of children and family members 3388 
dependant on the household income, and the nature of their participation in 3389 
social rehabilitation programs offered by the WCB (e.g., full or part-time 3390 
participation in job education, use of the employment agency, etc.). In 3391 
addition, participants completed the validated French versions of the following 3392 
questionnaires:  3393 
Asthma Quality of Life Questionnaire (AQLQ(S)) 3394 
The standardized version of the AQLQ(S) includes 32 items and evaluates 3395 
asthma quality of life across four life domains that may be negatively affected 3396 
by asthma. The life domains include 1) asthma symptoms 2) activity 3397 
limitations 3) emotional function and 4) exposure to environmental stimuli. 3398 
Every question is scored from one (extremely severe impairment of quality of 3399 
life) to seven (no impairment at all) and the total score is the mean of the four 3400 
scores (8). 3401 
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St-Georges Respiratory Questionnaire (SGRQ) 3402 
For this study we only used the section on respiratory symptoms from the St- 3403 
Georges Respiratory Questionnaire which includes eight questions and the 3404 
total score represents the sum of these elements. The total score ranges from 3405 
0 to 100 and a higher score indicates a worse HRQoL (9).  3406 
Psychiatric Symptom Index (PSI) 3407 
The PSI is a 29-item questionnaire elaborated to assess the presence and 3408 
intensity of psychological distress in the two weeks preceding the evaluation 3409 
(10). Items are scored using a four-point scale from 0 (never) to 3 (very 3410 
often). Total scores and subscale scores (depression, anxiety, anger and 3411 
cognitive disturbance) are calculated as a percentage of the total possible 3412 
score out of 100. Scores of >25 are considered to indicate clinically significant 3413 
distress (10).   3414 
Primary Care Evaluation of Mental Disorders (Prime-MD)  3415 
The PRIME-MD is a validated screening instrument designed to detect some 3416 
of the most common Diagnostic and Statistical Manual of Mental Disorders 3417 
(DSM) disorders seen in community and medical settings (11). It consists of a 3418 
27-item patient self-report section followed by a structured clinical interview 3419 
that is used to follow-up patient responses. The PRIME-MD evaluates 5 3420 
groups of mental disorders (mood, anxiety, somatoform, alcohol, eating), and 3421 
items were developed on the basis of criteria from the DSM-3rd edition 3422 
revised (DSM-III-R) (12) It has demonstrated very good sensitivity (83%) for 3423 
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any psychiatric diagnosis and excellent specificity (88%) across diagnostic 3424 
modules (11). 3425 
Spirometry and Methacholine Provocation Testing 3426 
All patients underwent standard spirometry according to ATS guidelines(13), 3427 
using the reference values derived by Knudson(14). Methacholine challenge 3428 
testing was performed according to a previously published protocol(15). 3429 
Normal responsiveness was set at a concentration of methacholine causing a 3430 
20% fall (PC20) in FEV1 of greater than 16 mg*mL-1(16).  3431 
Allergy Testing 3432 
Skin prick tests were performed at diagnosis of OA to assess atopic status 3433 
according to the method described by Pepys(17). Atopy was defined as 3434 
having at least one positive result to an aeroallergen.  3435 
Induced Sputum Analysis 3436 
Patients underwent sputum induction by inhaling increasing concentrations 3437 
(3%, 4%, and 5%) of hypertonic saline at diagnosis and at re-evaluation(18). 3438 
The samples were processed according to a previously published 3439 
protocol(19).  3440 
Compound Asthma Severity Score 3441 
Asthma severity was assessed at diagnosis and at re-evaluation. The asthma 3442 
severity at diagnosis, at re-evaluation and the proportion of permanent 3443 
disability that was allocated were calculated according to the Quebec 3444 
Workersʼ Compensation Board Scale for OA: 0% low severity, 100% 3445 
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maximum severity(20). This scale incorporates three factors in the same way 3446 
as the one proposed by the American Medical Association(21): level of 3447 
bronchial calibre, degree of bronchial responsiveness and need for 3448 
medication to control asthma(22). 3449 
Direct Costs of OA 3450 
We consulted the patientsʼ files at the Québec WCB to determine the costs of 3451 
compensation for OA at the time of the re-evaluation. We reported the 3452 
compensation for loss of income (CLI) and functional impairment (CFI) in this 3453 
study. CLI corresponds mainly to compensation for lost wages during the 3454 
rehabilitation period (up to two years) after the worker is removed from the 3455 
workplace. CFI is allocated at the time of re-evaluation by the WCB, about 3456 
two years after confirmation of the initial diagnosis and subsequent removal 3457 
from the workplace, and is calculated according to the WCB scale for OA.     3458 
Statistical analysis 3459 
Continuous data is reported as mean ±standard deviation or median 3460 
and 25 and 75 percentiles. Proportions were compared by using Chi–Square 3461 
or Fisherʼs exact test if the expected cell count was <5. Continuous variables 3462 
were compared by using the Mann-Whitney U test. We calculated 3463 
Spearmanʼs rho for correlation analysis between two continuous variables, 3464 
and we conducted point-biserial correlations between continuous and 3465 
categorical variables, but we did not correct the p-values for multiplicity. Prior 3466 
to performing linear regression, we performed logarithmic transformation and 3467 
then, applied the second power of the dependent variables AQLQ(S) and the 3468 
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PSI total scores. Presence of psychiatric mood and anxiety disorders was 3469 
assess by the PRIME-MD and coded as a dichotomous variable (yes, no). 3470 
Two models were fitted for each dependant variable. First, an a-priori 3471 
model which included factors set in our hypotheses as likely associated with 3472 
psychological outcomes (AQLQ(S), SGRQ and PSI): sex (male vs female), 3473 
age at re-evaluation, time intervals since diagnosis, the asthma severity 3474 
composite score at re-evaluation and the current employment status (working 3475 
vs. not working). Second, a full model that we have named “a posterior” which 3476 
included all significant covariates identified in the a priori model in whom the 3477 
coefficients had a p-value of <0.2 and new socioeconomic covariates 3478 
gathered at the time of diagnosis as well as at the time of re-evaluation. 3479 
Linear regression was used for continuous dependant variables and logistic 3480 
regression for the presence of mood and anxiety disorders according to the 3481 
PRIME-MD. For all data analyses, we used the statistical software package 3482 
SPSS V.16 (SPSS Inc., Chicago, USA). We considered a p-value of <0.05 as 3483 
significant. 3484 
3485 
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Results 3485 
Seventy-three subjects were eligible to participate as their claims were 3486 
reviewed by the two committees in Montreal for a permanent disability 3487 
indemnity during the studyʼs recruitment period. Out of these eligible 3488 
individuals, we were unable to contact five subjects and eight subjects 3489 
refused to participate, yielding a final sample of 60 subjects and a 3490 
participation rate of 82%. Participants did not differ from non-participants with 3491 
respect to sex, age at diagnosis, atopy, smoking status, lung function, hyper- 3492 
reactivity to methacholine, proportion of subjects with OA caused by low 3493 
molecular weight agents, and the number of years at the workplace with 3494 
symptoms (see results in the supplemental digital content section of this 3495 
journal).  3496 
Characteristics of the study sample at the time of their initial diagnosis 3497 
and at re-evaluation can be seen in Table 1. Fifty-five percent of participants 3498 
were working at the time of re-evaluation, 20% were retired, 20% were 3499 
unemployed and 5% were currently on re-training for another job. Thirty-one 3500 
percent reported their overall health status as being fair or poor.  3501 
Disease-specific quality of life, psychological distress, and the 3502 
frequency of psychiatric (mood and anxiety) disorders assessed at the re- 3503 
evaluation are shown in Table 2. Disease-specific quality of life measured 3504 
with the AQLQ(S) was moderately impaired and participants had a score in 3505 
the medium range of the SGRQ symptom subscale. Forty-seven percent of 3506 
the participants had a total score of ≥25 on the PSI, indicating a clinically 3507 
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significant level of psychological distress. Thirty-two percent of patients 3508 
screened positive for a mood disorder, and 15% screened positive for anxiety 3509 
disorder according to the PRIME-MD. Twelve percent had comorbid mood 3510 
and anxiety disorders concomitantly and 35% had mood and/or anxiety 3511 
disorder(s). 3512 
As shown in Table 3, FEV1(%predicted) was positively correlated with 3513 
all the AQLQ(S) subscale scores and total score, and negatively correlated 3514 
with the SGRQ symptom subscale score and the PSI total score. Furthermore 3515 
and not shown in Table 3 change in FEV1%predicted (FEV1%predicted at 3516 
diagnosis – FEV1%predicted at re-evaluation) was negatively correlated with 3517 
the symptom and emotional function subscale score (r=-0.266, p=0.042 and 3518 
r=-0.273, p=0.036 respectively) and positively with the SGRQ symptom score 3519 
(r=0.256, p=0.050). Not shown in Table 3 inhaled steroid dose was positively 3520 
correlated with the SGRQ symptom score (r=0.398, p=0.013), and the asthma 3521 
severity compound score was negatively correlated with the AQLQ(S) total 3522 
and subscale scores, the SGRQ symptom score and all PSI subscale scores 3523 
(with the exception of cognitive disturbances). For the induced sputum 3524 
analysis, the total sputum cell count was negatively correlated with all the 3525 
AQLQ(S) total and subscale scores (with the exception of environmental 3526 
stimuli), and positively correlated with the SGRQ symptom score (Table 3). 3527 
Not shown in Table 3, the proportion of eosinophils was negatively correlated 3528 
with having a diagnosis of mood disorder and having a mood and/or anxiety 3529 
disorder according to the PRIME-MD (r=-0.312, p=0.035 and r=-0.368, 3530 
   185 
	  
	  
p=0.012 respectively). The proportion of neutrophils was negatively correlated 3531 
with the AQLQ(S) activity limitation subscale score and positively correlated 3532 
with the SGRQ symptom score (r=-0.389, p=0.008 and r=0.375, p=0.010 3533 
respectively).  3534 
Participants receiving no treatment for asthma or taking only short- 3535 
acting bronchodilators as needed, had significantly less impaired disease- 3536 
specific quality of life (total AQLQ(S) 5.9 (4.9;6.4) vs. 3.9 (2.9;5.1), p<0.001 3537 
and a lower SGRQ symptom score 35.2 (21.1;40.8) vs. 64.1  (36.8;81.7), 3538 
p<0.001) as well as less psychological distress (total PSI 17.5 (6.0;27.0) vs. 3539 
28.5 (15.0;39.5), p=0.028) compared to those on regular (daily) anti-asthma 3540 
treatment. 3541 
Total asthma disease-specific quality of life was significantly different 3542 
according to employment status at re-evaluation: participants who were 3543 
working at the time had better disease-specific quality of life (AQLQ(S) 5.3 3544 
(Q1:Q3:4.2;6.3) and SGRQ: 38 (26;53)) than those who were unemployed 3545 
(AQLQ(S) 3.9 (3.1;4.4) and SGRQ 68 (40;86)) or retired (AQLQ(S): and 2.9 3546 
(2.3;5.3), p=0.001 and SGRQ 69 (39;79), p=.0.008) at the time of re- 3547 
evaluation. For psychological distress levels, there was a similar trend for the 3548 
PSI anxiety and depression scores: participants who were working at the time 3549 
had less psychological distress (anxiety 21.0 (Q1; Q3: 9;36) and depression 3550 
17.0 (3;3)) than those who were unemployed (anxiety 36.0 (21;48) and 3551 
depression 28.5 (23;33)) or retired (anxiety 30 (10.5;43.5), p=0.067 and 3552 
depression: 26.5 (11.8;47), p=0.088) at the time of re-evaluation.  3553 
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In the multivariate linear regression analysis, the AQLQ(S) total score 3554 
was significantly negatively correlated to the compound asthma severity score 3555 
at re-evaluation in the a priori model (Table 4). After applying stepwise linear 3556 
regression, the compound asthma severity score at the time of re-evaluation 3557 
and being married at diagnosis of OA were associated with worse quality of 3558 
life in the AQLQ(S) score; however, the p-values derived after applying 3559 
stepwise regression modelling are only approximate values. The SGRQ 3560 
symptom score was significantly positively associated to the compound 3561 
asthma severity score in the a priori model. After applying stepwise linear 3562 
regression to other socio-economic variables, and retaining asthma severity 3563 
within the model, being married, having low income and being employed for 3564 
more than five years with the same employer at the time of diagnosis were 3565 
related to poorer QOL scores according to the SGRQ. 3566 
The total PSI score had no significant association with the covariates in 3567 
the a priori model; however, being a labour union member at the time of 3568 
diagnosis was associated with the PSI score at re-evaluation in the “a- 3569 
posteriori” model (Table 4).  3570 
The median CLI cost was 55.6*103 CAD 3571 
(Q1;Q3:25.3*103CAD;124.1*103CAD), the median CFI cost was 12.0*103 3572 
CAD (2.5*103CAD;18.6*103CAD) and the median total cost for compensation 3573 
was  69.2*103 CAD (36.6*103CAD;135.5*103CAD). The correlation of the 3574 
asthma severity, disease-specific quality of life, and psychological distress 3575 
scores to direct costs for compensation are shown in Table 5. All AQLQ(S) 3576 
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subscale scores and the total score had a significant negative correlation with 3577 
CLI costs and this correlation remained significant with total costs for the total 3578 
score and all the subscores with the exception of the emotional function 3579 
score. The activity limitations sub-scale score had a small negative correlation 3580 
to the CFI costs. The SGRQ symptom score had a small to medium positive 3581 
correlation to the CLI and total cost. The PSI total and sub-scales scores did 3582 
not correlate to costs for compensation, with the exception of the anger score 3583 
(rho=0.285, p=0.028).  3584 
3585 
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Discussion 3585 
Our study shows that an high proportion of patients with OA have moderate 3586 
impairment in disease-specific quality of life, elevated levels of psychological 3587 
distress and a high prevalence of psychiatric (mood and anxiety) disorders 3588 
two years after their initial diagnosis.   3589 
Despite the fact that most of the study participants were no longer 3590 
working at the workplace that caused OA at the time of re-evaluation, 3591 
participants had moderately impaired quality of life measured according to the 3592 
AQLQ(S). This is in accordance with past studies showing that more than 3593 
70% of subjects continue to have symptoms and use asthma medication 3594 
despite being removed from the workplace for more than two years(23). 3595 
Airway hyperresponsiveness to methacholine tends to improve more rapidly 3596 
in the first 2.5 years, but slows down afterwards(24). In workers with different 3597 
allergic manifestations due to natural latex, Al-Otaibi reported a decrease of 3598 
disease specific quality of life impairment with increasing time since the 3599 
diagnosis was made and symptoms duration(25). In our study we did not 3600 
investigate a control group and therefore we cannot compare the level of 3601 
quality of life impairment with individuals without OA, however as shown in 3602 
the past despite matching for disease severity, subjects with OA seem to be 3603 
significantly more impaired in quality of life than control subjects without 3604 
OA(4).  3605 
In our study, between 35% and 47% of participants had clinically 3606 
significant levels of psychological distress and 35% met criteria for one or 3607 
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more current mood or anxiety disorders according to the PRIME-MD. Without 3608 
considering asthma severity, in non-OA patients seen in our hospital asthma 3609 
clinic, the prevalence of anxiety or mood disorder is similar, that is 31%(26). 3610 
Suffering from a chronic illness is known to be associated with higher 3611 
psychological distress in cross-sectional population studies(27) and in 3612 
patients attending primary care. In a WHO Study, the prevalence of 3613 
depressive disorder was reported to be between 10.4% and 7.9% for 3614 
generalized anxiety disorder(28). It has been demonstrated that physical 3615 
disability is a risk factor for the development of depressive disorders whereas 3616 
other studies have shown in healthy cohorts at baseline, that individuals with 3617 
depression have an increased risk of developing a new disabilities in the 3618 
following years(29).  3619 
Our study shows that the principal factor associated with impact on 3620 
quality of life and psychological outcomes was the severity of asthma. There 3621 
are conflicting findings concerning the correlation between objective 3622 
parameters of asthma severity and anxiety levels. Some studies show 3623 
significant correlations between peak expiratory flow variability and self- 3624 
reported anxiety in the Beck Anxiety Symptom Inventory(30) whereas other 3625 
studies could not report a correlation between psychological distress and lung 3626 
function(31, 32). Depression does not appear to be associated with objective 3627 
measures of asthma severity. In a pilot study, asthmatics with a history of 3628 
mood disorder seemed to have less severe airway obstruction and less 3629 
severe asthma(33). Elevated depression scores were associated with 3630 
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perceived asthma severity and risk, but not with intubation history, number of 3631 
hospitalizations or asthma medication history(34). Interestingly, we found a 3632 
correlation between the proportion of sputum eosinophils and mood disorder. 3633 
It has been shown that eosinophilic airway inflammation is more pronounced 3634 
following antigen challenge during final examinations among college students 3635 
and is associated with higher self-reported psychological stress(35).   3636 
In the multivariate linear regression a priori model, the asthma severity 3637 
compound score was the only factor significantly associated with the 3638 
AQLQ(S) total score. Other covariates such as sex, age, current employment 3639 
status, and the time since diagnosis of OA and consequent removal from the 3640 
causal allergen, all factors found significant at a p<0.2 level in the univariate 3641 
analysis, were not significantly associated with disease-specific quality of life. 3642 
However, in the a posteriori analysis, some socio-economic factors were 3643 
significantly associated with AQLQ(S) but not with psychological outcomes. 3644 
Being married at the time of diagnosis was associated with more severe 3645 
quality of life impairment, measured as the total AQLQ(S) and in the SGRQ 3646 
symptom score. In general, married individuals often have better health status 3647 
than their unmarried counterparts(36). However, singles seem to have better 3648 
health outcomes when compared to those in low-quality marriages, as shown 3649 
in hypertension research studies(37). Job loss due to OA and resultant 3650 
income and social status losses might influence quality of life; this might be 3651 
even more important in individuals who have a dependent spouse. 3652 
Participants being labour union members at the time of diagnosis had lower 3653 
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psychological distress levels at re-evaluation. The mission of a labour union is 3654 
to defend the economic, professional and social interests of workers, 3655 
especially in the workplace. Workers may thereby benefit from labour union 3656 
help in terms of complying to the requirements of filing a claim for 3657 
compensation. Moreover, they may receive support during the rehabilitation 3658 
phase (e.g. in finding a new workplace, exploring possibilities for re-education 3659 
programs, receiving legal support, etc.) thereby explaining lower levels of 3660 
psychological distress at the time of re-evaluation. Although employment 3661 
status at the time of re-evaluation was significantly related to quality of life 3662 
and psychological outcomes in the univariate analysis, this was not the case 3663 
in the multivariate analysis, in contrast to asthma severity that was 3664 
significantly correlated to quality of life and psychological outcomes both in 3665 
the univariate and multivariate analysis. Asthma severity has been shown in 3666 
other studies to be a weak although significant determinant for employment 3667 
status (38). 3668 
Another important finding of this study is the association between direct 3669 
costs and psychological outcomes. We found small to medium significant 3670 
correlations between quality of life measures and the anger subscale of the 3671 
PSI questionnaire and compensation costs. The relation was strongest with 3672 
the CFI compensation component, which reflects disease severity. As many 3673 
factors influence CLI costs (age and income at the time of diagnosis being the 3674 
most important ones), it is not surprising that we could not find any 3675 
association between quality of life, psychological distress and costs for CLI.  3676 
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We did not collect information about disease-specific quality of life and 3677 
psychological distress, and psychiatric morbidity (mood and anxiety 3678 
disorders) at the time of diagnosis, and therefore have no information about 3679 
the interaction of OA with psychological distress/psychiatric disorders and the 3680 
progression of both conditions. Furthermore, we did not systematically collect 3681 
information on medication used in treating psychiatric disorders. It is possible 3682 
that some individuals were treated successfully for psychiatric disorders, and 3683 
that the results of our study underestimate impairment in quality of life and 3684 
psychological distress in individuals with OA. In Quebec, a broad 3685 
compensation system for OA is in place. Even when compensation systems 3686 
appear to be effective, not all subjects with a high probability of asthma claim 3687 
compensation from the WCB or change workplaces to avoid the causal 3688 
agent(s)(39). In countries such as the United States, where disputes about 3689 
compensation are usually settled through litigation in an adversarial setting, 3690 
the impact on quality of life and psychological distress might be even more 3691 
pronounced. Compensation claims and costs for occupational injuries have 3692 
shown to be influenced by economic cycles. Compensation claims tend to 3693 
decline in recessions and increase in times of economic recovery(40). How 3694 
these factors influence quality of life and psychological distress in individuals 3695 
with OA is unknown. 3696 
A large proportion of patients with OA have significant impairment in 3697 
disease-specific quality of life with elevated levels of psychological distress 3698 
and psychiatric (mood and anxiety) disorders. Quality of life, as well as some 3699 
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psychological distress parameters at re-evaluation, correlate well with 3700 
objective measures of disease activity which seems to be the principal 3701 
determinant. However, besides the current asthma severity, socio-economic 3702 
factors, such as employment status, marital status, income, the number of 3703 
years of employment at the time of diagnosis also influence, though to a 3704 
lesser degree, disease-specific quality of life and psychological outcomes. 3705 
Finally, disease-specific quality of life correlates with the direct costs for 3706 
compensation by the WCB. Therefore, our findings underline the importance 3707 
of psychological distress and comorbid psychiatric disorders in patients with 3708 
OA. However, further studies are needed to prospectively investigate patients 3709 
in terms of the evolution of their quality of life, psychological distress levels 3710 
and psychiatric morbidity from the time of diagnosis to when patients are 3711 
removed from the workplace and undergo rehabilitation. Furthermore, future 3712 
studies are needed to investigate if intervention programs can reduce 3713 
psychological distress and/or prevent the development of psychiatric 3714 
morbidity in patients with OA and if the same factors influence quality of life 3715 
and psychological distress in countries with different medical and 3716 
compensation systems. 3717 
3718 
194 
References 3718 
1. Eisner MD, Katz PP, Lactao G, Iribarren C. Impact of depressive 3719 
symptoms on adult asthma outcomes. Ann Allergy Asthma Immunol. 3720 
2005;94:566-574. 3721 
2. Lavoie KL, Joseph M, Bacon SL. Psychological distress and 3722 
occupational asthma. Curr Opin Allergy Clin Immunol. 2009;9:103-109. 3723 
3. Richardson LP, Russo JE, Lozano P, McCauley E, Katon W. The effect 3724 
of comorbid anxiety and depressive disorders on health care utilization and 3725 
costs among adolescents with asthma. Gen Hosp Psychiatry. 2008;30:398- 3726 
406. 3727 
4. Malo JL, Boulet LP, Dewitte JD, et al. Quality of life of subjects with 3728 
occupational asthma. JAllergy ClinImmunol. 1993;91:1121-1127. 3729 
5. Yacoub MR, Lavoie K, Lacoste G, et al. Assessment of 3730 
impairment/disability due to occupational asthma through a multidimensional 3731 
approach. EurRespirJ. 2007;29:889-896. 3732 
6. Vandenplas O, Malo JL. Inhalation challenges with agents causing 3733 
occupational asthma. Eur Respir J. 1997;10:2612-2629. 3734 
7. Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management 3735 
of work-related asthma: American College Of Chest Physicians Consensus 3736 
Statement. Chest. 2008;134:1S-41S. 3737 
8. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a 3738 
standardized version of the Asthma Quality of Life Questionnaire. Chest. 3739 
1999;115:1265-1270. 3740 
   195 
	  
	  
9. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory 3741 
Questionnaire. RespirMed. 1991;85 Suppl B:25-31. 3742 
10. Illfeld FW. Further validation of a psychiatric symptom index in a 3743 
normal population. Psychol Rep. 1976;39:1215-1228. 3744 
11. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self- 3745 
report version of PRIME-MD: the PHQ primary care study. Primary Care 3746 
Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 3747 
1999;282:1737-1744. 3748 
12. American Psychiatric Association (APA). Diagnostic and statistical 3749 
manual of mental disorders. Washington DC 1987. 3750 
13. Standardization of Spirometry, 1994 Update. American Thoracic 3751 
Society. AmJRespirCrit Care Med. 1995;152:1107-1136. 3752 
14. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the 3753 
normal maximal expiratory flow-volume curve with growth and aging. 3754 
AmRevRespirDis. 1983;127:725-734. 3755 
15. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial 3756 
reactivity to inhaled histamine: a method and clinical survey. ClinAllergy. 3757 
1977;7:235-243. 3758 
16. Malo JL, Pineau L, Cartier A, Martin RR. Reference values of the 3759 
provocative concentrations of methacholine that cause 6% and 20% changes 3760 
in forced expiratory volume in one second in a normal population. 3761 
AmRevRespirDis. 1983;128:8-11. 3762 
196 
17. Pepys J. Skin tests for immediate, type I, allergic reactions. Proc R Soc 3763 
Med. 1972;65:271-272. 3764 
18. Pizzichini MM, Popov TA, Efthimiadis A, et al. Spontaneous and 3765 
induced sputum to measure indices of airway inflammation in asthma. 3766 
AmJRespirCrit Care Med. 1996;154:866-869. 3767 
19. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway 3768 
inflammation in induced sputum: reproducibility and validity of cell and fluid- 3769 
phase measurements. AmJRespirCrit Care Med. 1996;154:308-317. 3770 
20. Dewitte JD, Chan-Yeung M, Malo JL. Medicolegal and compensation 3771 
aspects of occupational asthma. EurRespirJ. 1994;7:969-980. 3772 
21. American Medical Association (AMA). Guides to the Evaluation of 3773 
Permanent Impairment. In: Cocchiarella L, Andersson GBJ, eds. Chicago IL: 3774 
American Medical Association; 2001:102-104. 3775 
22. Bernstein IL, Keskinen H, Blanc PD, Chan-Yeung M, Malo JL. 3776 
Medicolegal aspects, compensation aspects, and evaluation of 3777 
impairment/disabilitiy. In: Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI, 3778 
eds. Asthma in the Workplace. New York: Taylor & Francis; 2006:319-351. 3779 
23. Labrecque M, Khemici E, Cartier A, Malo JL, Turcot J. Impairment in 3780 
workers with isocyanate-induced occupational asthma and removed from 3781 
exposure in the province of Quebec between 1985 and 2002. J Occup 3782 
Environ Med. 2006;48:1093-1098. 3783 
   197 
	  
	  
24. Malo JL, Ghezzo H. Recovery of methacholine responsiveness after 3784 
end of exposure in occupational asthma. AmJRespirCrit Care Med. 3785 
2004;169:1304-1307. 3786 
25. Al-Otaibi S, Tarlo SM, House R. Quality of life in patients with latex 3787 
allergy. OccupMed(Lond). 2005;55:88-92. 3788 
26. Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What 3789 
is worse for asthma control and quality of life: depressive disorders, anxiety 3790 
disorders, or both? Chest. 2006;130:1039-1047. 3791 
27. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of 3792 
the general population with and without chronic medical conditions. Am J 3793 
Psychiatry. 1988;145:976-981. 3794 
28. Üstün TB, Sartorius N. Mental Illness in General Health Care. An 3795 
International study. Chichester: John Wiley & Sons; 2005. 3796 
29. Penninx BW. Depression and physical disability. In: Steptoe A, ed. 3797 
Depression and Physical Illness. Cambridge, UK: Cambridge University 3798 
Press; 2007:125-144. 3799 
30. Hommel KA, Chaney JM, Wagner JL, McLaughlin MS. Asthma- 3800 
Specific Quality of Life in Older Adolescents and Young Adults With Long- 3801 
Standing Asthma: The Role of Anxiety and Depression. J Clin Psychol Med 3802 
Settings. 2002;3;9:185-192. 3803 
31. Lavoie KL, Cartier A, Labrecque M, et al. Are psychiatric disorders 3804 
associated with worse asthma control and quality of life in asthma patients? 3805 
RespirMed. 2005;99:1249-1257. 3806 
198 
32. Rimington LD, Davies DH, Lowe D, Pearson MG. Relationship 3807 
between anxiety, depression, and morbidity in adult asthma patients. Thorax. 3808 
2001;56:266-271. 3809 
33. Nejtek VA, Brown ES, Khan DA, Moore JJ, Van Wagner J, Perantie 3810 
DC. Prevalence of mood disorders and relationship to asthma severity in 3811 
patients at an inner-city asthma clinic. Ann Allergy Asthma Immunol. 3812 
2001;87:129-133. 3813 
34. Janson-Bjerklie S, Ferketich S, Benner P, Becker G. Clinical markers 3814 
of asthma severity and risk: importance of subjective as well as objective 3815 
factors. Heart Lung. 1992;21:265-272. 3816 
35. Liu LY, Coe CL, Swenson CA, Kelly EA, Kita H, Busse WW. School 3817 
examinations enhance airway inflammation to antigen challenge. Am J Respir 3818 
Crit Care Med. 2002;165:1062-1067. 3819 
36. Wyke S, Ford G. Competing explanations for associations between 3820 
marital status and health. Soc Sci Med. 1992;34:523-532. 3821 
37. Holt-Lunstad J, Birmingham W, Jones BQ. Is there something unique 3822 
about marriage? The relative impact of marital status, relationship quality, and 3823 
network social support on ambulatory blood pressure and mental health. Ann 3824 
Behav Med. 2008;35:239-244. 3825 
38. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact 3826 
of work-related asthma. EurRespirJ. 2003;22:689-697. 3827 
   199 
	  
	  
39. Provencher S, Labreche FP, De GL. Physician based surveillance 3828 
system for occupational respiratory diseases: the experience of PROPULSE, 3829 
Quebec, Canada. OccupEnvironMed. 1997;54:272-276. 3830 
40. Workers' compensation and the business cycle. In: Institute for Work & 3831 
Health T, ON, Canada, ed.; 2009. 3832 
 3833 
3834 
200 
Table 1: Selected baseline characteristics of participants at the time of 3834 
diagnosis and re-evaluation (n=60) 3835 
At diagnosis 
Sex (male/female) 45 (75%)/15 (25%) 
Atopy 42 (70%) 
Causal agent (HMW/LMW/unknown) 26 (43%)/33 (55%)/1 (2%) 
Length of exposure to causal agent (years) 10.5 (3.1;22.8) 
Duration of symptoms prior to claim (years) 1.4 (0.1;7.5) 
Time interval between diagnosis and re-
evaluation (years) 
2.8 (2.5;4.3) 
Asthma severity compound score (%) 24 (16.0;32.5) 
At re-evaluation  
Age (years) 47.2 ±11.7 
Medication 
- No medication for asthma 
- Short acting Beta-agonists 
- Long acting Beta-agonists 
- Inhaled steroids  
- Dose of inhaled steroids (equivalent 
of budesonid in mcg) 
 
5 (8%) 
17 (28%) 
12 (20%) 
38 (63%) 
 
800 (800;1600) 
Smoking habit  
- Non-smoker 
- Ex-smoker 
- Smoker 
 
10 (16%) 
25 (42%) 
25 (42%) 
Type of rehabilitation program 
- No Program 
- Program without studies 
- Program with studies 
 
42 (70%) 
9 (15%) 
9 (15%) 
Employment status  
- Without job 
- Retraining  
- Retired 
- Other employer  
- Same employer 
 
12 (20%) 
3 (5%) 
12 (20%) 
20 (33%) 
13 (22%) 
Self reported overall health status 
- Excellent 
- Very good 
- Good 
- Fair 
- Poor 
 
2 (3%) 
15 (25%) 
24 (40%) 
8 (13%) 
11 (18%) 
FEV1% predicted  83 ±2 
FEV1/FVC% predicted  92 ±2 
Bronchial hyperresponsiveness to 
methacholine 
PC 20 mg.mL-1  
- >16 
- 2-16 
- 0.25-<2 
- <0.25 
 
 
16 (31%) 
19 (37%) 
14 (27%) 
3 (6%) 
Asthma severity compound score (%) 16 (10.3;31) 
Legend: Data are presented as n, mean ±standard deviation, median 3836 
(1.Quartile; 3.Quartile) exposure times are presented as median (1.Quartile; 3837 
3.Quartile) or n (%). HMW=High molecular weight allergen. LMW=Low 3838 
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molecular weight allergen. Mcg=microgram. FEV1=Forced expiratory volume 3839 
in one second. FVC=Forced vital capacity. PC20=Concentration of 3840 
methacholine to provoke a fall of 20% or more in FEV1. The asthma severity 3841 
compound score included objective parameters such as spirometry, 3842 
methacholine reactivity, and current medication use (0% low severity, 100% 3843 
maximum severity). Self reported overall health status according to the 3844 
question in the PRIME-MD (Primary Care Evaluation of Mental Disorders) 3845 
questionnaire.  3846 
3847 
202 
Table 2: Distribution of Quality of Life, Psychological Distress and Psychiatric 3847 
Syndromes at re-evaluation 3848 
 Frequency (n (%)) Score (median (Q1;Q3)) 
Juniper AQLQ   
Symptoms Domain  4.5 (3.5;6.0) 
Activity limitations Domain  4.6 (3.3;5.7) 
Emotional function Domain  5.0 (3.6;6.6) 
Exposure to environmental stimuli 
Domain 
 4.8 (3.3;5.8) 
Total  4.6 (3.6;5.9) 
SGRQ Asthma Symptom Score 
(%) 
 45 (32;71) 
Psychological distress  (PSI score >25)  
Depression 27 (45%) 23.0 (10.0;33.0) 
Anxiety 28 (47%) 24.0 (12.8;39.0) 
Anger 21 (35%) 19.0 (8.0;33.0) 
Cognitive disturbance 24 (40%) 24.5 (8.0;39.8) 
Total 28 (47%) 24.5 (10.8;37.8) 
Prime-MD   
 Mood disorders 19 (32%)  
-­‐ Major depression 8 (13%)  
-­‐ Dysthymia 3 (5%)  
-­‐ Minor depression 11 (18%)  
Anxiety disorders 9 (15%)  
-­‐ Panic disorder 1 (2%)  
-­‐ Generalized anxiety 1 (2%)  
-­‐ Unspecified anxiety 
disorder 
7 (8%)  
Legend: AQLQ(S)=Standardized version of the Juniper Asthma Quality of Life 3849 
Questionnaire; SGRQ : St. George Respiratory Questionnaire; 3850 
PSI=Psychiatric Symptom Index, PRIME-MD= Primary Care Evaluation of 3851 
Mental Disorders questionnaire 3852 
3853 
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Table 3: Cross-sectional correlation of QOL, psychological distress and 3853 
psychiatric syndromes with selected clinical, functional and inflammatory 3854 
parameters at re-evaluation 3855 
 3856 
Legend: Correlation reported as r with p-value. The p-values presented were 3857 
not corrected for multiplicity. Blank scales are considered p>0.05. 3858 
AQLQ(S)=Standardized version of the Juniper Asthma Quality of Life 3859 
Questionnaire; SGRQ : St. George Respiratory Questionnaire; 3860 
PSI=Psychiatric Symptom Index, PRIME-MD= Primary Care Evaluation of 3861 
Mental Disorders questionnaire. Asthma severity=Asthma severity score at 3862 
re-evaluation. 3863 
3864 
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Table 4: Multivariate analysis of quality of life, psychological distress and 3864 
psychiatric syndromes according to different socioeconomic factors 3865 
  AQLQ(S) Total SGRQ PSI Total Prime-
MD 
  A priori A 
posterio
ri 
A priori A 
posterio
ri 
A priori A 
posterio
ri 
A priori 
Sex -0.045 
(0.051)
, 0.388 
 6.535 
(7.430)
, 0.383 
 -0.064 
(0.307)
, 0.836 
 0.538 
(0.763)
, 0.481 
Not 
married 
 0.084 
(0.038), 
0.034 
 -13.414 
(5.266), 
0.014 
   
Other 
than low 
income 
   18.067 
(7.377), 
0.018 
   
With 
employe
r for less 
than 5 
years 
   11.166 
(5.338), 
0.042 
   
Informatio
n 
collected 
at 
diagnosis 
Not a 
labour 
union 
member 
     0.492 
(0.233), 
0.039 
 
Age 
(years) 
-0.002 
(0.002)
, 0.331 
 0.258 
(0.305)
, 0.402 
 0.000 
(0.013)
, 0.964 
 0.057 
(0.035)
, 0.107 
Time 
since 
Diagnosi
s (years) 
-0.002 
(0.007)
, 0.834 
 0.729 
(1.071)
, 0.499 
 0.037 
(0.047)
, 0.432 
0.058 
(0.033), 
0.083 
0.023 
(0.109)
, 0.836 
Asthma 
severity 
(%) 
-0.004 
(0.001)
, 0.007 
-0.004 
(0.001), 
<0.001 
0.483 
(0.192)
, 0.015 
0.713 
(0.126), 
<0.001 
0.003 
(0.009)
, 0.718 
 -0.35 
(0.022)
, 0.118 
Informatio
n 
collected 
at re-
evaluation 
Not 
employe
d 
-0.069 
(0.050)
, 0.173 
-0.076 
(0.045), 
0.095 
5.509 
(7.283)
, 0.453 
 0.299 
(0.303)
, 0.329 
 -0.783 
(0.746)
, 0.294 
 R2 0.404 0.440 0.349 0.471 0.105 0.144 0.176 
Legend: Data presented as β (SE), p-value. For the a-posteriori model the 3866 
following variables were considered AQLQ(S)=Standardized version of the 3867 
Juniper Asthma Quality of Life Questionnaire; SGRQ : St. George Respiratory 3868 
Questionnaire; PSI=Psychiatric Symptom Index, PRIME-MD= Primary Care 3869 
Evaluation of Mental Disorders questionnaire 3870 
 3871 
3872 
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Table 5: Correlation of QOL and psychological parameters with costs for 3872 
compensation 3873 
  CFI costs CLI costs Total costs 
Symptoms  -0.309, 0.017 -0.290, 0.039 
Activity limitations -0.279, 0.045 -0.353, 0.006 -0.337, 0.015 
Emotional function  -0.424, 0.001  
Exposure to 
environmental stimuli 
 -0.358, 0.005 -0.282, 0.045 
AQLQ(S) 
Total  -0.381, 0.003 -0.325, 0.020 
SGRQ Symptom score  0.357, 0.005 0.283, 0.044 
PSI Anger  0.285, 0.028  
Legend: Correlation reported as r with p-value. The p-values presented were 3874 
not corrected for multiplicity. CFI: compensation for income loss, CLI: 3875 
compensation for impairment. Correlation reported as r with p-value. 3876 
AQLQ(S)=Standardized version of the Juniper Asthma Quality of Life 3877 
Questionnaire; SGRQ : St. George Respiratory Questionnaire; 3878 
PSI=Psychiatric Symptom Index, PRIME-MD= Primary Care Evaluation of 3879 
Mental Disorders questionnaire 3880 
3881 
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Figure 1: 3881 
 3882 
 3883 
Legend: AQLQ(S)=standardized version of the Asthma Quality of Life 3884 
Questionnaire; SGRQ= St-Georges Respiratory Questionnaire; 3885 
PSI=Psychiatric Symptom Index; PRIME-MD=Primary Care Evaluation of 3886 
Mental Disorders 3887 
3888 
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Supplemental Digital Content 3888 
 3889 
Methods 3890 
Study design, setting and participants 3891 
This was a cross-sectional study investigating patients who claimed 3892 
compensation for occupational asthma (OA) at the Workersʼ Compensation 3893 
Agency of Quebec (Commission de la santé et sécurité du travail du Québec; 3894 
CSST) in the years 2004 to 2006. Patients who were no longer exposed to 3895 
the offending allergens causing OA for two years or more were evaluated by 3896 
two of the four Quebec CSST medical committees in Montreal (Montreal 3897 
Chest Institute and Hôpital du Sacré-Coeur) for a permanent disability 3898 
indemnity. In Quebec, all patients who claim compensation for OA undergo 3899 
specific inhalation testing to confirm a diagnosis of OA. The methods used for 3900 
specific challenge testing using different work related allergens have been 3901 
described before (1) and this method is considered to be the reference 3902 
standard for the diagnosis of OA (2). Therefore in all of the patients included 3903 
in this study showed a positive response to a specific inhalation test. In this 3904 
study the definition of asthma is therefore based on workplace associated 3905 
respiratory symptoms and a positive result in the specific inhalation test. All 3906 
claimants scheduled for evaluation by the committees were asked to 3907 
participate in this study on a voluntary basis.  3908 
Patients were assessed on two occasions: when the initial OA 3909 
diagnosis was made and the claim filed with the Workersʼ Compensation 3910 
208 
Agency (diagnosis), and when the participants were re-evaluated to 3911 
determine compensation for permanent disability approximately two years 3912 
later. Patients underwent the same testing protocol on both occasions (see 3913 
details below). However, questions regarding patientsʼ employment status at 3914 
the time, participation in rehabilitation programs, socio-economic factors as 3915 
well as validated psychological and quality-of-life questionnaires, were added 3916 
to their investigation at the two-year re-evaluation point.  3917 
Patients were assured that the medical committee would not be 3918 
informed of participation or decline of participation in this study nor of the test 3919 
results. They were given compensation for their study participation to cover 3920 
expenses like loss of salary and transportation or parking fees. All study 3921 
participants gave written consent for their participation. The research protocol 3922 
was approved by the Research Ethical Committee of our hospital (CER de 3923 
lʼHôpital Sacré-Coeur, Montreal).  3924 
Measures at diagnosis 3925 
All patients investigated underwent standard spirometry, methacholine 3926 
challenge testing and if participants could produce sputum on induction 3927 
examination, induced sputum. The type of agent causing OA, medication use, 3928 
smoking status, and data on socio-economic status such as income, 3929 
employment status, and company size were recorded from the WCBʼs report. 3930 
Measures at re-evaluation 3931 
Approximately two years after receiving their initial diagnosis, all patients 3932 
completed a questionnaire on chest and upper airway symptoms, the interval 3933 
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of time between the onset of symptoms and the submission of their claim to 3934 
the WCB, medication use, home allergen exposure, and tobacco 3935 
consumption. Patients also completed a questionnaire assessing whether 3936 
they were still exposed to the offending agent, as well as a questionnaire 3937 
assessing socio-economic factors including their employment at time, salary, 3938 
education history, country of origin, number of children and family members 3939 
dependant on the household income, and the nature of their participation in 3940 
social rehabilitation programs offfered by the WCB (e.g., full or part-time 3941 
participation in job education, use of the employment agency, etc.). In 3942 
addition, participants completed the validated French versions of the following 3943 
questionnaires:  3944 
Asthma Quality of Life Questionnaire (AQLQ(S)) 3945 
The standardized version of the AQLQ(S) includes 32 items and evaluates 3946 
asthma quality of life across four life domains that may be negatively affected 3947 
by asthma. The life domains include 1) asthma symptoms 2) activity 3948 
limitations 3) emotional function and 4) exposure to environmental stimuli. 3949 
Every question is cored from one (extremely severe impairment of quality of 3950 
life) to seven (no impairment at all) and the total score is the mean of the four 3951 
scores (3). 3952 
St-Georges Respiratory Questionnaire (SGRQ) 3953 
For this study we only used the section on respiratory symptoms from the St- 3954 
Georges Respiratory Questionnaire which includes eight questions and the 3955 
210 
total score represents the sum of these elements. The total score ranges from 3956 
0 to 100 and a higher score indicates a worse HRQoL (4).  3957 
Psychiatric Symptom Index (PSI) 3958 
The PSI is a 29-item questionnaire elaborated to assess the presence and 3959 
intensity of psychological distress in the two weeks preceding the evaluation 3960 
(5). Items are scored using a four-point scale from 0 (never) to 3 (very often). 3961 
Total scores and subscale scores (depression, anxiety, anger and cognitive 3962 
disturbance) are calculated as a percentage of the total possible score out of 3963 
100. Scores of >25 are considered to indicate clinically significant distress (5).   3964 
Primary Care Evaluation of Mental Disorders (Prime-MD)  3965 
The PRIME-MD is a validated screening instrument designed to detect some 3966 
of the most common Diagnostic and Statistical Manual of Mental Disorders 3967 
(DSM) disorders seen in community and medical settings (6). It consists of a 3968 
27-item patient self-report section followed by a structured clinical interview 3969 
that is used to follow-up patient responses. The PRIME-MD evaluates 5 3970 
groups of mental disorders (mood, anxiety, somatoform, alcohol, eating), and 3971 
items were developed on the basis of criteria from the DSM-3rd edition 3972 
revised (DSM-III-R) (7). It has demonstrated very good sensitivity (83%) for 3973 
any psychiatric diagnosis and excellent specificity (88%) across diagnostic 3974 
modules (6). 3975 
Spirometry and Methacholine Provocation Testing 3976 
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All patients underwent standard spirometry according to ATS guidelines(8) at 3977 
diagnosis and at re-evaluation, using the reference values derived by 3978 
Knudson(9). Methacholine challenge testing was performed according to a 3979 
previously published protocol(10). Normal responsiveness was set at a 3980 
concentration of methacholine causing a 20% fall (PC20) in FEV1 of greater 3981 
than 16 mg*mL-1(11).  3982 
Allergy Testing 3983 
Skin prick tests were performed at diagnosis of OA to assess atopic status 3984 
according to the method described by Pepys(12). Atopy was defined as 3985 
having at least one positive result to an aeroallergen.  3986 
Induced Sputum Analysis 3987 
Patients underwent sputum induction by inhaling increasing concentrations 3988 
(3%, 4%, and 5%) of hypertonic saline at diagnosis and at re-evaluation(13). 3989 
The samples were processed according to a previously published 3990 
protocol(14).  3991 
Compound Asthma Severity Score 3992 
Asthma severity was assessed at diagnosis and at re-evaluation. The asthma 3993 
severity at diagnosis, at re-evaluation and the proportion of permanent 3994 
disability that was allocated were calculated according to the Quebec 3995 
Workersʼ Compensation Board Scale for OA (Table 1) (15). This scale 3996 
incorporates three factors in the same way as the one proposed by the 3997 
American Medical Association(16): level of bronchial calibre, degree of 3998 
bronchial responsiveness and need for medication to control asthma(17). 3999 
212 
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Table 1: Quebec system of compensation for occupational asthma: criteria 4000 
used to determine permanent disability 4001 
Class Level of 
bronchial 
obstruction* 
Level of bronchial 
responsiveness$ 
Need for 
medication 
Percentage 
disability 
1 0 0 None 0 
2A 0 1 None 5 
2B 0 1 BDT if 
needed 
8 
2C 0 1 BDT 
regularly 
10 
2D 0 2 None 10 
2E 0 2 BDT reg or if 
needed 
13 
2F 0 3 BDT reg or if 
needed 
15 
3A 1 1 BDT reg or if 
needed 
18 
3B 1 2 BDT reg or if 
needed 
20 
3C 1 3 BDT reg or if 
needed 
25 
4A 2 1-2 BDT reg or if 
needed 
28 
4B 2 3 BDT reg or if 
needed 
33 
5A 3 1-2 BDT reg or if 
needed 
50 
5B 3 3 BDT reg or if 
needed 
60 
6 4 1-2-3 BDT reg or if 
needed 
100 
Legend: Group with oral steroids and with or without inhaled steroids: add 3% 4002 
for inhaled steroids, ad 10% for oral steroids. *: level of bronchial obstruction 4003 
(FEV1 and/or FEV1/FVC) determined at least 8 h after inhaled beta2- 4004 
adrenergic agent and 48 h after oral theophylline, as follows: 0 = >85% pred; 4005 
1 = 71–85% pred; 2 = 56–70% pred; 3 = 40–55% pred; and 4 = <40% pred. 4006 
$: level of bronchial hyperresponsiveness determined as follows: 0 = PC20 4007 
>16mg·ml-1; 1 = PC20 2–16 mg·ml-1; 2 = PC20 0.25–2 mg·ml-1; 3 = PC20 4008 
≤0.25 mg·ml-1. PC20 assessed by the method of Cockcroft and co-workers 4009 
(10). BDT: bronchodilator therapy; PC20: provocative concentration producing 4010 
a 20% fall in FEV1; reg: regularly (daily). 4011 
Direct Costs of OA 4012 
214 
We consulted the patientsʼ files at the Québec WCB to determine the costs of 4013 
compensation for OA at the time of the re-evaluation. We reported the 4014 
compensation for loss of income (CLI) and functional impairment (CFI) in this 4015 
study. CLI corresponds mainly to compensation for lost wages during the 4016 
rehabilitation period (up to two years) after the worker is removed from the 4017 
workplace. CFI is allocated at the time of re-evaluation by the WCB, about 4018 
two years after confirmation of the initial diagnosis and subsequent removal 4019 
from the workplace, and is calculated according to the WCB scale for OA.     4020 
Statistical analyses 4021 
Proportions are reported as absolute numbers and relative frequencies. 4022 
Continuous data is reported as mean ±standard deviation or median and 25 4023 
and 75 percentiles, if non-normally distributed. Distribution of continuous 4024 
variables was verified visually by plotting histograms. Proportions were 4025 
compared by using Chi – Square or Fisherʼs exact test where  the expected 4026 
cell count was <5. Continuous variables were compared by using the Mann- 4027 
Whitney U test. We calculated Spearmanʼs rho for correlation analysis 4028 
between two continuous variables, and we conducted point-biserial 4029 
correlations between continuous and categorical variables, but we did not 4030 
correct the p-values for multiplicity. Prior to performing linear regression, we 4031 
performed logarithmic transformation and then, the second power of the 4032 
dependent variables AQLQ(S) and PSI overall scores. Presence of 4033 
psychiatric mood and anxiety disorders was assessed by the PRIME-MD and 4034 
coded as a dichotomous variable (yes, no). 4035 
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First, we analysed the a priori model with factors set in our hypotheses as 4036 
likely associated with psychological outcomes (AQLQ(S), SGRQ and PSI): 4037 
gender (male vs. female), age at re-evaluation, time intervals since diagnosis, 4038 
the asthma severity composite score at re-evaluation and the  employment 4039 
status at the time (working vs. not working). Secondly, we performed a 4040 
univariate analysis of the dependent variables with different socio-economic 4041 
covariates gathered at the time of diagnosis as well as at the time of re- 4042 
evaluation. We then performed a linear regression analysis with covariates 4043 
with a p-value <0.2 identified in univariate analysis, and covariates identified 4044 
in the a priori model in which the coefficients had a p-value of <0.2 in the 4045 
model. The same scheme was applied for the logistic regression analysis of 4046 
the dichotomous variable. Similarly, we performed a logistic regression 4047 
analysis for the dependent dichotomous variable having mood or anxiety 4048 
disorder diagnosed, according to the Prime-MD. For analysis of the data, we 4049 
used a statistical software package (SPSS V.16, SPSS Inc., Chicago, USA). 4050 
We considered a p-value of <0.05 as significant. 4051 
 4052 
Results 4053 
Recruitment and characteristics of study participants versus non-participants 4054 
Seventy-three subjects were eligible to participate as their claims were 4055 
reviewed by the two committees in Montreal for a permanent disability 4056 
indemnity during the studyʼs recruitment period. Out of these eligible 4057 
individuals, we were unable to contact five subjects and eight subjects 4058 
216 
refused to participate, yielding a final sample of 60 subjects and a 4059 
participation rate of 82%. The baseline characteristics of the study 4060 
participants as well as the non-participants at the time of diagnosis of OA can 4061 
be seen in Table 2. 4062 
4063 
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Table 2: Characteristics of study participants versus non-participants at the 4063 
time of diagnosis of occupational asthma 4064 
 Participants 
(n=60) 
Non-participants 
(n=13) 
p-value 
Male gender 45 (75%) 12 (92%) 0.273 
Age (years) 42 (15) 39 (21) 0.795 
Atopy 42 (70%) 11 (85%) 0.491 
Smoking habit 
 
- smoker 
- ex-smoker 
- non-smoker 
 
 
10 (16%) 
25 (42%) 
25 (42%) 
 
 
2 (15%) 
9 (70%) 
2 (15%) 
0.153 
FEV1% predicted 86 (25) 78 (35) 0.264 
FVC% predicted 91 (15) 80 (21) 0.143 
Bronchial 
hyperresponsiveness 
to methacholine 
PC 20 mg.mL-1 
0.87 (2.30) 0.32 (0.75) 0.155 
Causal agent is a 
high molecular 
allergen 
27 (45%) 5 (38%) 0.632 
Duration of 
symptoms prior to 
claim (years) 
1.4 (7.3) 3.6 (15.0) 0.141 
Legend: Data are presented as n (%) or median (interquartile range). PC20= 4065 
concentration of methacholine to provoke a fall in FEV1 of 20% or more. 4066 
Atopy= presence of at least one immediate skin reaction to 15 ubiquitous 4067 
aeroallergens. 4068 
4069 
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Abstract 4144 
 4145 
Background 4146 
The Juniper Asthma Specific Quality of Life Questionnaire (AQLQ(S)) is a 4147 
questionnaire that allows measurement of disease specific quality of life. We 4148 
wanted to examine correlations between the (AQLQ(S)) general and different 4149 
subscale scores and both psychiatric morbidity and levels of psychological 4150 
distress in individuals with occupational asthma (OA) and to determine if 4151 
results in the emotional function subscale allow identification of individuals 4152 
with clinically significant psychological distress or current psychiatric 4153 
disorders. 4154 
 4155 
Methods 4156 
This was a cross-sectional study of individuals with OA who were assessed 4157 
during a re-evaluation for permanent disability, after they were no longer 4158 
exposed to the sensitizing agent. Patients underwent a general 4159 
sociodemographic and medical history evaluation, a brief psychiatric interview 4160 
(Primary Care Evaluation of Mental Disorders, PRIME-MD) and completed a 4161 
battery of questionnaires including the AQLQ(S), the St-Georges Respiratory 4162 
Questionnaire (SGRQ), and the Psychiatric Symptom Index (PSI).  4163 
 4164 
Results 4165 
224 
There was good internal consistency (Cronbach alpha=0.936 for the AQLQ(S) 4166 
total score) and construct validity for the AQLQ(S) (Spearman rho=-0.693 for 4167 
the SGRQ symptom score and rho=-0.650 for the asthma severity score). 4168 
There were medium to large correlations between the total score of the 4169 
AQLQ(S) and the SGRQ symptom score (r=-.693), and PSI total (r=-.619) and 4170 
subscale scores (including depression, r=-.419; anxiety, r=-.664; anger, r=- 4171 
.367; cognitive disturbances, r=-.419). A cut-off of 5.1 on the AQLQ(S) 4172 
emotional function subscale (where 0 = high impairment and 7 = no 4173 
impairment) had the best discriminative value to distinguish individuals with or 4174 
without clinically significant psychological distress according to the PSI, and a 4175 
cut-off of 4.7 best distinguished individuals with or without a current 4176 
psychiatric disorder according to the PRIME-MD.  4177 
 4178 
Conclusions 4179 
Impaired quality of life is associated with psychological distress and 4180 
psychiatric disorders in individuals with OA. Findings suggest that the 4181 
AQLQ(S) questionnaire may be used to identify patients with potentially 4182 
clinically significant levels of psychological distress.  4183 
4184 
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Background 4216 
 4217 
Asthma is a chronic inflammatory disorder of the airways. Occupational 4218 
asthma (OA) is asthma that is caused and maintained by conditions 4219 
attributable to the occupational environment and not to stimuli encountered 4220 
outside the workplace [1]. The impact of a disease on a patientʼs health and 4221 
well-being is individual. According to Paul Jones, “A patientʼs health-related 4222 
quality of life is the result of a generic disturbance to health common to all 4223 
patients with the disease, modulated by factors that are internal and unique to 4224 
the individual.” [2]. Health-related quality of life questionnaires should 4225 
therefore contain items evaluating physical, psychological and social 4226 
domains, and in general, the item content of a questionnaire should be 4227 
derived from patients rather than health professionals [3].  4228 
There are a variety of different measures available to determine 4229 
asthma-related quality of life according to a recent review [4]. One of the most 4230 
commonly used measures is the Asthma Quality of Life Questionnaire 4231 
(AQLQ) developed in Canada by Juniper and co-workers. This questionnaire 4232 
is available in approximately 80 languages, and changes in AQLQ scores 4233 
have been shown to have strong correlations with changes in asthma control 4234 
and medication usage [5]. Juniper and co-workers found moderate cross- 4235 
sectional correlations of the AQLQ subscales with the psychosocial function 4236 
domain of the Sickness Impact Profile and the emotion subscale of the Rand 4237 
General Health Survey [5]. The standardized version of the AQLQ(S) has 4238 
228 
been shown to have a moderate cross-sectional correlation (r=0.48) with the 4239 
mental component summary measures of the Short Form-36 questionnaire [5, 4240 
6]. 4241 
Previous research has demonstrated a link between health-related 4242 
quality of life and an increased risk of all-cause mortality and healthcare use 4243 
in individuals with asthma [7, 8]. The goal of asthma treatment is therefore to 4244 
gain control of symptoms, which relies upon various self-management 4245 
behaviors such as daily symptom self-monitoring, adherence to medication, 4246 
refraining from smoking, as well as managing environmental asthma triggers. 4247 
Chronic negative mood states such as depressive or anxiety disorders may 4248 
interfere with motivation to engage in these self-management behaviors, and 4249 
have been linked to worse asthma-related quality of life [9]. Having 4250 
depression has also been shown to be associated with medication non- 4251 
adherence in patients suffering from different medical conditions,[10] and 4252 
anxiety disorders have been shown to be related to increased use of 4253 
bronchodilators (reliever medication) and decreased use of controller 4254 
medication such as inhaled corticosteroids among asthmatics [9, 11]. Early 4255 
diagnosis of chronic negative mood states therefore offers the opportunity to 4256 
begin specific anti-anxiety or anti-depressive therapy (i.e., psychotherapy or 4257 
pharmacotherapy), and has the potential to reverse these adverse disease 4258 
outcomes.  4259 
The aim of this study was to assess the correlation between asthma- 4260 
specific quality of life and both levels of psychological distress and psychiatric 4261 
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disorders assessed by standardized tools, in patients with OA. Specifically, 4262 
this study examined the correlation between general and different subscale 4263 
scores on the AQLQ(S) on the one hand and, on the other hand, levels of 4264 
psychological distress and rates of psychiatric disorders, and the extent to 4265 
which the responses on the emotion subscale of the AQLQ(S) allowed for the 4266 
identification of individuals with significant psychological distress or 4267 
psychiatric disorders (i.e., patients who met diagnostic criteria for depressive 4268 
and anxiety disorders according to the Diagnostic and Statistical Manual of 4269 
Mental Disorders, 4th Edition, DSM-IV). 4270 
4271 
230 
Methods 4271 
 4272 
Study design, setting and participants 4273 
 This was a cross-sectional study of patients who claimed 4274 
compensation for OA at the Workersʼ Compensation Agency of Quebec 4275 
(“Commission de la santé et sécurité du travail du Québec” (“CSST”)) in the 4276 
years 2004 to 2006. Patients who were no longer exposed to the sensitizing 4277 
agents causing OA for two years or more were evaluated by two of the four 4278 
Quebec CSST medical committees in Montreal (Montreal Chest Institute and 4279 
Hôpital du Sacré-Coeur) for a permanent disability indemnity. In Quebec, all 4280 
patients who claim compensation for OA undergo specific inhalation testing to 4281 
confirm a diagnosis of OA. All claimants scheduled for evaluation by the 4282 
committees were asked to participate in this study on a voluntary basis. 4283 
Patients were assessed when the participants were re-evaluated to determine 4284 
compensation for permanent disability. Patients were assured that the 4285 
medical committee would not be informed of participation, nor of the 4286 
assessment results. They were given compensation for their study 4287 
participation to cover expenses like loss of salary and transportation or 4288 
parking fees. All study participants gave written, informed consent for their 4289 
participation. The research protocol was approved by the Research Ethical 4290 
Committee of Hôpital du Sacré-Coeur de Montreal.  4291 
 4292 
Measures 4293 
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 All patients underwent standard spirometry and methacholine 4294 
challenge testing. All patients completed a questionnaire on chest and upper 4295 
airway symptoms, medication use, home allergen exposure, and smoking 4296 
status. Patients also completed a questionnaire assessing whether they were 4297 
still exposed to the sensitizing agent, as well as a questionnaire assessing 4298 
socio-economic factors. In addition, participants completed the validated 4299 
French versions of the following questionnaires:  4300 
 4301 
Asthma Quality of Life Questionnaire (AQLQ(S)) 4302 
 The standardized version of the AQLQ(S) includes 32 items and 4303 
evaluates asthma quality of life across four domains that may be negatively 4304 
affected by asthma. The domains include 1) asthma symptoms 2) activity 4305 
limitations 3) emotional function and 4) exposure to environmental stimuli. 4306 
Every question is scored from one (severe impairment) to seven (no 4307 
impairment), and the total score is the mean of the four scores [6]. Information 4308 
on psychometric properties of this instrument have been published [12].  4309 
 4310 
St-Georges Respiratory Questionnaire (SGRQ) 4311 
 For this study, patients completed the section on respiratory symptoms 4312 
from the SGRQ to assess the patientʼs perception of their recent respiratory 4313 
problems.  4314 
This section of the questionnaire includes eight items where individuals 4315 
choose the appropriate answer on a 5-point Likert scale. Each item in the 4316 
232 
questionnaire has an empirically derived weight. The total score is 4317 
representing the sum of these items. The total score ranges from 0 to 100 4318 
and a higher score indicates a worse symptom-related HRQoL [13]. 4319 
Information on psychometric properties of this instrument have been 4320 
published [12]. 4321 
 4322 
Psychiatric Symptom Index (PSI) 4323 
 The PSI is a 29-item questionnaire designed to assess the presence 4324 
and intensity of psychological distress levels in the past two weeks [14]. Items 4325 
are scored using a four-point scale from 0 (never) to 3 (very often). Total and 4326 
subscale scores (depression, anxiety, anger and cognitive disturbance) are 4327 
calculated as a percentage of the total possible score out of 100. Scores of 4328 
>20 are considered to indicate clinically significant levels of psychological 4329 
distress [14]. Information on psychometric properties of this instrument have 4330 
been published [15]. 4331 
 4332 
Primary Care Evaluation of Mental Disorders (Prime-MD)  4333 
The PRIME-MD is a validated brief screening instrument designed to 4334 
detect some of the most common psychiatric disorders seen in community 4335 
and medical settings [16]. It consists of a 27-item patient self-report section 4336 
followed by a structured clinical interview that is used to follow-up patient 4337 
responses. The PRIME-MD evaluates 5 groups of mental disorders (mood, 4338 
anxiety, somatoform, alcohol, eating), and items are based on the diagnostic 4339 
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criteria from the DSM [17]. It has demonstrated very good sensitivity (83%) for 4340 
any psychiatric diagnosis and excellent specificity (88%) across diagnostic 4341 
modules [16]. We administered the mood (depressive) and anxiety disorder 4342 
modules, given they are the most prevalent psychiatric disorders seen in 4343 
asthma patients. We then classified individuals in two groups: either as 4344 
having a mood and/or anxiety disorder (any psychiatric disorder) or not 4345 
having either mood or anxiety disorder (no psychiatric disorder). Information 4346 
on psychometric properties of this instrument have been published [18]. 4347 
 4348 
Spirometry and Methacholine Provocation Testing 4349 
 All patients underwent standard spirometry according to ATS 4350 
guidelines[19], using the reference values derived by Knudson[20]. 4351 
Methacholine challenge testing was performed according to a previously 4352 
published protocol[21]. Normal responsiveness was set at a concentration of 4353 
methacholine causing a 20% fall (PC20) in FEV1 of greater than 16 mg*mL- 4354 
1[22].  4355 
 4356 
Compound Asthma Severity Score 4357 
 OA severity was calculated according to the Quebec Workersʼ 4358 
Compensation Board Scale for OA: 0% = low severity, 100% = maximum 4359 
severity[23]. This scale assesses three factors in the same way as the one 4360 
proposed by the American Medical Association[24]: level of bronchial caliber, 4361 
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degree of bronchial responsiveness, and need for medication to control 4362 
asthma[25]. 4363 
 4364 
Statistical analyses 4365 
 Continuous data are reported as means ± standard deviations or 4366 
medians and 25 and 75 percentiles. Proportions were compared by using 4367 
Chi–Square or Fisherʼs exact test if the expected cell count was <5. 4368 
Continuous variables were compared by using the Mann-Whitney U test. For 4369 
all data analyses, we used the statistical software package SPSS V.19 (SPSS 4370 
Inc., Chicago, USA). A p-value of <0.05 was considered statistically 4371 
significant. 4372 
 4373 
 Measures of reliability 4374 
 Cronbach alphaʼs were calculated to assess the internal consistency of 4375 
the AQLQ(S) total score and each subscale score. Cronbachʼs alpha is a 4376 
numerical coefficient for reliability. The coefficient value ranges from 0 to 1, 4377 
and the higher the score, the more reliable is the generated scale [26]. 4378 
 4379 
 Measures of validity 4380 
 We calculated Spearmanʼs rho for correlation analyses between two 4381 
continuous variables, and we conducted point-biserial correlations which 4382 
allow measurement of the correlation between a continuous variable 4383 
(AQLQ(S) or PSI total or subscale scores) and a dichotomous variable (any 4384 
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psychiatric disorder or no psychiatric disorder according Prime-MD) [27]. The 4385 
correlation was considered small for correlation coefficients between 0.1 and 4386 
0.3, medium between 0.3 and 0.5 and high between 0.5 and 1. 4387 
 4388 
 Receiver operator characteristic (ROC) curve and Youden Index (YI) 4389 
 In order to determine the best cut-off level of the AQLQ(S) emotion 4390 
subscale score for the diagnosis of clinically relevant anxiety and depressive 4391 
symptoms according to the PSI, and mood and/or anxiety disorders according 4392 
to the PRIME-MD, a ROC curve was plotted. The YI was calculated to 4393 
capture the performance of the diagnostic test and to obtain the cut-off in the 4394 
AQLQ(S) emotion subscale score. YI was calculated as follows: 4395 
(Sensitivity+Specificity)-1 [28].  4396 
 4397 
 Linear and logistic regression models 4398 
As data of the dependent variable (PSI anxiety and depression 4399 
subscale scores) were not normally distributed we performed logarithmic 4400 
transformation and then, applied the second power to this data prior to 4401 
performing linear regression. The presence of a psychiatric disorder (mood 4402 
and/or anxiety) was assess by the PRIME-MD and coded as a dichotomous 4403 
variable (yes, no). We used the presence of psychiatric disorder as 4404 
dependent variable and entered the questions of the AQLQ(S) emotions 4405 
subscale score as independent variables in the model. We used the 4406 
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automatic stepwise procedure of the statistical package with a probability of F 4407 
≤0.05 to enter and the probability of F ≥0.10 to remove the co-variate.  4408 
4409 
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Results 4409 
 4410 
Patient characteristics 4411 
 Seventy-three subjects were eligible to participate during the study 4412 
period. We were unable to contact five subjects and eight subjects refused to 4413 
participate, yielding a final sample of 60 subjects and a participation rate of 4414 
82%. Participants did not differ from non-participants with respect to sex, age 4415 
at diagnosis, atopy, smoking status, lung function, hyper-reactivity to 4416 
methacholine, proportion of subjects with OA caused by low molecular weight 4417 
agents, and the number of years at the workplace with symptoms (data not 4418 
shown).  4419 
The mean age of participants was 47.2 ±11.7 years, 75% (n=45) of 4420 
which were male. The median duration of exposure to the causal agent was 4421 
10.5 years (Q1;Q3: 3.1;22.8 years). A total of 42% (n=25) were current 4422 
smokers. Fifty-five percent (n=33) of participants were working at the time of 4423 
re-evaluation, 20% (n=12) were retired, 20% (n=12) were unemployed, and 4424 
5% (n=3) were currently on re-training for another job. Thirty-one percent 4425 
(n=19) reported their overall health status as being fair or poor.  4426 
Asthma-specific quality of life, levels of psychological distress, and the 4427 
frequency of psychiatric disorders assessed at the re-evaluation are shown in 4428 
Table 1. Thirty five percent (n=21) had one or more psychiatric disorder, 19 of 4429 
whom had a mood disorder, 9 of whom had an anxiety disorder, and 2 of 4430 
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whom had both a mood and anxiety disorder according to the PRIME-MD 4431 
evaluation.  4432 
 4433 
Psychometric properties of the AQLQ(S) 4434 
The internal consistency for the AQLQ(S) in this sample was high, with 4435 
Cronbach alphaʼs of 0.934 for the emotion, 0.951 for the symptom, 0.922 for 4436 
the activity, and 0.819 for the environment subscale scores, and 0.936 for the 4437 
total score. The observed cross-sectional correlations between the AQLQ(S) 4438 
total and subscale scores with the compound asthma severity score 4439 
incorporating lung function, bronchial hyperactivity, and current medication 4440 
support a discriminative validity of the AQLQ(S) and can be seen in Table 2.  4441 
 4442 
Correlation between AQLQ and asthma severity 4443 
We investigated the construct validity of the AQLQ(S) and calculated 4444 
correlation coefficients for the different AQLQ(S) scores with the compound 4445 
asthma severity score according to the Quebec Workersʼ Compensation 4446 
Board Scale for OA as well as the symptom score of the SGRQ. All 4447 
combinations of scores between the continuous measures yielded significant 4448 
medium to high correlations (Table 2). 4449 
 4450 
Correlation between AQLQ and measures of psychological distress 4451 
We then calculated correlation coefficients for the different AQLQ(S) 4452 
scores with the PSI total and subscale scores. All combinations of scores 4453 
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between the continuous measures yielded significant medium to high 4454 
correlations, which can be seen in Table 2. The highest correlation was found 4455 
between the PSI anxiety subscale score and the AQLQ(S) total score and 4456 
most of the AQLQ(S) subscale scores.  4457 
We then investigated the diagnostic properties of the AQLQ(S) emotion 4458 
subscale for the detection of clinically significant levels of psychological 4459 
distress according to the anxiety and depression subscales of the PSI. The 4460 
highest Youden index of 0.53 was obtained when choosing less than 5.1 4461 
points as the cut-off for the diagnosis of clinically significant anxiety according 4462 
to the PSI (Figure 1). Fifteen individuals were misclassified: Ten individuals 4463 
had AQLQ(S) scores greater than 5.1 points but were classified as having 4464 
scores greater than 20 points on the PSI anxiety subscale, whereas 5 4465 
individuals had scores than 5.1 points on the AQLQ(S) emotion subscale but 4466 
had scores less than 20 on the PSI anxiety subscale (Figure 2). By using this 4467 
cut-off sensitivity was 72%, specificity 79%, positive predictive value 84% and 4468 
negative predictive value 66% for the diagnosis of clinically significant anxiety 4469 
symptoms according to the PSI. The highest Youden index of 0.63 was 4470 
obtained when choosing less than 5.1 points as the cut-off for the diagnosis of 4471 
clinically significant depressive symptoms (Figure 1). Eleven individuals were 4472 
misclassified: Six individuals had AQLQ(S) scores greater than 5.1 points but 4473 
were classified as having scores greater than 20 points on the PSI depression 4474 
subscale, whereas 5 individuals had scores less than 5.1 points in the 4475 
AQLQ(S) emotion subscale but had scores less than 20 points on the PSI 4476 
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depression subscale (Figure 2). By using this cut-off sensitivity was 81%, 4477 
specificity 82%, positive predictive value 84% and negative predictive value 4478 
79% for the diagnosis of clinically significant depressive symptoms according 4479 
to the PSI. 4480 
When performing linear regression on the PSI anxiety subscale score 4481 
as the dependent variable, the questions “feeling concerned about having 4482 
asthma” and “feeling afraid of getting out of breath” were significantly 4483 
associated (ß=-0.222 S.E. 0.106, p=0.041 and ß=-0.220, S.E. 0.104, 4484 
R2=0.040). The question “feeling afraid of getting out of breath” was 4485 
associated with the PSI depression subscale score and the PSI total score 4486 
(ß=-0.332 S.E. 0.084, p<0.001, R2=0.231and ß=-0.392, S.E. 0.078, 4487 
R2=0.313, respectively). 4488 
 4489 
Correlation between AQLQ and measures of psychiatric disorders 4490 
We calculated point bi-serial correlations with individuals having an 4491 
anxiety disorder, mood disorder, or any psychiatric disorder according to the 4492 
PRIME-MD. Having any mood or any psychiatric disorder showed significant 4493 
correlations in the medium range for all the AQLQ(S) subscale scores and the 4494 
AQLQ(S) total score. There was a small point-biserial correlation between 4495 
having anxiety disorder and the AQLQ(S) emotional function subscale score, 4496 
but not with the AQLQ(S) total score. 4497 
For classifying patients with any psychiatric disorder according to the 4498 
PRIME-MD, a cut-off of less than 4.7 points in the AQLQ(S) emotion subscale 4499 
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misclassified 17/60 individuals: Six individuals had AQLQ(S) scores of  4500 
greater or equal 4.7 points but were classified as having at least one 4501 
psychiatric disorder, whereas 11 individuals had scores less than 4.7 points 4502 
but were classified as not having a psychiatric disorder according the PRIME- 4503 
MD (sensitivity 71%, specificity 72%, positive predictive value 58% and 4504 
negative predictive value 82%, area under the curve 0.736 (95% CI 0.609- 4505 
0.863; data not illustrated)). When classifying patients with any psychiatric 4506 
disorder according the PRIME-MD, 4 out of 21 individuals had scores of ≤20 4507 
points on the PSI anxiety subscale and/or AQLQ(S) scores of ≥5.1 on the 4508 
emotion subscale. Five out of 21 individuals with a psychiatric disorder had 4509 
scores of ≤20 points on the PSI depression subscale and/or had AQLQ(S) 4510 
scores of ≥5.1 on the emotion subscale (Figures 2a and 2b).  4511 
After conducting stepwise logistic regression with any anxiety disorder 4512 
according PRIME-MD as dependent variable, the question “feeling concerned 4513 
about the need to use medication” was the only one with a marginal 4514 
association (ß=0.346, S.E. 0.178, p=0.052, Cox&Snell R2: 0.062). When any 4515 
mood disorder and any psychiatric disorder were used as dependent 4516 
variables, the question “feeling afraid of getting out of breath” showed 4517 
significant association with both (any mood disorder= ß=0.456, S.E. 0.165, 4518 
p=0.006, Cox&Snell R2: 0.137; any psychiatric disorder = ß=0.508, S.E. 4519 
0.169, p=0.003, Cox&Snell R2: 0.166).  4520 
4521 
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Discussion   4521 
 4522 
We found high correlations between impaired asthma-specific quality of life 4523 
and standard measures of psychological distress, and moderate correlations 4524 
between impaired asthma-specific quality of life and psychiatric morbidity (i.e., 4525 
mood and anxiety disorders) in individuals with OA. A cut-off value of <5.1 on 4526 
the AQLQ(S)ʼs emotion subscale could reliably identify individuals with 4527 
clinically significant levels of depressive and/or anxiety symptoms who need 4528 
further evaluation by an validated psychiatric interview.  4529 
There is limited evidence about the association of psychological stress 4530 
and asthma morbidity in individuals with OA [29]. When considering the 4531 
available evidence about the impact of this stress on individuals with non- 4532 
occupational asthma, we can imagine that an additional psychological burden 4533 
is associated with OA. This is in accordance with past findings where subjects 4534 
with OA had slightly but significantly higher impairment in asthma-specific 4535 
quality of life than those with non-occupational asthma, even when controlling 4536 
for asthma severity [30]. In a study of asthmatics affiliated with a health 4537 
maintenance organization in the USA, patients with work exacerbated of 4538 
asthma had lower quality of life measured according to the mood disturbance, 4539 
social disruptions, and health concerns subscales of the Markʼs Asthma 4540 
Quality of Life questionnaire, compared to those individuals with no work 4541 
exacerbated asthma [31].  4542 
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Various and probably many unknown factors contribute to impairment 4543 
of quality of life in individuals with asthma. Malo and co-workers have 4544 
reported a weak but significant correlation between the original AQLQ with 4545 
FEV1, bronchial responsiveness, and asthma severity in a more extensive 4546 
sample of individuals with occupational and non-occupational asthma [30]. 4547 
The AQLQ(S) used in our study and the original AQLQ questionnaires 4548 
distinguish themselves on one point: in the AQLQ(S)ʼs five generic activities 4549 
(strenuous exercise, moderate exercise, work-related activities, social 4550 
activities, and sleep) replaced specific activities that could be chosen by the 4551 
patient in the original questionnaire [6]. We could reproduce these findings 4552 
and could find a larger correlation of the AQLQ(S) subscales and total score 4553 
with the objective asthma severity score. We also found a large correlation 4554 
between the symptom domain of a widely used quality of life questionnaire in 4555 
chronic obstructive lung disease – the SGRQ, which provides support for 4556 
quality of life being related to factors other than objective markers of disease 4557 
severity.  4558 
It is currently unknown how treatment of psychological distress or 4559 
psychiatric morbidity (either using psychotherapy or pharmacotherapy) might 4560 
affect asthma and psychosocial outcomes in individuals with OA. Disease 4561 
management programs for major depressive disorders have been shown to 4562 
be beneficial in reducing the severity of the depression, maintaining 4563 
employment, increasing short term adherence to medication and improving 4564 
the individuals quality of life while being cost-effective [32]. It a recent 4565 
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systematic review, Lerner and Henke have shown that individuals with 4566 
depression have higher unemployment rates, more absenteeism and lower 4567 
at-work performance than individuals without depression [33]. When on 4568 
medical leave, individuals with poor mental health are at risk for prolonged 4569 
work absence [34]. Co-morbid psychiatric disorders are one of the reasons for 4570 
the adverse socioeconomic outcomes in regards of unemployment and 4571 
income loss. As these disorders can influence the individualʼs adherence to 4572 
medication, lifestyle behaviors such as smoking and managing environmental 4573 
asthma triggers, it could at least partially explain the persistent 4574 
symptomatology and bronchial hyperresponsiveness in many individuals with 4575 
OA seen even years after termination of the exposure to a sensitizing agent 4576 
[35, 36].  4577 
We found medium to large correlations between the individual 4578 
AQLQ(S) and the PSI. In point-biserial correlations between AQLQ(S) and 4579 
PRIME-MD outcomes such as having psychiatric disorder the correlations 4580 
were in the range small to medium. In a population sample in Australia, major 4581 
depression according to the PRIME-MD was associated with dyspnoea, 4582 
wakening at night and morning symptoms in asthmatics and these symptoms 4583 
were shown to have the greatest impact on decrease in quality of life scores 4584 
in the SF-36 [37]. When using the Hospital Anxiety and Depression (HAD) 4585 
scale, Rimington and co-workers found moderate correlation of the HAD 4586 
depression subscale and a somewhat lower correlation of the HAD anxiety 4587 
subscale with the AQLQ symptoms subscore in a sample of asthmatic 4588 
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patients attending GP offices in the UK [38]. In that study, hardly any 4589 
correlation of HAD anxiety and depression subscales on the one hand and 4590 
lung function expressed as forced expiratory volume in one second (FEV1) or 4591 
peak flow on the other hand could be demonstrated [38]. In contrast, Hommel 4592 
and co-workers reported anxiety and depression to influence asthma specific 4593 
quality of life measured with the Living with Asthma Questionnaire (LWAQ). 4594 
When performing regression analysis, they demonstrated that anxiety had an 4595 
independent main effect on LWAQ when the model was controlled for 4596 
depression [39]. The impact of concomitant depression and anxiety seems to 4597 
be even more deleterious for health-related quality in life in individuals with 4598 
chronic obstructive pulmonary disease [40].  4599 
The AQLQ(S) has been used in a large variety of clinical therapeutic 4600 
trials and many cross-sectional studies on patients with OA. Measuring 4601 
quality of life with the AQLQ(S) allows us to determine the impact of asthma 4602 
on respiratory symptoms, emotional function and activity limitation, as well as 4603 
environmental stimuli. These factors are important to acknowledge in clinical 4604 
practice when assessing a patient with asthma. In our sample of individuals 4605 
with OA who have been removed from exposure to the sensitizing agent, 4606 
using a cut-off point of 5.1 in the emotional function subscale most reliably 4607 
distinguishes individuals with significant psychological distress, whereas a 4608 
cut-off of 4.7 can be used to identify individuals who are at risk of relevant 4609 
psychiatric disorder according to the PRIME-MD evaluation. It is not the 4610 
intention of the authors to suggest that the evaluation of patients with the 4611 
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AQLQ(S) emotional subscale can replace a structured diagnostic interview by 4612 
a psychiatrist – which is considered to be the gold standard - for the diagnosis 4613 
of psychiatric diseases. Questionnaires such as the Hospital Anxiety and 4614 
Depression Scale (HADS) have been shown to have a sensitivity of 66-78% 4615 
and specificity of 83-97% for the diagnosis of either depression or anxiety 4616 
disorders in a general practice setting [41]. Therefore even administration of 4617 
tools specifically designed to screen for psychiatric disorders would not allow 4618 
making an accurate diagnosis and starting treatment without performing a 4619 
structured psychiatric interview. The advantage of using the AQLQ(S) 4620 
questionnaire is that it is widely available and regularly used in clinical 4621 
practice and trials. It can therefore be used as a screening test. Considering 4622 
the results of the emotional subscale will not only allow to measure the impact 4623 
of asthma on quality of life but also to identify some individuals in whom a 4624 
more extensive investigation such as a structured psychiatric interview is 4625 
warranted. The diagnostic performance of the test using a cut-off of <5.1 in 4626 
the emotional subscale score of the AQLQ(S) is modest for identification of 4627 
clinically important psychological distress according to the PSI. But the 4628 
performance is less for the diagnosis of current psychiatric disorders 4629 
according to the PRIME-MD which relies on the diagnostic criteria for 4630 
depressive and anxiety disorders according to the Diagnostic and Statistical 4631 
Manual of Mental Disorders, 4th Edition, DSM-IV. In fact the positive predictive 4632 
value for the diagnosis of current psychiatric disease by using a cut-off of 4.7 4633 
is close to the predictive value of flipping a coin and would even be lower 4634 
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when this test would be performed in a population with a lower prevalence of 4635 
psychiatric disorders. There is very limited data suggesting that anxiety and 4636 
depression are more common in workers in whom the asthma is related to the 4637 
workplace [42]. In our study all individuals were compensated for OA and one 4638 
could expect that the prevalence of mood and anxiety disorders is more 4639 
prevalent in this population than in most other populations of asthmatics. 4640 
However there is currently no data available to conclude that the prevalence 4641 
of psychiatric disorders is lower in individuals with uncompensated OA or in 4642 
individuals with work-exacerbated asthma. Further studies are needed to 4643 
compare the correlation of psychiatric disorders and psychological distress 4644 
with asthma specific quality of life measures, such as the AQLQ(S), in 4645 
individuals with OA, work-exacerbated asthma and asthma that is unrelated 4646 
to the workplace. [41] 4647 
The AQLQ(S) emotional function subscale respondents report on 4648 
different aspects that have been grouped in this domain by the developers of 4649 
this questionnaire in which the items relate to three broad dimensions 4650 
(concerns, anger and anxiety). When considering individual questions of this 4651 
domain, the one about feeling afraid of getting out of breath was significantly 4652 
associated with the PSI depression subdomain and PRIME-MD mood 4653 
disorder whereas the questions about feeling concern about having asthma 4654 
and about the need to use medication were significantly associated with PSI 4655 
anxiety levels and PRIME-MD anxiety disorders respectively. Since our 4656 
analysis was descriptive, we do not suggest to reduce items that have not 4657 
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shown significant correlation with psychologic distress or psychiatric disorders 4658 
from the emotions subdomain of the AQLQ(S) questionnaire.  4659 
Whereas the PSI is a continuous measure that provides information 4660 
about the number and severity of psychological symptoms, PRIME-MD 4661 
diagnoses are categorical: individuals are classified as having a particular 4662 
disorder or not based on having fulfilled a defined number of diagnostic 4663 
criteria. Therefore, the severity of psychiatric disorders as measured by the 4664 
PRIME-MD cannot be quantified[43]. Clinically, anxiety and depressive 4665 
symptoms (and disorders) overlap significantly, so it can sometimes be 4666 
difficult to determine if these disorders are separate entities or different 4667 
manifestations of the same disorder [39]. Due to the limited number of 4668 
individuals with OA included in our study, we were not able to examine 4669 
associations between AQLQ(S) scores and individual mood and anxiety 4670 
disorders (e.g. panic disorder, generalized anxiety disorder). To demonstrate 4671 
these associations, studies with larger samples of individuals with OA are 4672 
needed. Further our sample consisted of manly male workers with OA and 4673 
therefore one must be cautious when extrapolating our findings to a 4674 
population of female workers as the prevalence of the different forms of 4675 
psychiatric disorders might be different [9]. 4676 
Our study does not allow us to determine the relation of causation. We 4677 
did not have information available about psychological distress or any 4678 
psychiatric disorder prior to the development of OA or at the time the 4679 
diagnosis of OA was made. Furthermore, we did not gather information about 4680 
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concurrent or past behavioural or medical therapy for psychiatric disorders in 4681 
each individual. To our knowledge, the prevalence of psychiatric disorders at 4682 
the time of diagnosis of OA and its devolution after removal from the causing 4683 
agent or workplace is currently unknown and thus other studies are needed to 4684 
investigate these factors in prospective investigations. It is unclear how 4685 
interventions specifically targeted to decrease psychological distress or 4686 
psychiatric disorders change the natural course of both conditions OA and 4687 
concurrent mental disorders.  4688 
An important strength of the present study is that extensive objective 4689 
assessments including spirometry, measurement of nonspecific bronchial 4690 
hyperreactivity, and specific inhalation testing were performed in all 4691 
individuals, the latter of which is considered the reference standard for a 4692 
diagnosis of OA [44, 45].  4693 
 4694 
Conclusions: 4695 
 4696 
Our study suggests that it is important to consider concomitant psychological 4697 
distress and psychiatric morbidity in individuals with OA, even when their 4698 
exposure to the causing allergen has ended. By performing disease-specific 4699 
quality of life assessment with the AQLQ(S), individuals with significant 4700 
psychological distress or psychiatric disorder could be identified and more 4701 
elaborative and conclusive investigations and if necessary treatment be 4702 
offered. 4703 
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Table 1: Description of Quality of Life, Psychological Distress and 4853 
Psychiatric Disorders  4854 
 Frequency (n (%)) Score (median 
(Q1;Q3)) 
Juniper AQLQ(S)   
Symptoms  4.5 (3.5;6.0) 
Activity limitations  4.6 (3.3;5.7) 
Emotional function  5.0 (3.6;6.6) 
Exposure to environmental 
stimuli 
 4.8 (3.3;5.8) 
Total  4.6 (3.6;5.9) 
SGRQ Asthma Symptom 
Score (%) 
 45 (32;71) 
Psychological distress  (PSI score >20)  
Depression 32 (53) 23.0 (10.0;33.0) 
Anxiety 36 (60) 24.0 (12.8;39.0) 
Anger 30 (50) 19.0 (8.0;33.0) 
Cognitive disturbance 31 (52) 24.5 (8.0;39.8) 
Total 34 (57) 24.5 (10.8;37.8) 
Prime-MD   
Any psychiatric disorder  21 (35)  
Any mood disorder 19 (32)  
-­‐ Major depression 8 (13)  
-­‐ Dysthymia 3 (5)  
-­‐ Minor depression 11 (18)  
Any anxiety disorder 9 (15)  
-­‐ Panic disorder 1 (2)  
-­‐ Generalized anxiety 1 (2)  
-­‐ Other anxiety disorder 7 (8)  
Legend: AQLQ(S)=Standardized version of the Juniper Asthma Quality of Life 4855 
Questionnaire; SGRQ : St. George Respiratory Questionnaire; 4856 
PSI=Psychiatric Symptom Index, PRIME-MD= Primary Care Evaluation of 4857 
Mental Disorders questionnaire 4858 
4859 
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Table 2: Correlation of the Asthma Quality of Life Questionnaire by 4859 
Juniper with Psychiatric Symptom Index, the PRIME-MD evaluation, the 4860 
St. George Respiratory Questionnaire and the Asthma Severity 4861 
Compound Score 4862 
 AQLQ 
Symptoms 
AQLQ 
Activity 
limitations 
AQLQ 
Emotional 
functions 
AQLQ 
Exposure to 
environmental 
stimuli 
AQLQ 
Total 
Score 
Asthma 
Severity 
Compound 
Score 
-0.582* -0.611* -0.627* -0.561* -0.650* 
      
SGRQ 
Symptom 
Score 
-.686* -.650* -.610* -.574* -.693* 
      
PSI Anxiety -.623* -.648* -.609* -.616* -.664* 
PSI Anger -.331* -.376* -.344* -.404* -.367* 
PSI 
Depression 
-.558* -.611* -.507* -.639* -.605* 
PSI 
Cognitive 
disturbance 
-.426* -.401* -.373* -.432* -.419* 
PSI Total 
Score 
-.583* -.613* -.553* -.622* -.619* 
      
PRIME-MD 
Anxiety  
0.254 0.163 
 
0.261§ 0.213 0.236 
PRIME-MD 
Mood  
0.352* 0.381* 0.334* 0.402* 0.393* 
PRIME-MD 
Psychiatric 
disorder 
0.396* 0.361* 0.389* 0.427* 0.417* 
Legend: * p<0.01, § p<0.05 4863 
4864 
   259 
	  
	  
Figure 1. Receiver operator curves for the AQLQ(S) emotion subscore 4864 
in the diagnosis of clinically significant anxiety or depression.  4865 
4866 
 4867 
Legend: ROC=Receiver operator characteristic curve. ROC for AQLQ(S) 4868 
emotion subscore in the diagnosis of clinically significant anxiety (>20 points 4869 
in the PSI anxiety subscore; AUC 0.740 (95%CI 0.608-0.872)). ROC for 4870 
AQLQ(S) emotion subscore in the diagnosis of clinically significant 4871 
260 
depression (>20 points in the PSI depression subscore; AUC 0.843 (95%CI 4872 
0.741-0.945)) 4873 
4874 
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Figure 2. Scatterplots showing the correlation of the AQLQ(S) emotion 4874 
with the PSI anxiety subscale and the correlation of the AQLQ(S) 4875 
emotion with the PSI depression subscale.  4876 
4877 
 4878 
Legend: PSI=Psychiatric symptom index; AQLQ(S)=Asthma Quality of Life 4879 
Questionnaire; FP=false-positive; FN=false-negative 4880 
3. Discussion 4881 
 4882 
In this research, we were able to show that: 4883 
1. in the first contribution: Socio-economic factors are associated with 4884 
asthma-specific health outcomes in individuals with OA in Quebec. Individuals 4885 
who were older, with income  of >$30,000 CAD$ and OA to HMW allergens, 4886 
were able to remain longer in their workplace with symptoms before removal 4887 
of exposure. Such a delay was associated with more respiratory symptoms, a 4888 
higher risk of persistent bronchial hyperresponsiveness and higher direct 4889 
costs for compensation.  4890 
2. in the second manuscript: About half of the study participants had clinically 4891 
significant levels of psychological distress, with a correlation between  4892 
psychological distress and clinical markers of OA. Some socio-economic 4893 
factors present at diagnosis of OA were associated with quality of life, 4894 
symptoms and psychological distress measures at re-evaluation 4895 
independently of asthma severity. Being married was associated with worse 4896 
asthma-specific quality of life and worse asthma symptoms in the SGRQ 4897 
symptoms score. Low income and being employed for more than 5 years with 4898 
the same employer at the time of diagnosis were associated with worse 4899 
asthma symptoms. Being a labour union member at the time of diagnosis was 4900 
associated with less psychological distress.  4901 
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3. in the third part of our work, measuring asthma-specific quality of life in 4902 
individuals with OA using  the Juniper Asthma Quality of Life Questionnaire 4903 
(AQLQ(S)) demonstrates high internal consistency, good construct validity 4904 
when compared with other quality-of-life measures such as the symptom 4905 
subdomain of the SGRQ and asthma severity parameters such as lung 4906 
function, bronchial hyperreactivity and asthma medication use. Considering 4907 
the results of the emotional subscale of the AQLQ(S) not only allows us to 4908 
measure the impact of asthma on quality of life, but also helps to identify 4909 
individuals with clinically significant psychological distress for whom a more 4910 
extensive investigation, such as a structured psychiatric interview, is 4911 
warranted. 4912 
 In this general discussion, I will: 4913 
1. Present the strengths and limitations of our study 4914 
2. Extend the discussion of points raised in the discussion sections of the 4915 
specific papers 4916 
3. Outline and emphasize the originality and the possibility for generalization 4917 
of our results. 4918 
4919 
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3.1. Strengths and limitations of this study 4919 
 4920 
Strengths 4921 
 4922 
Confirmation of diagnosis 4923 
 4924 
For this project, we were able to recruit over 80% of individuals whose 4925 
diagnosis of OA had been confirmed using objective measures, including the 4926 
gold standard for the diagnosis of OA, i.e. specific inhalation testing. For all of 4927 
our participants, the diagnosis of OA led to compensation from the Workersʼ 4928 
Compensation Board of Quebec. This is extremely important, since in most 4929 
studies in the field of OA the diagnosis is not confirmed by specific inhalation 4930 
testing, and therefore the studies also include workers with work-exacerbated 4931 
asthma, leading to misclassification of cases. There are very few countries for 4932 
which a sample of subjects with OA confirmed by SIC would have been 4933 
available for study. To our knowledge, in addition to Quebec, only Finland and 4934 
Belgium use SIC, considered as the gold standard for confirming a diagnosis. 4935 
These tests are mandatory in these countries to establish a diagnosis of OA 4936 
for compensation agencies. 4937 
The study participants agreed to undergo extra testing in addition to 4938 
the usual information requested by the Workersʼ Compensation Board. To 4939 
ascertain DAP two years after diagnosis, the worker is interviewed by a 4940 
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physician on current respiratory symptoms and medication use. He then 4941 
undergoes evaluations using lung function tests and BPT with methacholine. 4942 
Additional investigations, such as sputum induction, filling out study 4943 
questionnaires, and a PRIME-MD evaluation, can easily take one to two 4944 
hours in addition to the time already required for the compulsory 4945 
investigations.  4946 
 4947 
 4948 
Characteristics of participants and non-participants 4949 
 4950 
We were able to show that those who refused to participate had similar 4951 
baseline characteristics such as gender, age, atopy status, smoking 4952 
behaviour, lung function, types of causal agents for OA and time with 4953 
symptoms prior to filing a claim with the Workersʼ Compensation Board. 4954 
Similar to the statistics reported by the Workersʼ Compensation Board of 4955 
Quebec, diisocyanates and flour were among the most frequent causes of OA 4956 
in our study sample (483). It is therefore unlikely that significant selection bias 4957 
affected the results when considering the population of individuals with 4958 
compensated OA in Quebec/Canada. 4959 
 4960 
 4961 
4962 
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The variety of functional and socioeconomic information obtained 4962 
 4963 
In the field of OA, many other studies investigated their participants 4964 
only by recording basic respiratory symptoms, lung function, AHR, and 4965 
medication use. However, the impact of OA on an individual is far greater. 4966 
Thus, the evaluation of these patients requires a multidimensional approach 4967 
(410). We have attempted to characterize the type of inflammation present by 4968 
investigating induced sputum. We have also added an extensive standardized 4969 
evaluation of respiratory symptoms, such as the SGRQ and, equally 4970 
importantly, an extensive assessment of quality of life and psychological 4971 
outcomes. 4972 
Regarding quality of life, we used a disease-specific quality of life 4973 
measure, the AQLQ(S) questionnaire developed by Juniper et al., which is 4974 
surely the most widely disseminated quality of life questionnaire used in the 4975 
field of asthma (460, 465). Because there is evidence that patients have 4976 
increased levels of psychological distress, which mainly derives from studies 4977 
that investigated individuals with asthma unrelated to the workplace, we used 4978 
the PSI to measure psychological distress levels. To diagnose the most 4979 
frequent mental disorders in primary care, we used the PRIME-MD 4980 
evaluation.  4981 
 4982 
 4983 
4984 
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Previous studies have paid little attention to socioeconomic factors and OA 4984 
 4985 
As discussed in the Introduction section of this thesis, various socio- 4986 
economic factors are associated with the development, course, and outcome 4987 
of many medical conditions. With regard to OA, previous studies have 4988 
focused on mainly two issues: employment status and loss of income (65, 4989 
160, 177, 178, 180, 183, 396, 398-403, 405, 406, 441, 454). Other important 4990 
factors were often not considered. These included being born either in 4991 
Canada or abroad, salary at the time of onset of OA, employment status at 4992 
the time of re-assessment, marital status, having dependent children to 4993 
support, or specific factors at work, such as company size, number of years 4994 
employed, or being unionized. Additionally, we could obtain individual 4995 
objective data from the Workersʼ Compensation Board records. 4996 
Referring to these data provided information on important issues that 4997 
were not previously analyzed: 1. if the individual was assisted with finding a 4998 
new job, had occupational counseling, or was granted support for re- 4999 
education; 2. precise information on the costs that the Workersʼ 5000 
Compensation Board had to spend on IRR and DAP for each participant. The 5001 
latter information was unique and has not been previously published.  5002 
 5003 
 5004 
5005 
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Limitations 5005 
 5006 
Sample size 5007 
 5008 
The relatively small number of individuals included in our analysis (N = 5009 
60) is an important limitation. Small sample sizes increase the risk that the 5010 
sample is not representative of the population one wishes to study and can 5011 
lead to erroneous inferences. A small sample size increases the risk of Type I 5012 
and II errors: A Type I error occurs if we reject a null hypothesis that is 5013 
actually true for the population, whereas a Type II error occurs if we fail to 5014 
reject a null hypothesis that is actually not true for the population (484). Non- 5015 
participants might differ from participants regarding various asthma-related 5016 
and socio-economic outcomes.  5017 
One can hypothesize that individuals who have lower socio-economic 5018 
status, who are migrants, and who have difficulty understanding and speaking 5019 
the local language are more reluctant to participate in this kind of study. Yet, 5020 
we had a relatively small proportion (20%) of non-participants. Moreover, we 5021 
showed that the characteristics of non-participants were similar to those of 5022 
participants. 5023 
To increase the sample size, one might extend the inclusion criteria or 5024 
the time during which individuals can be included in the study. In our case, 5025 
including workers with OA examined by other Workersʼ Compensation Board 5026 
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committees (B committee of Montreal, Sherbrooke and Quebec City) might 5027 
have been a possibility. According to our estimates, including these workers 5028 
might have increased the sample size by approximately one third. However, 5029 
performing sputum induction and analyzing these specimens require 5030 
specialized equipment and experience and are not routinely available in 5031 
hospitals where the Workersʼ Compensation Board committees meet and 5032 
examine claimants. Indeed, examination of induced sputum is not routinely 5033 
performed in Sherbrooke or during investigations by the other Workersʼ 5034 
Compensation Board committee in Montreal (Montreal Chest Hospital) and 5035 
Quebec City (Hôpital Laval).  5036 
In addition, despite the fact that the PRIME-MD was designed for use 5037 
in general practice, the people who administer this questionnaire should have 5038 
acquired some experience with this instrument before using it for a research 5039 
study. To limit the inter-observer variability, we decided that all of the 5040 
additional tests required for this study should be performed by members of 5041 
our research team at the Sacré-Coeur Hospital. Because the compulsory 5042 
investigations already take half a day and due to distance constraints, we 5043 
thought that only a few individuals with OA who were investigated in 5044 
Sherbrooke and Quebec would have come to Montreal to participate in our 5045 
study if they were offered the chance to participate. Finally, as alluded to 5046 
before, we did not want to recruit participants in other study centers outside of 5047 
the province of Quebec because the criteria and tests used for diagnosing OA 5048 
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are less stringent and the eligibility criteria for compensation differ 5049 
substantially. 5050 
For this investigation, we studied workers who had made claims for 5051 
compensation for OA to the Quebec CSST between 2004 and 2006. These 5052 
individuals were recruited for this study at the time of their re-evaluations for 5053 
DAP about two and a half years after their diagnoses. Extending the inclusion 5054 
criteria and including individuals who made claims after 2006 was not 5055 
possible, as this would have precluded analyzing the data obtained during the 5056 
candidateʼs studies in Montreal. Extending the criteria to include individuals 5057 
who made claims before 2004 would have required contacting these 5058 
individuals and repeating all measures that were done during the past 5059 
investigation for the settlement of DAP. This ”excess” information would not 5060 
have been in synchrony with the routine information obtained at the time of 5061 
assessment by a Workersʼ Compensation Board committee.  5062 
 5063 
 5064 
Recall bias 5065 
 5066 
In immunological asthma, the appearance of respiratory symptoms is 5067 
often gradual, and recall bias is possible for the time of appearance of 5068 
symptoms and therefore the interval a subject reported being symptomatic in 5069 
the workplace. We tried to minimize that bias by consulting the most reliable 5070 
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documented source of information, the official Workersʼ Compensation Board 5071 
report.  5072 
 5073 
 5074 
Study design  5075 
 5076 
The study design used was partly longitudinal (for clinical and 5077 
functional data) and partly cross-sectional (for other outcomes). We did not 5078 
collect information about disease-specific quality of life and psychological 5079 
distress, and psychiatric morbidity (mood and anxiety disorders) at the time of 5080 
diagnosis, and therefore have no information about the interaction of OA with 5081 
psychological distress/psychiatric disorders and the progression of both 5082 
conditions. Furthermore, we did not systematically collect information on 5083 
medication used in treating psychiatric disorders. It is possible that some 5084 
individuals were treated successfully for psychiatric disorders, and that the 5085 
results of our study underestimate impairment in quality of life and 5086 
psychological distress in individuals with OA. However, we assume that the 5087 
number of individuals with treatment for psychiatric disorders in the study 5088 
sample was small. Furthermore, we figure out that information about current 5089 
or past psychotherapy and medical treatment for psychiatric disorders was 5090 
not recorded with the same precision and details as treatment for asthma, 5091 
since the individuals were claiming compensation for a pulmonary disease. 5092 
To our knowledge, the prevalence of psychiatric disorders at the time of 5093 
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diagnosis of OA and its devolution after removal from the causing agent or 5094 
workplace is currently unknown; further studies are therefore needed to 5095 
investigate these factors in prospective investigations.  5096 
Due to the limited number of workers with OA included in our study, we 5097 
were not able to examine associations between AQLQ(S) scores and 5098 
individual mood and anxiety disorders (e.g. panic disorder, generalized 5099 
anxiety disorder). To demonstrate these associations, studies with larger 5100 
samples of individuals with OA are needed. Furthermore, our sample 5101 
consisted of mainly male workers with OA; we must therefore be cautious 5102 
when extrapolating our findings to a population of female workers, as the 5103 
prevalence of different forms of psychiatric disorders may be different (379). 5104 
5105 
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3.2. Interpretation of study findings 5105 
 5106 
Some of the issues discussed in the following section were included in 5107 
the discussion sections of specific manuscripts, although not sufficiently 5108 
extensively, which justifies the following discussion. 5109 
 5110 
Manuscript no. 1 5111 
 5112 
Eligibility for compensation for OA as well as compensation processes 5113 
differ depending on the country or even province.  Individuals with OA may 5114 
therefore choose not to file a claim with the Workersʼ Compensation Board 5115 
and instead remain exposed to the causing allergen in the workplace (397). 5116 
Even in Quebec, where an effective compensation system is in place, a study 5117 
by Provencher et al. showed that there were approximately three times more 5118 
individuals identified by OA specialists as having a high probability of OA per 5119 
year than individuals whose claims were actually compensated each year by 5120 
the Workersʼ Compensation Board (453). There are sparse data on 5121 
characteristics and disease outcomes for individuals with OA who choose not 5122 
to file a claim with the Workersʼ Compensation Board. It seems that the most 5123 
frequent causal agents are no different in individuals with suspected OA than 5124 
in those whose OA is accepted by the Workersʼ Compensation Board. In the 5125 
study by Provencher and co-workers, about 15% of reported cases of OA 5126 
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were not covered by the Workersʼ Compensation Board and were therefore 5127 
not eligible for compensation. This was especially the case for workers with 5128 
agricultural activities and those with suspected OA where farm animals were 5129 
suspected of causing asthma (453).  5130 
There are several reasons for which claims for OA may not be reported 5131 
to the compensation agencies. Many compensation agencies in Canada have 5132 
shifted to so-called “experience-rating” of the premiums that need to be paid 5133 
by employers, meaning that premiums in subsequent years will be higher for 5134 
employers who file more claims (337). The advantage of such an approach is 5135 
that employers are interested in improving workplace safety, as it may lead to 5136 
a lower number of claims and therefore lower costs. However, employers may 5137 
“encourage” their workers not to report injuries or occupational diseases. 5138 
Some employers may even pay premiums for those workers who do not call 5139 
in sick and do not report workplace injuries. Further, it is possible that 5140 
employers outsource unsafe work to smaller companies where workplace 5141 
health and safety issues may be taken less seriously. Such workplaces may 5142 
not accept trade unions, or they may hire contract employees such as 5143 
seasonal workers on a temporary work permit who may not know that they 5144 
are covered by the Workersʼ Compensation Board or may be reluctant to file 5145 
a claim for fear of losing their work permit.  Self-employed workers, who are 5146 
frequently not covered by the Workersʼ Compensation Board, will therefore 5147 
not file a claim if an occupational disease or injury occurs (337). 5148 
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One of the original aims of this study was to investigate whether 5149 
participants born outside Canada would take longer before filing a claim with 5150 
the Workersʼ Compensation Board compared to individuals who were born in 5151 
Canada, resulting in worse socio-economic and OA outcomes. However, the 5152 
sample included only 9 (15%) individuals with migrant backgrounds. Probably 5153 
due to the heterogeneous nature of major socio-economic factors in this 5154 
migrant population, as well as the small sample size, the disease and socio- 5155 
economic outcomes determined in this study did not differ according to 5156 
immigration status. 5157 
As discussed in the Introduction of this thesis, higher income is in 5158 
general associated with better health outcomes;  this association was 5159 
confirmed by Wilkins and co-workers for the Canadian setting (485). Absolute 5160 
poverty usually refers to having less than an absolute minimum income level 5161 
based on the costs of basic needs (486). In Canada, the definition of low 5162 
income set by Statistics Canada is frequently used. However, the cut-off is set 5163 
differently every year, so it is difficult to objectively select a minimum set of 5164 
necessities for basic life (486). Quebec is the province with the highest 5165 
proportion of individuals living on a low income (19%) compared to other 5166 
provinces in Canada (the Canadian average is 16%) (486). We defined low 5167 
income as having an income at the time of diagnosis that was less than 110% 5168 
of the cut-off value for low income as defined by Statistics Canada. Even 5169 
using that stricter definition, the Quebec average was below the national 5170 
average. One explanation for this finding is that workers who are eligible for 5171 
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compensation are more often skilled workers with somewhat higher salaries 5172 
than unskilled workers who may work in part-time jobs or smaller companies 5173 
and may work on temporary employment contracts.  5174 
Twenty-eight study participants, or 48% of the study population, were 5175 
members of a labour union. Also, about two-thirds of the participants were 5176 
employed by a company with more than 20 employees. In larger companies, 5177 
workplace health and safety issues are usually taken more seriously, with 5178 
safety training offered and formal operating procedures and rules laid down.  5179 
The proportion of larger companies that host trade unions is higher (486). 5180 
Further, there is a higher likelihood of inspections by government agencies or 5181 
Workersʼ Compensation Board representatives in response to worker or union 5182 
complaints about health and safety conditions (337). Also, it is far more 5183 
difficult to relocate a worker with OA to stop ongoing exposure to the causal 5184 
agent in a small company, where job opportunities are limited and the 5185 
workers may all work in the same room. Small company size has been shown 5186 
to be a risk factor for job change or unemployment in individuals with OA 5187 
(399). 5188 
In the article published in the European Respiratory Journal, we 5189 
showed that workers who are older, earn a higher salary and have asthma 5190 
related to HMW allergens are exposed for a longer time with symptoms prior 5191 
to removal from exposure. Our study was the first to investigate associations 5192 
between socio-economic factors and this important prognostic factor. 5193 
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Older workers generally earn higher salaries, are more likely to have 5194 
dependent children and may encounter more problems in finding a new job. 5195 
These factors may make subjects more reluctant to report to a medicolegal 5196 
agency. Also, individuals with dependent children remain exposed for a 5197 
longer time with symptoms prior to removal from exposure, as they may 5198 
hesitate to claim compensation because they fear losing not only their job and 5199 
income, but also their self-esteem and status as a provider for the family. 5200 
Most of these arguments would also hold for married men. 5201 
We also found that subjects with an educational profile higher than the 5202 
secondary level tended to be exposed for a longer time with symptoms prior 5203 
to removal from exposure, which is different from findings published by other 5204 
researchers. Low educational level has been identified as a risk factor for 5205 
work-related asthma in the young population (406), for a delay until a 5206 
diagnosis of OA is made (441) and as a predictor for unemployment after a 5207 
diagnosis of OA (160, 399). However, when we controlled the analysis for 5208 
other important covariates (sex, immigration and marital status, income, age, 5209 
having dependent children to support), education, probably because of its 5210 
association with income, was no longer significantly associated with the 5211 
number of years of exposure with symptoms before removal from exposure. 5212 
In our study, higher income was associated with a longer exposure in 5213 
the workplace with symptoms prior to removal from exposure. This is contrary 5214 
to the findings of a study by Poonai and co-workers in Ontario/Canada, in 5215 
which the time taken to obtain a diagnosis of OA was longer in subjects with a 5216 
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low household income (441). This difference might be explained by the fact 5217 
that the outcome of our study was slightly different. We measured the median 5218 
exposure time with symptoms before removal from exposure, while in the 5219 
study by Poonai, the mean duration of symptoms was determined before the 5220 
final clinical diagnosis was made. However, in a later study by the same 5221 
researchers, lower household income was no more related with time to 5222 
diagnosis of OA (454). The time it takes to make a final diagnosis depends on 5223 
many factors, such as awareness and the availability of information about OA 5224 
to workers, employers and physicians, as well as access to specialized 5225 
centres. Other important factors may include the severity of symptoms, the 5226 
nature and extent of work exposure and the compensation that is offered. We 5227 
explain the difference in our findings by the fact that the comprehensive 5228 
system of management and compensation of OA in Quebec does not prevent 5229 
workers with lower income from claiming compensation, but rather allows 5230 
them to seek help and investigation without significant loss of income and 5231 
with an opportunity to retrain into a new job at a similar or even higher salary. 5232 
By contrast, workers with higher income and higher education are probably 5233 
more hesitant to claim as they have more to lose in terms of income and 5234 
retraining opportunities. Part-time workers may fear job loss or refusal of 5235 
employment insurance eligibility, while workers in well-paid jobs face a 5236 
possible loss of income or social status (42). OA is a condition that, according 5237 
to the results of our study, may have more detrimental effects on workers with 5238 
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higher socio-economic status, a situation that is the reverse of what is found 5239 
for most health conditions.  5240 
Prolonged exposure of symptomatic workers in their workplace was 5241 
associated with: 1) increased asthma severity at diagnosis and persistent 5242 
bronchial hyperresponsiveness with the need for increased anti-asthma 5243 
medication at re-evaluation, more than two-and-a-half years after cessation of 5244 
exposure; and 2) higher direct costs for the medico-legal compensation 5245 
agency.  5246 
Most follow-up studies of OA have consistently shown that the duration 5247 
of exposure with symptoms was the principal determinant for the persistence 5248 
of asthma after cessation of exposure (53, 173, 174).  However, even after 5249 
adjusting for asthma severity in our model, socio-economic factors (income 5250 
and dependent children), as well as age and the nature of the agent, 5251 
remained significantly associated with the length of time with symptoms prior 5252 
to removal from exposure, which demonstrates that these factors play a 5253 
significant role on their own. These findings are unique. They also show that 5254 
socioeconomic factors, which have been largely neglected in previous studies 5255 
to date, play a critical role in OA. Past studies failed to demonstrate that 5256 
subjects with more severe asthma are more likely to be unemployed after 5257 
diagnosis (160, 180, 399). However, none of these studies investigated direct 5258 
costs to the medico-legal agency for compensation for lost income and 5259 
functional impairment. In this respect, our study must also be considered as 5260 
original because we could analyze precise information on costs for 5261 
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compensation, which information was kindly provided to us by the Quebec 5262 
Workersʼ Compensation Board. 5263 
 In the multivariate analysis, higher age and remaining exposed in the 5264 
workplace with symptoms for more than 12 months were associated with 5265 
higher direct costs for compensation even after controlling for employment 5266 
status. In a working population, indirect costs due to absenteeism and 5267 
presenteeism related to asthma may even be higher than direct costs (362). 5268 
Individuals with asthma have been shown to have lower levels of self-related 5269 
work-effectiveness due to their condition (354, 357, 358), and it has been 5270 
shown that in chronic conditions such as asthma, more work performance is 5271 
lost from presenteeism than from absenteeism (487).  5272 
 5273 
 5274 
Manuscript no. 2 5275 
 5276 
In the second article, published in the Journal of Occupational and 5277 
Environmental Medicine, we were able to show that a high proportion of 5278 
patients with OA have moderate impairment in disease-specific quality of life, 5279 
elevated levels of psychological distress and a high prevalence of psychiatric 5280 
(mood and anxiety) disorders two years after their initial diagnosis.   5281 
Despite the fact that most of the study participants were no longer 5282 
working at the workplace that caused OA at the time of re-evaluation, 5283 
participants had moderately impaired quality of life as measured with the 5284 
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AQLQ(S). This is in line with past studies showing that more than 70% of 5285 
subjects continue to have symptoms and use asthma medication despite 5286 
having been removed from the workplace for more than two years (488). In 5287 
workers with different allergic manifestations due to natural latex, Al-Otaibi 5288 
and co-workers reported a decrease in disease-specific quality of life 5289 
impairment with increasing  time since the diagnosis was made and duration 5290 
of symptoms (409).  5291 
There is limited evidence for the association of psychological stress 5292 
and asthma morbidity in individuals with OA [29]. When considering the 5293 
available evidence about the impact of this stress on individuals with non-OA, 5294 
we can imagine that an additional psychological burden is associated with 5295 
OA. This is in line with past findings showing that subjects with OA had 5296 
slightly but significantly higher impairment in asthma-specific quality of life 5297 
than those with non-OA, even after controlling for asthma severity (407). In a 5298 
study of asthmatics affiliated with a health maintenance organization in the 5299 
United States, patients with WEA had lower quality of life, as measured by  5300 
the mood disturbance, social disruption and health concern subscales of the 5301 
Sydney Asthma Quality of Life questionnaire, compared to those with no 5302 
WEA (166).  5303 
In our study, between 35% and 47% of participants had clinically 5304 
significant levels of psychological distress and 35% met criteria for one or 5305 
more current mood or anxiety disorders according to the PRIME-MD. Without 5306 
considering asthma severity, in non-OA patients seen in our hospital asthma 5307 
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clinic, the prevalence of anxiety or mood disorder was comparable at 31% 5308 
(379). In our study, all the subjects were compensated for OA; it would be 5309 
reasonable to expect that the prevalence of mood and anxiety disorders is 5310 
greater in this population than in most other populations of asthmatics. 5311 
However, there are currently no data available that would lead us to conclude 5312 
that the prevalence of psychiatric disorders is lower in individuals with 5313 
uncompensated OA or in those with WEA. We are not aware of any other 5314 
study that has determined the prevalence of psychiatric disease in a 5315 
population of patients with OA, with the exception of the study by Yacoub et 5316 
al. in our clinic population that reported 35% of OA patients having possible or 5317 
probable anxiety disorder and 23% possible or probable dysthymia (410).  5318 
Our study shows that the principal factor associated with impact on 5319 
quality of life and psychological outcomes is the severity of asthma. There are 5320 
conflicting findings concerning the correlation between objective parameters 5321 
of asthma severity and anxiety levels. Some studies show significant 5322 
correlations between peak expiratory flow variability and self-reported anxiety 5323 
in the Beck Anxiety Symptom Inventory (489), whereas other studies did not 5324 
report any correlation between psychological distress and lung function (384, 5325 
490). Depression does not appear to be associated with objective measures 5326 
of asthma severity. In a pilot study, asthmatics with a history of mood 5327 
disorders seemed to have less severe airway obstruction and less severe 5328 
asthma (491). Elevated depression scores were associated with perceived 5329 
asthma severity and risk, but not with intubation history, number of 5330 
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hospitalizations or asthma medication history (492). Interestingly, we found a 5331 
correlation between the proportion of sputum eosinophils and mood 5332 
disorders. It has been shown that eosinophilic airway inflammation is more 5333 
pronounced following antigen challenge during final examinations among 5334 
college students and is associated with higher self-reported psychological 5335 
stress (377).  5336 
While the PSI questionnaire provides a continuous measure of the 5337 
number and severity of psychological symptoms, PRIME-MD diagnoses are 5338 
categorical: individuals are classified by the presence or absence of a 5339 
particular disorder based on the presence or absence of a defined number of 5340 
diagnostic criteria according to the DSM-IV. Therefore, the severity of 5341 
psychiatric disorders as measured by the PRIME-MD cannot be quantified 5342 
(493). Clinically, anxiety and depressive symptoms (and disorders) overlap 5343 
significantly, so it can sometimes be difficult to determine whether these 5344 
disorders are separate entities or different manifestations of the same 5345 
disorder (489). 5346 
In this study, for the first time, we identified risk factors that were 5347 
present at the time of OA diagnosis and were associated with decreased 5348 
disease-specific quality of life, increased psychological distress, and a 5349 
diagnosis of psychiatric disease later in time when the individuals were re- 5350 
evaluated to set the DAP. 5351 
In the multivariate linear regression a priori model, the asthma severity 5352 
compound score was the only factor significantly associated with the 5353 
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AQLQ(S) total score. Other covariates, such as sex, age, current employment 5354 
status and the time since diagnosis of OA and consequent removal from the 5355 
causal allergen, all factors found significant at a p<0.2 level in the univariate 5356 
analysis, were not significantly associated with disease-specific quality of life.  5357 
Being married at the time of diagnosis was associated with more 5358 
severe quality of life impairment, measured as the total AQLQ(S) and in the 5359 
SGRQ symptom score. In general, married individuals often have better 5360 
health status than their unmarried counterparts (494). However, the contrary 5361 
is also true: very close relationships such as an unhappy marriage may have 5362 
a negative effect on mental health (265) whereas singles seem to have better 5363 
health outcomes when compared to those in low-quality marriages, as shown 5364 
in hypertension research studies (268). Job loss due to OA and resulting 5365 
income and social status losses may influence quality of life; this could be 5366 
even more important in individuals who have a dependent spouse.  5367 
Participants who were members of labour unions at the time of 5368 
diagnosis had lower psychological distress levels at re-evaluation. The 5369 
mission of a labour union is to defend the economic, professional and social 5370 
interests of workers, especially in the workplace. Workers may thereby benefit 5371 
from labour union assistance in terms of complying with the requirements of 5372 
filing a claim for compensation. Moreover, they may receive support during 5373 
the rehabilitation phase (e.g. in finding a new workplace, exploring 5374 
possibilities for re-training programs, receiving legal support, etc.), which 5375 
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would explain lower levels of psychological distress at the time of re- 5376 
evaluation.  5377 
Although employment status at the time of re-evaluation was 5378 
significantly related to quality of life and psychological outcomes in the 5379 
univariate analysis, this was not the case in the multivariate analysis, in 5380 
contrast to asthma severity, which was significantly correlated to quality of life 5381 
and psychological outcomes in both the univariate and multivariate analyses.  5382 
In workers with asthma due to diisocyanates, quality of life and perception of 5383 
asthma symptoms were related to employment status and asthma control 5384 
even after controlling for various confounders such as age, smoking, sex and 5385 
atopy status (403). 5386 
Another important finding that has previously never been investigated 5387 
in the field of OA was the association between direct costs and psychological 5388 
outcomes. We found small to medium significant correlations between quality 5389 
of life measures and the anger subscale of the PSI questionnaire and 5390 
compensation costs. The correlation was strongest with the CFI 5391 
compensation component, which reflects disease severity. As many factors 5392 
influence CLI costs (age and income at the time of diagnosis being the most 5393 
important factors), it is not surprising that we could not find any association 5394 
between quality of life, psychological distress and costs for CLI. 5395 
 5396 
 5397 
Manuscript no. 3 5398 
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 5399 
In the third article, published in Health and Quality of Life Outcomes, 5400 
we found high correlations between impaired asthma-specific quality of life 5401 
and standard measures of psychological distress, and moderate correlations 5402 
between impaired asthma-specific quality of life and psychiatric morbidity (i.e. 5403 
mood and anxiety disorders). We also found that a cut-off value of <5.1 on the 5404 
AQLQ(S)ʼs emotion subscale could reliably identify individuals with clinically 5405 
significant levels of depressive and/or anxiety symptoms who require further 5406 
evaluation by a validated psychiatric interview. To our knowledge, the use of 5407 
a disease-specific quality of life measure like the AQLQ(S) to identify 5408 
individuals with a high probability of psychiatric disease has not been 5409 
previously published and, thus, is unique. In addition, information on internal 5410 
consistency and construct validity of the AQLQ(S) in a study population of 5411 
individuals with OA have not been previously reported. Therefore, our study 5412 
contributes to the on-going validation of this instrument.  5413 
Various and probably many unknown factors contribute to impairment 5414 
of quality of life in individuals with asthma. Malo and co-workers have 5415 
reported a weak but significant correlation between the original AQLQ with 5416 
FEV1, bronchial responsiveness and asthma severity in a more extensive 5417 
sample of individuals with occupational and non-OA (407). The AQLQ(S) 5418 
used in our study and the original AQLQ questionnaires differ on one point: in 5419 
the AQLQ(S), five generic activities (strenuous exercise, moderate exercise, 5420 
work-related activities, social activities and sleep) replaced specific activities 5421 
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that could be chosen by the patient in the original questionnaire (465). We 5422 
were able to reproduce these findings and find a larger correlation of the 5423 
AQLQ(S) subscales and total score with the objective asthma severity score. 5424 
We also found a high correlation between the symptom domain of a widely 5425 
used quality of life questionnaire in chronic obstructive lung disease – the St. 5426 
Georgeʼs Respiratory Questionnaire, which provides support for quality of life 5427 
being related to factors other than objective markers of disease severity.  5428 
We found medium-to-high correlations between the individual AQLQ(S) 5429 
and the PSI. In point-biserial correlations between AQLQ(S) and PRIME-MD 5430 
outcomes such as having a psychiatric disorder, the correlations were in the 5431 
range of small to medium. In a population sample in Australia, major 5432 
depression according to the PRIME-MD was associated with dyspnoea, 5433 
waking at night and morning symptoms in asthmatics, and these symptoms 5434 
were shown to have the greatest impact on decrease in quality of life scores 5435 
in the SF-36 (383). When using the Hospital Anxiety and Depression (HAD) 5436 
scale, Rimington and co-workers found a moderate correlation of the HAD 5437 
depression subscale and a somewhat lower correlation of the HAD anxiety 5438 
subscale on the one hand with the AQLQ symptoms subscore on the other 5439 
hand in a sample of asthmatic patients attending primary care offices in the 5440 
UK (490). In that study, hardly any correlation between HAD anxiety and 5441 
depression subscales on the one hand and lung function expressed as forced 5442 
expiratory volume in one second (FEV1) or peak flow on the other hand could 5443 
be demonstrated (490). By contrast, Hommel and co-workers reported that 5444 
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anxiety and depression influenced asthma-specific quality of life measured 5445 
with the Living with Asthma Questionnaire (LWAQ). When performing 5446 
regression analysis, these authors demonstrated that anxiety had an 5447 
independent main effect on LWAQ when the model was controlled for 5448 
depression (489).  5449 
Given the frequent co-occurrence of psychological distress or 5450 
psychiatric morbidity in individuals with OA, it would be of great help to have 5451 
tools available that are easy to administer and can be used to identify 5452 
individuals at risk for these conditions. The AQLQ(S) has been used in a large 5453 
variety of clinical therapeutic trials and many cross-sectional studies carried 5454 
out in patients with OA. Measuring quality of life with the AQLQ(S) allows us 5455 
to determine the impact of asthma on respiratory symptoms, emotional 5456 
function, activity limitation as well as environmental stimuli. These factors are 5457 
also important to acknowledge in clinical practice when assessing a patient 5458 
with asthma. In our sample of individuals with OA who have been removed 5459 
from exposure to the sensitizing agent, using a cut-off point of 5.1 in the 5460 
emotional function subscale most reliably distinguishes individuals with 5461 
significant psychological distress, whereas a cut-off of 4.7 can be used to 5462 
identify individuals who are at risk of relevant psychiatric disorders according 5463 
to the PRIME-MD evaluation. We do not suggest that the evaluation of 5464 
patients with the AQLQ(S) emotional subscale can replace a structured 5465 
diagnostic interview by a psychiatrist – which is considered to be the gold 5466 
standard – for the diagnosis of psychiatric diseases. Questionnaires such as 5467 
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the HAD have been shown to have a sensitivity of 66-78% and specificity of 5468 
83-97% for the diagnosis of either depression or anxiety disorders in a 5469 
general practice setting (476). Therefore, even the administration of tools 5470 
specifically designed to screen for psychiatric disorders would not make it 5471 
possible to arrive at an accurate diagnosis and start treatment without 5472 
performing a structured psychiatric interview. The advantage of using the 5473 
AQLQ(S) questionnaire is that it is widely available and regularly used in 5474 
clinical practice and trials. It could therefore be used as a screening test: 5475 
Considering the results of the emotional subscale would not only enable us to 5476 
measure the impact of asthma on quality of life, but also help to identify some 5477 
individuals for whom a more extensive investigation, such as a structured 5478 
psychiatric interview, is warranted. The diagnostic performance of the test 5479 
using a cut-off of <5.1 in the emotional subscale score of the AQLQ(S) is a 5480 
modest means of identifying clinically important psychological distress 5481 
according to the PSI. However, performance is lower for the diagnosis of 5482 
current psychiatric disorders according to the PRIME-MD, which relies on, 5483 
diagnostic criteria for depressive and anxiety disorders as based on the 5484 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, DSM-IV. In 5485 
fact, the positive predictive value for the diagnosis of current psychiatric 5486 
disease using a cut-off of 4.7 is close to the predictive value of flipping a coin, 5487 
and would even be lower when this test is performed in a population with a 5488 
lower prevalence of psychiatric disorders.  5489 
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Importantly, we must mention that it is not known whether interventions 5490 
specifically targeted to decrease psychological distress or psychiatric 5491 
disorders change the natural course of both conditions, that is OA and 5492 
concurrent mental disorders. It is also currently not known whether treatment 5493 
of psychological distress or psychiatric morbidity (using either psychotherapy 5494 
or pharmacotherapy) might affect asthma and psychosocial outcomes in 5495 
individuals with OA. Disease management programs for major depressive 5496 
disorders have been shown to be beneficial in reducing the severity of 5497 
depression, maintaining employment, increasing short-term adherence to 5498 
medication and improving the individualʼs quality of life while being cost- 5499 
effective (495). There is limited evidence from a randomized controlled trial in 5500 
individuals with mild and moderate asthma suggesting that cognitive 5501 
behavioral therapy is associated with improvements in mood, lung function, 5502 
medication adherence, and asthma-related quality of life (496). 5503 
 In a recent systematic review, Lerner and Henke have shown that 5504 
individuals with depression have higher unemployment rates, more 5505 
absenteeism and lower at-work performance than individuals without 5506 
depression (497). When on medical leave, individuals with poor mental health 5507 
are at risk for prolonged work absence (498). Co-morbid psychiatric disorders 5508 
are one of the reasons for adverse socio-economic outcomes in terms of 5509 
unemployment and income loss. Since these disorders can influence the 5510 
individualʼs adherence to medication, lifestyle behaviours such as smoking 5511 
and managing environmental asthma triggers, this could at least partially 5512 
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explain the persistent symptomatology and bronchial hyperresponsiveness in 5513 
many individuals with OA seen even years after the end of exposure to a 5514 
sensitizing agent (152, 499). 5515 
 5516 
 5517 
3.2.1. Originality of results  5518 
 5519 
Only a few previous studies have investigated the associations 5520 
between socio-economic factors and asthma-specific outcomes and only one 5521 
pilot study has investigated psychiatric distress and the prevalence of mental 5522 
disorders in individuals with OA.  5523 
 5524 
- This is the first descriptive study that sought to characterize individuals with 5525 
OA diagnosed by SIC by studying various important socio-economic factors 5526 
and their associations with disease and cost outcomes.  5527 
 5528 
- Despite the limited sample size, the high participation rate and the good 5529 
characterizations of the study participants by the extensive investigations, 5530 
including SIC, minimize the risks of significant bias and misclassifications. 5531 
 5532 
- We have found intriguing results that were contrary to the study hypothesis. 5533 
Indeed, the finding that having a higher revenue is associated with more 5534 
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severe disease is highly original and contrary to what is almost consistently 5535 
found for all types of diseases. These unexpected results should encourage 5536 
other researchers who work in developed and lesser-developed countries to 5537 
initiate similar studies.  5538 
 5539 
- We were able to show for the first time that those individuals with symptoms 5540 
who remain in the workplace for a shorter time not only have less severe 5541 
asthma, but this shorter time interval is also associated with lower costs for 5542 
compensation for the Workersʼ Compensation Board when compared with 5543 
those individuals for whom this interval is longer. 5544 
 5545 
- We showed that some socio-economic factors at the time of OA diagnosis 5546 
were associated with worse quality of life and increased the psychiatric 5547 
distress levels about two and a half years later when the individuals were re- 5548 
evaluated by the Workersʼ Compensation Board. These associations have not 5549 
been previously investigated in a prospective manner for OA. 5550 
 5551 
- We have provided additional validation of the AQLQ(S) questionnaire 5552 
developed by Juniper et al. in a study population of individuals with OA and 5553 
have shown that the emotional function sub-domain of this questionnaire can 5554 
identify individuals with clinically significant levels of psychiatric distress.  5555 
 5556 
 5557 
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3.2.2. Generalization of results 5558 
 5559 
The medico-legal and socioeconomic aspects of OA in Quebec as a “model” 5560 
reflective of the situation in developed countries 5561 
 5562 
In the study, the effects of various socioeconomic factors were 5563 
targeted, examined and quantified in Quebec/Canada, where a broad 5564 
compensation system is in place. Although it is highly likely that socio- 5565 
economic factors also play a role in other parts of the world, their nature and 5566 
impact would need to be examined in relation to specific compensation 5567 
systems in place. In countries where workersʼ compensation includes costs 5568 
for re-education, loss of salary, and impairment (DAP), our findings can 5569 
probably be extrapolated to these countries with an expectation of similar 5570 
associations.  5571 
  The compensation system in Quebec should be considered as a 5572 
reference standard worldwide because of its excellence in diagnosis, the 5573 
quality of readaptation programs offered by the Quebec CSST, and the 5574 
leading role played by the CSST in allocating permanent impairment/disability 5575 
compensation. Compared to the situations in many industrialized countries, 5576 
OA is less common than pneumoconiosis in developing countries. As 5577 
reported by Jeebhay and Quirce in a recent review, the spectrum of OA- 5578 
causing agents is more diverse and less consistent due to uneven industrial 5579 
development in developing countries (500).  5580 
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In these countries, the relatively under-developed or even non-existent 5581 
surveillance systems probably result in significant underreporting of this 5582 
condition (500). In developing countries, the management of individuals with 5583 
OA is often poor and diagnosis is often based on clinical impressions, history 5584 
findings, and simple diagnostic tools rather than on the results of SIC or other 5585 
elaborated tests, such as analysis of inflammation by BPT, ENO, and sputum 5586 
cell counts (500, 501). In developing countries there is often inadequate or no 5587 
compensation available for OA (500). The ways in which these differences 5588 
between developed and less-developed countries might be associated with 5589 
different socioeconomic outcomes warrant further investigation. 5590 
In countries such as the United States, where disputes about 5591 
compensation are usually settled through litigation in an adversarial setting, 5592 
the impact on quality of life and psychological distress might be even more 5593 
pronounced and other socio-economic factors might be associated with OA 5594 
outcomes. In other countries like France, compensation for OA relies on lists 5595 
of accepted causative agents and a compatible history. If a worker has 5596 
proven occupational disease but the causative substance is not listed, he/she 5597 
has to make a claim through a judicial procedure (397). Switzerland and 5598 
Germany have lists of accepted causative agents. If a substance is not on the 5599 
list, the worker can still be compensated if evidence from epidemiologic 5600 
studies prove a strong association in a given exposure group with the 5601 
development of OA. Uncertainty as to whether a claim will be accepted or not 5602 
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will most likely have a negative impact on quality of life and increase 5603 
psychological distress in these individuals.  5604 
In countries where possibilities of retraining for a new job are poor and 5605 
are limited to younger individuals, older individuals may remain exposed in 5606 
the workplace or leave the workplace. Depending on the compensation 5607 
system, they will suffer a pronounced loss of income and may have severe 5608 
limitations in quality of life and increased psychological distress compared to 5609 
others who live in countries where re-training and compensation for loss of 5610 
income are offered, even for individuals of older age. 5611 
Compensation claims and costs for occupational injuries have been 5612 
shown to be influenced by economic cycles. Compensation claims tend to 5613 
decline in recessions and rise in times of economic recovery (502). How 5614 
these factors influence quality of life and psychological distress in individuals 5615 
with OA is unknown. Therefore, the outcomes of our study might have been 5616 
different if repeated a few years later when economic growth differed from 5617 
what it was in 2004-2006.  5618 
 5619 
 5620 
5621 
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3.3. Conclusions 5621 
 5622 
Advanced age, having a higher salary and having OA to HMW 5623 
allergens all seem to predict a longer interval during which a subject is 5624 
symptomatic in the workplace; this consequently increases the severity of 5625 
asthma at diagnosis. Therefore, surveillance programs are needed that are 5626 
designed to identify such workers in their workplace and allow for the removal 5627 
of the causal occupational allergen or the reassignment of the worker to a 5628 
new workplace.  5629 
Our study suggests that it is important to consider quality of life, 5630 
concomitant psychological distress and psychiatric morbidity in individuals 5631 
with OA, even once their exposure to the causing allergen has ended. A large 5632 
proportion of patients with OA have significant impairment in disease-specific 5633 
quality of life, with elevated levels of psychological distress and psychiatric 5634 
(mood and anxiety) disorders. Quality of life, as well as some psychological 5635 
distress parameters at re-evaluation, correlates well with objective measures 5636 
of disease activity, which seems to play the principal role.  5637 
Socio-economic factors, such as employment status, marital status, 5638 
income and the number of years of employment at the time of diagnosis also 5639 
influence disease-specific quality of life and psychological outcomes, though 5640 
to a lesser degree.  5641 
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Disease-specific quality of life correlates with direct costs for 5642 
compensation by the Workersʼ Compensation Board. One can assume that 5643 
impaired quality of life correlates to a similar degree with indirect costs for 5644 
absenteeism and presenteeism. These findings underline the importance of 5645 
psychological distress and comorbid psychiatric disorders in patients with OA. 5646 
Easy-to-administer tools for the detection of individuals with such conditions 5647 
are available and should be used.  5648 
By performing disease-specific quality of life assessment with the 5649 
AQLQ(S), we could identify individuals with significant psychological distress 5650 
or psychiatric disorders and offer more elaborate and conclusive 5651 
investigations, such as a standardized psychiatric interview and treatment if 5652 
necessary. 5653 
 5654 
 5655 
5656 
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3.4. Implications and suggestions for further research 5656 
 5657 
3.4.1. Implications of the study results on the management of workers 5658 
with possible OA 5659 
 5660 
When we identify socio-economic factors that are associated with 5661 
prolonged symptomatic exposure in the workplace that leads to worse 5662 
disease-specific and higher costs for compensation, targeted screening and 5663 
surveillance programs can be initiated, with the goal of identifying individuals 5664 
whose respiratory symptoms have recently developed in the workplace. 5665 
 This would mean that surveillance programs could be initiated in 5666 
industries where workers are exposed to HMW allergens, are older, and are 5667 
known to have higher incomes. As a theoretical example, we could imagine a 5668 
program involving well-skilled laboratory workers exposed to enzymes used 5669 
for protein biochemistry. Screening could be done using a screening 5670 
questionnaire that is sensitive for the diagnosis of WRA, such as the one 5671 
used recently by Labrecque et al. (193). Individuals identified with such a 5672 
questionnaire could then rapidly undergo a standardized evaluation to either 5673 
confirm or rule out OA. The results of our study that showed that a prolonged 5674 
time with symptoms is associated with worse asthma outcomes and higher 5675 
costs for compensation could lead to physicians and decision makers of the 5676 
Workersʼ Compensation Board becoming aware that a swift, broad 5677 
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investigation is necessary to decrease the risk of a severe course of OA. This 5678 
could lead to a shorter time interval that an individual has to wait before he 5679 
gets appropriate clinical investigations in a tertiary center for SIC and 5680 
workplace assessment by an occupational hygienist. 5681 
Those individuals with asthma could be evaluated with questionnaires 5682 
like the AQLQ(S) to determine their impairments in quality of life. Married 5683 
individuals, those that are not unionized, have low incomes, and have been 5684 
with the same employer for longer times or those with severe impairments in 5685 
the emotional sub-domain of the AQLQ(S) should be preferentially referred to 5686 
a psychiatrist for mental disorder evaluations. Due to the associations of 5687 
these socio-economic factors with higher compensation costs, the additional 5688 
costs required to diagnose and treat psychiatric disorders might be lower in 5689 
the long term than the costs that accumulate if these disorders are not taken 5690 
into account. This would be true if identification and treatment of these 5691 
disorders are associated with better asthma treatment compliance resulting in 5692 
lower asthma severity.  5693 
Asthma severity is taken into account when individuals are investigated 5694 
by the Workersʼ Compensation Board to set compensation for DAP. However, 5695 
the major part of the compensation expenses is incurred for income 5696 
replacement and rehabilitation. Untreated, clinically significant psychiatric 5697 
disease will most likely impede successful reintegration in the workforce and, 5698 
thus, will significantly increase these costs.  5699 
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We have shown that, at about two and a half years after a diagnosis of 5700 
OA, there is a very high prevalence of mood and anxiety disorders when 5701 
individuals are re-evaluated by the Workersʼ Compensation Board to grant 5702 
permanent disability indemnity. Currently, airway caliber, 5703 
hyperresponsiveness, and medication use are the only criteria used to 5704 
determine levels of impairment by the Quebec Workersʼ Compensation 5705 
Board. Thus, disability, which represents the impact of impairment, is not 5706 
assessed. Results of the AQLQ(S) or psychological questionnaires such as 5707 
the PSI or the PRIME-MD evaluation should be advocated to provide 5708 
additional information that can be used for assessing disability. The findings 5709 
of our study might influence decision makers to incorporate evaluations using 5710 
instruments like the PRIME-MD or a psychiatric assessment to diagnose 5711 
mental disorders in this population.  5712 
 5713 
 5714 
3.4.2. Implications for future research projects 5715 
 5716 
1. Immigration status  5717 
 5718 
It will be important to determine the effect of immigration status on 5719 
asthma-specific outcomes in a larger sample of individuals with OA because 5720 
there were too few subjects born out of Canada in our sample. However, 5721 
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when planning such a study, researchers must consider the heterogeneity of 5722 
such a population and limit their investigation to a subgroup of workers with a 5723 
specific background, e.g. immigrants who come from South America, and 5724 
work in a blue-collar profession. These individuals have been shown to be 5725 
more vulnerable to developing allergies when moving to more industrialized 5726 
host countries (245).  5727 
 5728 
 5729 
2. Studies in workers with work-exacerbated asthma and asthma not related 5730 
to the workplace 5731 
 5732 
One must compare the correlation of psychiatric disorders and 5733 
psychological distress with asthma-specific quality of life measures, such as 5734 
the AQLQ(S), not only in workers with OA but also those with WEA and 5735 
asthma that is unrelated to the workplace. Compensation for WEA differs in 5736 
various countries. In Quebec, compensation for WEA is difficult to obtain 5737 
because a positive result for SIC is requested before compensation is 5738 
granted. In other countries like the UK, benefits for workers diagnosed with 5739 
OA and WEA are small. Given the often similar outcomes regarding asthma 5740 
severity, medication needs, loss of employment and income are considered in 5741 
practice as one entity; so-called work related asthma (165). 5742 
 5743 
 5744 
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3. Studies in subjects with other types of workplace related diseases  5745 
 5746 
It would be interesting to investigate if the associations found in our 5747 
study also hold true for respiratory alveolitis or pneumoconiosis. It might be 5748 
expected that in countries where compensation is granted for OA and 5749 
respiratory alveolitis, similar socio-economic factors would be associated with 5750 
disease outcomes.  5751 
Unlike that for OA, the natural disease course of pneumoconiosis is 5752 
usually different; progression of the disease is more closely related to the 5753 
intensity and the cumulative dose of exposure to inorganic dusts in the 5754 
workplace (503). Some workers with mild disease may even remain in the 5755 
workplace when exposure is controlled by technical measures and by using 5756 
personal protective devices. Nevertheless, even when the worker is 5757 
completely removed from the causative workplace, there is only limited, if any 5758 
improvement in lung function, unlike OA where complete recovery can occur. 5759 
Therefore, it can be hypothesized that different associations between disease 5760 
outcomes and socio-economic factors exist, at least after a diagnosis of the 5761 
condition and subsequent removal from the workplace.  5762 
Validation of the tools used in our study could be done with individuals 5763 
referred to the hospital by the Workersʼ Compensation Board for investigating 5764 
pneumoconiosis. However, it would be relevant to replace the AQLQ(S) with a 5765 
validated version of the SGRQ, which was developed to assess disease- 5766 
specific quality of life impairments in patients with interstitial lung disease 5767 
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(504). To assess disease severity, total lung function needs to be determined 5768 
with a body plethysmograph to assess possible lung restriction, measure the 5769 
transfer factor, perform spiroergometry, and analyze blood gases at rest and 5770 
during peak exercise. Tools like the PSI and the PRIME-MD could be used in 5771 
the same manner. It would also be possible to collect information regarding 5772 
costs for compensation by the Workersʼ Compensation Board and use the 5773 
same questionnaire on socio-economic factors as the one we used. 5774 
Another condition outside the field of respiratory disease is 5775 
occupational allergic contact dermatitis. This condition can develop only in 5776 
individuals who have been previously exposed to a workplace substance and 5777 
have acquired sensitization to that substance. As with OA, prolonged 5778 
exposure results in more severe disease expression and can lead to regional 5779 
or even hematogenous dissemination of the disease. As with OA, eczema 5780 
can persist even after exposure has ended and individuals can still have 5781 
severe impairments in their quality of life (505, 506). Dalgard et al. showed 5782 
that individuals with lower education levels and mid-level incomes had a 5783 
higher prevalence of allergic contact dermatitis compared to those with higher 5784 
education and income levels (507). It can be hypothesized that the same 5785 
associations between socio-economic factors and disease outcomes would 5786 
be found in individuals with this disease entity, as we have shown for 5787 
individuals with OA. For such a study, however, one needs to replace the 5788 
AQLQ(S) with an alternative measure like the Dermatology Life Quality Index, 5789 
which has been validated with individuals with chronic hand eczema (508).  5790 
304 
 5791 
 5792 
4. Need for a long-term prospective study 5793 
 5794 
One must prospectively investigate patients in terms of the evolution of 5795 
their quality of life, psychological distress levels and psychiatric morbidity from 5796 
the time individuals enter the workforce, at the time the first respiratory 5797 
symptoms occur at work, when OA is diagnosed and patients are removed 5798 
from the workplace and undergo rehabilitation. This would help to determine if 5799 
asthma and psychiatric conditions occur simultaneously or if one precedes 5800 
the other. Workers could be prospectively investigated over the next few 5801 
years to determine how the adverse socio-economic outcomes we have found 5802 
in individuals about two years after a diagnosis of OA affects long-term 5803 
outcomes such as asthma control and compensation costs. In this regard, 5804 
one could evaluate the effect of asthma severity or control status as well as 5805 
the effects of high psychological distress and psychiatric disorders on 5806 
outcomes, such as employment status and the amount of time between 5807 
removal from work until successful reintegration into the workforce. We then 5808 
need to study the effects of asthma and socio-economic factors on 5809 
absenteeism, productivity at the workplace and subsequently indirect costs.  5810 
 5811 
 5812 
5813 
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5. Test for usefulness of interventions 5813 
  5814 
Before we can implement routine screening for psychiatric disorders in 5815 
clinical investigations for OA, we need to investigate what impact a diagnosis 5816 
of mental disorders has on the clinical management of these workers. We 5817 
have to demonstrate that it is feasible to refer these individuals for further 5818 
investigations and that treatment can be effectively administered. Then, we 5819 
need to investigate whether intervention programs can reduce psychological 5820 
distress and/or prevent the development of psychiatric morbidity in patients 5821 
with OA, and whether the same factors influence quality of life and 5822 
psychological distress in countries with different medical and compensation 5823 
systems. 5824 
 5825 
 5826 
6. Developing and testing other tools 5827 
 5828 
When the benefits of routine screening can be proven, questionnaires 5829 
and instruments should be developed that are specifically designed and 5830 
validated to diagnose mental disorders in individuals with respiratory diseases 5831 
like asthma. Instruments like the PRIME-MD have been criticized on the 5832 
grounds that the results obtained for those with medical illness might be 5833 
confounded by the medical illness itself (509). Questionnaires like the HADS 5834 
have been proposed and adopted by some because they do not include 5835 
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potentially confounding items. However, this questionnaire has been criticized 5836 
because only sparse data on psychometric properties and validity are 5837 
available (509). Therefore, other measures like the HADS should be 5838 
investigated in study populations with OA.  5839 
 The results of our study suggest that the AQLQ(S) emotional 5840 
functioning subscale can be used to identify patients with potentially clinically 5841 
significant levels of psychological distress. However, this concept, the utility of 5842 
the questionnaire and the feasibility to include this measure in the evaluation 5843 
of patients need to be investigated prospectively in a clinical population 5844 
referred for the investigation of OA.  5845 
 The extra time needed for additional tests in a clinical setting should be 5846 
limited as much as possible and should not interfere with the measures and 5847 
exams that are necessary to diagnose OA. In our study, self-administration of 5848 
the questionnaires, evaluations with the PRIME-MD, and performing sputum 5849 
induction took one to two hours in addition to the basic examinations that 5850 
were requested to set the DAP. These investigations were guided and 5851 
supervised by a technician. Therefore, shorter forms of already established 5852 
questionnaires should be developed and validated, which could then be 5853 
included in routine investigations and might even be administered to 5854 
individuals with limited literacy.  5855 
Questionnaires could be administered electronically by e-mail or on 5856 
touch-screen computers. Questionnaires in an e-mail format allow 5857 
respondents to respond immediately and can be sent to patients the day 5858 
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before they arrive at the clinic for specialist investigations. The results of 5859 
these questionnaires might even be used to plan additional investigations 5860 
(e.g., evaluation by a psychiatrist). The data are easy to compile and enter 5861 
directly into a database, such as electronic patient files. Electronic 5862 
questionnaires have the advantage that errors during administration can be 5863 
pointed out to the respondent and the responses can be accepted only after 5864 
the errors are corrected or missed questions are answered.  5865 
 To better evaluate the current status of asthma, tests should be used 5866 
that have been shown to be closely correlated with other objective markers of 5867 
disease severity, such as symptoms, airway hyperresponsiveness to external 5868 
stimuli, and inflammation in the airways. AHR can be assessed by performing 5869 
BPTs with direct (e.g., methacholine, as currently used in Quebec) or indirect 5870 
stimuli (e.g., exercise, hypertonic saline, and mannitol).  5871 
In a pilot study conducted in our hospital, we showed that BPT with 5872 
mannitol was a useful test for assessing impairment/disability and asthma 5873 
activity in workers with OA. This was because mannitol can better 5874 
discriminate subjects according to the severity of their disease when 5875 
expressed as airflow limitation, and airway inflammation reflective of 5876 
eosinophilic inflammation and ENO levels (143). Furthermore, performing 5877 
BPT with mannitol allows for collecting sputum at the same time, which 5878 
results in less time needed for an examination. However, these promising 5879 
results need to be verified in larger prospective studies. 5880 
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